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SUMMARY 
Nrf2 project 
The protein nuclear factor erythroid 2-related factor 2 (Nrf2) is a transcription factor that 
provides protection against oxidative stress and the dysfunction of this pathway has been 
suggested to be implicated in many neurodegenerative diseases. The aim of this thesis was to 
identify novel Nrf2 activators that disrupt the protein-protein interaction between Nrf2 and 
Keap1 and thereby induce increased expression of antioxidant enzymes and protective genes. 
The crystal structure of the Keap1-Nrf2 interface was used to perform a virtual screen and 
compounds from the screen were assayed using a cellular nuclear complementation assay that 
measures the nuclear translocation of Nrf2 from the cytosol. Although two novel compounds 
were found to increase the Nrf2 nuclear translocation, they had low activity and further 
characterisation did not provide sufficient evidence of a Nrf2-Keap1 robust interaction.  
iGluRs project 
AMPA and kainate receptors are ionotropic glutamate receptors (iGluRs) that are important for 
excitatory transmission and synaptic plasticity and are linked to several neurological disorders 
such as epilepsy, schizophrenia and autism. This project aimed to find novel allosteric 
modulators binding in the ligand-binding domain (LBD) of the GluA2 and GluK1 and GluK2 
subtypes of AMPA and kainate receptors, respectively, using protein purification and X-ray 
crystallography methodologies. Fragment screening for GluA2 identified eight novel fragments, 
five of which were located at the dimer interface and three located in a novel site near the 
glycine-threonine dipeptide linker. As regards kainate receptors, structural information on the 
Gluk1 and GluK2 LBD was obtained, both proteins were soaked with in-house fragments with 
one compound displaying 20% occupancy in the GluK2 dimer interface. These data form the 
basis of future studies in the search for novel drugs for the treatment of epilepsy and 
schizophrenia.  
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CHAPTER 1 
GENERAL INTRODUCTION TO DRUG DISCOVERY 
 
1.1 OVERVIEW OF THE DRUG DISCOVERY PROCESS  
Developing a new drug from initial research to a commercial  final product is a long and complex 
process that can take around 12 to 15 years or more and costs around $2.6 billion (Hughes et al. 
2011; Mullin 2014). Usually a target is a protein and/or pathway involved in pathology, so the 
modification of the target will result in a beneficial therapeutic effect. The idea for a target 
identification can originate from academic or industrial research, usually both work in 
collaboration to build enough supporting evidence for a desired target (target validation). Once 
a target is chosen, academia and/or industry design a variety of early processes to identify 
molecules that are able to satisfy the characteristics of a suitable drug. Some of those early 
stages are target validation, assay development, high throughput screening, hit identification 
and lead optimisation, which conclude in preclinical and clinical stages (Fig. 1.1).  
 
 
Figure 1.1. Drug Discovery process. Drug discovery comprises the initial stages of target 
identification and validation to clinical trials for regulatory approval (Adapted from Gopinathan 
et al. 2015). 
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Target identification and validation 
The first step of a drug discovery process is the target identification, which means identifying a 
molecular target for a drug molecule. A molecular target is usually a molecule involved in 
biological processes, usually a protein in isolation or in complex, is associated with a disease. A 
drug molecule or a small compound binding to the molecular target (i.e. protein) can have 
therapeutic effects in the disease related to the molecular target. This stage itself is focused on 
identifying the correct drug targets for a specific disease, which usually does not have treatment 
or is in some way insufficient. Some methods used for target identification are 
chemoproteomics, phenotypic screening and gene association studies (Hughes et al. 2011). The 
most common molecular drugs are small molecules which bind in specific proteins, however, 
other approaches for new drugs have been investigated. For example, the development of lipid 
drugs such as Vascepa, approved by the FDA in 2012. This drug targets the modulation of 
cholesterol levels and prevents cardiovascular disease and pancreatitis (Hiatt & Smith 2014).  
Another example is the development of small molecule drugs (glycomimetics) that mimic the 
function of carbohydrates involved in disease-protein interactions  (Ernst & Magnani 2009). 
More recently mRNA-based drugs have been developed by Moderna Therapeutics and 
AstraZeneca, the most recent is AZD8601 which has possible regenerative and healing 
properties in heart failure, diabetic wound and ischaemic vascular diseases. AZD8601 is a mRNA 
modified drug that is currently under phase I clinical trial in patients with type II diabetes mellitus 
(Mullard, 2016 & NCT02935712, clinicaltrials.gov).  
A potential target must undergo a validation process, which is focused on demonstrating the 
effect of a target disruption on disease-related relevant pathology. Transgenic animals and gene 
knockout experiments allow the observation of phenotypic changes as a result of gene 
manipulation. These techniques are established approaches for target validation in vivo in 
animal models (Hughes et al. 2011). However, some animal models are difficult to compare to 
human processes. Proteomics is a technique for the study of proteins expressed in cells, this 
technique is also used for target validation by identifying novel proteins required for biological 
processes. These proteins might act as a potential drug target in a specific-related disease (Kopec 
et al., 2005). Other well-established techniques includes antisense technology and RNA 
interference (RNAi) that help disrupting the expression of a particular gene (Hughes et al. 2011). 
If a drug target fails in the target identification and validation steps it suggests that the drug will 
not work for a molecular target involved in disease or might not be safe to use in humans 
(Hughes et al. 2011). 
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Lead identification 
When a drug target is identified and validated, research will focus on lead discovery (hit 
identification and screening assays).  In this stage high-throughput screening is commonly used 
to identify potential candidates for a lead generation (hit-to-lead). Hit-to-lead phase is focused 
in refining each hit to produce a more potent and selective compound to be studied in in-vivo 
models (Hughes et al. 2011). 
 
Lead Optimisation 
This stage is focused on the search for optimal efficacy, in which compounds are modified to 
improve potency, selectivity, pharmacodynamics and pharmacokinetics properties. 
Toxicological properties are tested in this stage, such as in vitro genotoxicity measured by the 
Ames test and in vivo toxicity model using the Irwin observation test that measures physiological 
and behavioural functions for new substances (Hughes et al. 2011). After lead optimisation 
compounds are ready for final characterisation before preclinical studies (Hughes et al. 2011).  
 
Preclinical testing and clinical trials 
Preclinical studies are required before the initiation of clinical studies to establish if a drug is safe 
in humans; studies are focused on finding out potential toxicity. According to the U.S. Food & 
Drug Administration (FDA) guidelines, preclinical research must provide detailed information on 
dosing and toxicity levels using good laboratory practices (GLP).  
The aim of clinical studies is to test if the candidate drug is safe and well-tolerated and has 
efficacy in human volunteers. FDA has human guidelines for drug testing that include 
characterisation of absorption, metabolism, excretion, toxicity and undesired side effects. 
Clinical trials are defined by three to four phases according to the FDA.   
Phase 0, a reduced dose of the drug is given to a small group of volunteers to observe the 
expected drug behaviour in humans. This dose is too small to observe a full therapeutic effect 
but gives important preliminary information. The main objective of this phase is to accelerate 
the development and approval of new drugs.  
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Phase I, studies to evaluate safety, side effects and dosage range in terminally ill volunteers.  
Phase II, testing drug in patients with a disease or condition and comparison of the drug to a 
placebo. Safety and short-term adverse events are also monitored. 
Phase III, similar to phase II studies safety and adverse events in a larger patient population, 
different dosages and in combination with other available treatments (drugs).  
Phase IV, studies after FDA has approved market release of a drug. Final studies to obtain any 
additional information about safety, efficacy and optimal use.  
(clinicaltrials.gov and FDA guidelines) 
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1.2 HIT IDENTIFICATION  
Hit identification is the process of identifying a small molecule “compound” with activity against 
the desired target (i.e., protein). The obtained compounds will be identified by a screening 
approach such as high-throughput screening or structure-based drug design. There are 
additional different screening approaches used for compound identification (Fig. 1.2). For 
example, fragment screening, in which compound solutions are soaked and incubated with 
protein crystals to obtain structural information of the binding mode by fragments. Virtual 
screen is another method use for screening virtual compounds in the well-known structure 
binding sites. Other screening approaches are; focused screen, physiological screen and NMR 
screen.  
 
Figure 1.2. Different screening strategies used in the hit identification process (Hughes et al. 
2011). 
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1.2.1 HIGH-THROUGHPUT SCREENING (HTS)  
High-throughput screening (HTS) is currently a standard method for drug discovery research. 
HTS is a method of screening and assaying a large amount of compound libraries against the 
specific drug target (Szymański et al. 2012). The main purpose of this large screening is to identify 
novel lead compounds active against a molecular drug target by using robotic technologies such 
as liquid handling and robotic automation, multi-platform plate readers, high content imaging 
tools, sensitive detectors and data processing software (Target discovery institute-Nuffield 
department of Medicine; 2017). The main advantage of HTS compared to other screening 
approaches is the ability to screen large-scale libraries in a quick and low cost process. 
Commonly, HTS assays are performed in microtiter plates ranging from 96-, 384- or 1536-well 
formats. A number of active hits will be obtained after screening compound libraries, these hits 
will be further interrogated through hit validation studies. The ability to screen a large range of 
compounds can give important information on the interaction of compounds into biological 
processes in a quick automated manner. For that reason, HTS is an important currently used 
method in drug discovery research; it is estimated that HTS has provided economic savings of 
130 million dollars over the development of a new drug (Szymański et al. 2012).   
 
1.2.2 STRUCTURE-BASED DRUG DISCOVERY 
Structure-based drug discovery is the design and development of a compound as a drug 
candidate and is based on the determination of the three-dimensional structure of the protein 
by X-ray crystallography or nuclear magnetic resonance (NMR) spectroscopy. Homology models 
and virtual screening can be used when the structure of the target is not available, using well-
known structures of a related protein. The use of structure-based methods are increasing rapidly 
and playing an important role in the research of drug discovery and frequently can be used as a 
complementary method with HTS.  
 
1.2.2.1 X-RAY CRYSTALLOGRAPHY  
X-ray crystallography is the technique used in structure-based drug discovery to obtain 3D-
structural molecular information from a crystallize protein. The recombinant gene of the target 
is cloned into a vector to express into a host (usually bacteria strains) and produce the protein 
target. The protein obtained needs to be as pure as possible, homogenous and correctly folded 
in solution. The pure protein sample is prepared at high concentration in controlled dehydration 
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experiments (crystallisation) to force the protein to form crystals. Crystallisation occurs when 
the concentration of the protein reaches the precipitation (supersaturation or metastable) zone. 
Crystallisation experiments usually examine and test a wide range of variables, such as pH, 
temperature, protein, buffer, salt and precipitant concentrations, plate format (hanging drop, 
sitting drop and under oil), solution volumes and drop ratio (Merz et al. 2010).  
When crystallisation experiments result in adequate quality crystalline solid form (larger size 
and singular form), these are exposed to an X-ray beam to obtain diffraction patterns. The 
processing of the diffraction data is mathematically complex, however, there are many software 
packages such as MOSFLM, HKL-3000R and XDS and computational programs such as CCP4 with 
established algorithms to facilitate the data processing (Otwinowski & Minor 1997; Smyth & 
Martin 2000). The collected X-ray diffraction data records the measurement of the intensity of 
the electromagnetic waves. Each reflection of the diffraction pattern correlates to a wave 
containing an amplitude and a phase value. The amplitude is obtained by using the intensity 
data, however the phase information is lost during the data collection, this is known as the 
“phase problem” (Taylor 2010). The diffraction data will be transformed into structural 
information by solving the phase problem. 
There are different approaches to solve the phase problem, the most popular method is 
molecular replacement (MR) which utilizes the existence of a previously known structure of a 
similar protein homologous to the structure to be solved (Büttner et al. 2015). Other methods 
less commonly used for solving the phase problem are; single-wavelength anomalous diffraction 
(SAD), multi-wavelength anomalous diffraction (MAD), single-isomorphous replacement (SIR) 
and multiple isomorphous replacement (MIR; Hendrickson & Ogata 1997; Smyth & Martin 2000; 
Taylor 2010). Isomorphous replacement and anomalous replacement methods require previous 
information of the heavy atoms and anomalous scattering atoms of the substructure 
respectively (Table 1.1).  
Once the phase problem is solved an electron density map is generated for structural refinement 
to obtain the final molecular structure model. Optimised crystals are usually soaked with 
fragments to collect information about a protein structure in complex with ligands, these ligands 
will need further chemistry optimisation to improve drug-like properties. Ligands that are able 
to bind in the protein structure will be further tested in an in vitro assay to study the relationship 
between binding and function.  
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Table 1.1. Phasing methods used in structural solution (Adated from Taylor, 2010). 
Method Previous knowledge  Comments 
Molecular 
replacement (MR) 
Homology model 
available  
Homology model sharing at least 30% of 
sequence identity 
Isomorphous 
replacement (SIR/MIR) 
Heavy-atom 
substructure 
Soak crystals with heavy atoms solution  
Anomalous 
replacement 
(SAD/MAD) 
Anomalous-atom 
substructure 
SAD reduces potential radiation damage 
compared to MAD when collecting 
 
 
Figure 1.3. X-ray crystallography procedure. Target protein is expressed and purified to obtain 
diffracting crystals, diffraction data is used for phase determination and calculation of electron 
density map. The electron density map obtained is used for molecular model building and 
structural refinement where phases and electro density maps are improved (Büttner et al. 2015). 
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 1.2.2.2 NMR STRUCTURE DETERMINATION  
Nuclear magnetic resonance (NMR) spectroscopy is an analytical technique used for the 
determination of physical and chemical properties of atoms in molecules using the magnetic 
properties of atomic nuclei (Berg et al. 2002). This technique is an indirect method that uses 
computer calculations parametrized empirically for characterizing the 3D-conformation of 
proteins. Similar to X-ray crystallography the protein sample has to be in solution for protein 
expression and purification experiments. For structure determination, the collection of different 
2D and 3D NMR spectra is necessary for the generation of a resonance spectrum measurement. 
Advantages of this technique are; the information of molecular parameters (chemical shifts, 
angles and distances), coupling constants and chemical kinetics, and the potential to study the 
solvent influence in the protein sample (Rzepa 1996). Some disadvantages of this technique for 
structure determination are the difficulty in identifying which NMR peak corresponds to which 
nuclei in the spectrum, the re-assignment of the spectrum for each ligand in complex with the 
protein and most analysis are limited to protein below 30 kDa (Hubbard 2011).  
 
 Figure 1.4. Structure determination by NMR spectroscopy. Example of the different 3D spectra 
using multiple-isotopes 13C, 15N and 1H  for generation of protein structure (Adapted from 
Hubbard 2011). 
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1.2.2.3 VIRTUAL SCREENING  
Virtual screening (Fig. 1.5) is a technique used for structure-based drug discovery in which large 
libraries of small molecules are computationally screened against a target structure (i.e. a 
protein-protein binding pocket). In order to perform a virtual screen it is necessary to have 
deposited known structures of the target in the protein data bank (PDB; Lionta et al. 2014). The 
libraries are drug-like compounds that have been previously synthesised as commercial 
compounds. The general process starts with identifying the binding site of the target and 
selecting a specific compound database (library). The database used usually corresponds to a 
collection of physically available compounds; each drug discovery research group has a 
preferred database according to the target of study. The next step is performing molecular 
docking of each compound into the binding site of the target. Docking studies predict the 
orientation of the compound into the target site to form a stable complex by sampling the 
coordinate space of the binding site and ranking each possible compound pose.  There is a wide 
range of docking software such as; molecular operating environment (MOE), mutually 
orthogonal latin squares (MOLS), SwissDock, GOLD and DOCK. These software packages use 
sampling algorithms to generate a score system which measures different parameters of the 
predicted binding mode, for example, the free energy of the binding, surface of the dynamics, 
ligand flexibility and the clashing or impact of the pocket (Lyne 2002; Lionta et al. 2014). MOE is 
a fully integrated drug discovery software package with a wide range of applications such as 
structure- and fragment-based design, pharmacophore discovery, medicinal chemistry and 
biologics applications, protein and antibody modelling, molecular simulations, cheminformatics 
and quantitative structure-activity relationships (QSAR) models. MOLS is a software program 
specialised for peptide modelling and protein-ligand docking (Paul & Gautham 2016). An 
advantage of SwissDock is that it uses a web server to predict the possible interactions between 
a target protein and a small molecule, it is accessible through a web browser and results can be 
viewed online (Grosdidier et al. 2011). GOLD is software used for binding mode predictions that 
utilizes the Chemscore scoring function for predicting ligand binding (Verdonk et al. 2003). 
Finally, the DOCK software uses a geometric matching algorithm to superimpose the ligand into 
the binding pocket to obtain receptor flexibility and force-field based scoring analysis.  
The compounds filtered by molecular docking and scoring go through several post-analysis tools 
to filter the compounds that are suitable for further analysis. Some common post-analysis filter 
steps include medicinal chemistry studies, toxicity, chemical reactivity and drug-like similarity. 
After the compounds are selected, they will be tested in a biological in vitro or in vivo assay 
format. Some advantages of virtual screening are the rapid and low cost of screening a large 
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amount of compound libraries, large amount of virtual screen and docking computational 
programs and the ability to predict binding mode of a specific target. Some disadvantages are 
the requirement to know the three-dimensional information deposited in the PDB, the need for 
further filtered parameters and it cannot substitute a biological assay screen such as high-
throughput screening (HTS). However, both methods can complement each other for the 
selection of novel compounds. Usually virtual screening is performed first and then compounds 
hits are tested with HTS.  
 
Figure 1.5. Structure-based virtual screening approach. The starting point is identifying the 
binding site of the target in previously known structures and the selection of an adequate 
compound database. Molecular docking and scoring will then be performed using 
computational software to further post-analyse to selected compounds using filtering tools such 
as, pan-assay interference compounds (PAINS) and absorption, distribution, metabolism and 
excretion (ADME) properties filters and finally test selected compounds in vitro assays (Lionta et 
al. 2014). 
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CHAPTER 2 
NUCLEAR FACTOR ERYTHROID 2-RELATED FACTOR 2 (NRF2) 
 
2.1 ABSTRACT 
The normal function of the antioxidant defence pathways are essential for cell survival. 
Dysfunction and up-regulation of the oxidative stress pathways are implicated with the 
pathogenesis of many neurodegenerative diseases, including Alzheimer disease, Parkinson’s 
disease and Amyotrophic lateral sclerosis. The protein nuclear factor erythroid 2-related factor 
2 (Nrf2) is an important transcription factor that functions to regulate the redox balance against 
oxidative and electrophilic stresses. The Nrf2-Kelch-like ECH-associated protein 1 (Keap1) 
pathway acts as a sensor in response to oxidative/electrophilic stress. The Nrf2-Keap1 
dissociates in response to oxidative stress and Nrf2 translocates to the nucleus to increase the 
expression of protective genes and antioxidant enzymes such as the phase II detoxifying 
enzymes glutathione S-transferase (GST), quinone reductase (QR), heme oxygenase-1 (HO-1) 
and NAD(P)H quinone oxidoreductase 1 (NQO1). Accordingly, Nrf2 is an attractive cellular 
pathway for drug discovery. In order to identify a novel Nrf2 activator that disrupts the Nrf2-
Keap1 protein-protein interaction, a virtual screen was performed based upon the known 
structure of the protein-protein interface between Nrf2-Keap1 and evaluated compounds in a 
DiscoveRx nuclear complementation assay that measures the translocation of Nrf2 from the 
cytoplasm to the nucleus. In this assay, sulforaphane was used as a positive control and had an 
EC50 of 400 ± 55 nM. In silico screening of a library of over 3 million compounds identified a 
number of virtual screening “hits” of which 122 were purchased and evaluated further. Of these 
compounds, five produced an activation ranging from 15-100% relative to the sulforaphane 
control (which was defined as 100% activity).  However, the use of a ROS-Glo assay showed that 
three of these five compounds were activating the pathway non-specifically by themselves 
producing free radicals rather than disrupting the protein-protein interaction. Two novel 
compounds appeared to increase Nrf2 nuclear translocation in a Keap1-Nrf2 cell-based assay. 
However, both compounds displayed relative low activity and there was insufficient evidence of 
Nrf2-Keap1 robust interaction and so a no-go decision of the project was made.  
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2.2 INTRODUCTION   
2.2.1 THE NRF2-ARE SYSTEM  
The NFE2L2 gene encodes for a 68 kDa protein, the nuclear factor erythroid 2-related factor 2 
(Nrf2), which belongs to a family of proteins characterised by their cap ‘n’ collar (CNC) protein 
structure. These CNC proteins are basic leucine zipper (bZIP) transcription factors that are 
characterised by the presence of a conserved 43 amino acid CNC domain in the C-terminal region 
which acts as a DNA binding domain, CNC domain is located in Neh1 region of Nrf2 (Fig. 2.1). In 
the nucleus, bZIP proteins heterodimerize with other proteins (musculoaponeurotic 
fibrosarcoma oncogene homolog, small MAF or c-JUN) which are then be able to bind to specific 
DNA sites called anti-oxidant response elements (ARE; Nguyen et al. 2009). Nrf2 is the major 
transcription factor that binds with members of the small musculoaponeurotic fibrosarcoma 
(MAF) family and consequently it binds to ARE sites which are able to regulate the transcription 
of hundreds of cytoprotective genes (including antioxidants) and thereby protect cells from 
environmental stresses and enhance cell survival (Katsuoka et al. 2005; Blank 2008). Accordingly 
Nrf2 is essential for the cellular response pathways against different types of stress  (Kensler et 
al. 2007; Kumagai et al. 2013; Sandberg et al. 2014). 
 
Figure 2.1. Summary of Nrf2 structure. Nrf2 protein contains 605 amino acids and six Nrf2-
embedded contact homology (Neh) domains (Neh1-6). The CNC-bZIP located in the Neh1 region, 
CNC shown with a red asterisk. Within the C-terminal region, the Neh1, Neh3 and Neh6 domains 
are responsible for DNA binding, transcriptional activity and degradation signal respectively. 
Cromodomain-helicase-DNA-binding protein 6 (CHD6) in Neh3 is a chromatin-remodelling 
protein that plays an important role in transcription regulation.  The N-terminal region contains 
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the Neh2, Neh4 and Neh5 domains which are important for binding with Keap1, regulation of 
Nrf2 target gene expression and interaction with  CREB-binding protein (CBP) and p300 proteins 
respectively (Boutten et al. 2011). The linear sequence of the protein Q16236-1 UniProtKB is 
also shown, displaying the different domains of the protein.   
 
Nrf2 contains six Nrf2-Erythroid-derived CNC homology (Neh) domains (Neh1-6; Fig. 2.1). The 
Neh2 domain is important for binding with the cytosolic repressor protein Kelch-like erythroid 
cell embedded contact homology (ECH)-associated protein (Keap1). Under normal conditions 
Nrf2 binds to Keap1 under which conditions Nrf2 is inactive and the Nrf2-Keap1 complex is 
directed towards Nrf2 ubiquitination and subsequent proteasomal degradation using the CUL-3 
E3 ubiquitin ligase complex (Fig. 2.3; Motohashi & Yamamoto 2004; Kensler et al. 2007). Keap1 
has been demonstrated to regulate Nrf2 protein levels either by enhancing its rate of 
degradation or altering its cellular localisation. The process of Nrf2 degradation is relatively rapid, 
with the normal half-life of Nrf2 being 18.5 minutes, suggesting that turnover of Nrf2 is an 
important process in normal cells (Itoh et al. 2003).  
Keap1 (Fig. 2.2 & 2.3) is a 69-kDa rich in cysteine residues protein, which act as a sensor of stress 
signals. Modification of these cysteine residues (i.e. oxidation to form disulphide bonds) results 
in conformational changes in Keap1 which then releases Nrf2. One proposed model of Nrf2 
dissociation is the “hinge and latch” mechanism, in which Keap1 homodimer binds with two 
sites of the Neh2 domain of Nrf2 (29-DLG and 79-ETGE). Conformational changes of Keap1 by 
cysteine modifications cause disruption of the low affinity site with Nrf2 DLG (the latch) causing 
Nrf2 accumulation,  dissociation and prevention of the proteasome ubiquitination process (Fig. 
2.4; Suzuki et al. 2013). 
Once released from Keap1, Nrf2 is phosphorylated by cytosolic kinases which activate Nrf2 
resulting in the protein translocating into the nucleus where it can heterodimerize with sMAF or 
c-JUN proteins. These complexes then bind to antioxidant response elements (ARE) and induce 
the expression of several ARE-responsive genes, including phase II detoxifying enzymes and 
antioxidants (Fig. 2.3). This adaptive response will enhance cell survival to several types of stress 
mediated by electrophiles and free radicals (Kensler et al. 2007). 
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Figure 2.2. Keap1 protein structure and sequence. Protein is formed by five domains; the N-
terminal region (NTR), the bric-a-brac, tram-track, broad complex domain (BTB), the intervening 
region (IVR) and the C-terminal region (CTR; Coople 2012; Baird et al. 2014).  Sequence Q14145-
1, UniProtKB; the colours correspond to the different domains of the protein structure. (Adapted 
from Baird et al. 2014).  
 
2.2.2 Nrf2 phosphorylation 
The Nrf2-Keap1 interaction is not the only factor regulating stability and cellular localisation of 
Nrf2. A number of kinases are reported to directly phosphorylate Nrf2. For example, p38 
mitogen-activated protein kinases (MAPKs) can phosphorylate multiple serine residues (Ser-
215,408 and 577) of Nrf2 promoting its association with Keap1 and blocking its nuclear 
translocation (Keum et al. 2006; Sun et al. 2009; Bryan et al. 2013). p38 MAPKS are the only 
kinases that have been shown to reduce the Nrf2 nuclear translocation, however the exact 
interaction has not been confirmed. In contrast, protein kinase C (PKC) has an important role in 
promoting nuclear translocation of Nrf2 and facilitating the release from Keap1 by directly 
phosphorylating Nrf2 at serine 40 (Huang et al., 2002). Similarly the phosphatidylinositol 3-
kinase (PI3K) is important in regulating the Nrf2 pathway, however the specific mechanism is yet 
not clear (Wang et al. 2008) . The c-Jun N-terminal kinase (JNK), and the extracellular signal-
regulated kinase (ERK) have an important part in activation of Nrf2, since both kinases have been 
shown to accelerate the release from Keap1 and stimulate the nuclear translocation of Nrf2 (Xu 
et al. 2006). In addition, the tyrosine kinase Fyn phosphorylates the Nrf2 tyrosine 568 to induce 
the nuclear export and proteasome degradation, regulating the Nrf2-ARE system (Sandberg et 
al. 2014). In recent studies the protein kinase RNA-like endoplasmic reticulum kinase (PERK) also 
showed some interaction with Nrf2, however the site of phosphorylation is still unclear (Nakaso 
et al., 2003, Cullinan et al., 2003,  Xu et al., 2006 &  Bryan et al. 2013).  
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Figure 2.3. Summary of the Nrf2-ARE cellular protection pathway. Under basal conditions, Nrf2 
is targeted to ubiquitin degradation by the Keap1/Cul3 E3 ubiquitin ligase complex. Under 
conditions of oxidative stress, cysteine-rich Keap1 is oxidised and the resulting conformational 
change releases Nrf2 which is then phosphorylated and undergoes translocation into the 
nucleus where it associates with small MAF and then promotes the expression of ARE-driven 
genes (Adapted from Lee et al. 2005).  GSTs, Glutathione S-transferases; NQO1, 
NAD(P)H:quinone oxidoreductase 1; GCLs, Glutamate cysteine ligase subunit; HO-1, Heme 
oxygenase 1; UGT, UDP-glucuronosyltransferase and TXNRD1, thioredoxin reductase 1. 
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Figure 2.4. Diagram of the “Hinge and Latch” model of Nrf2 releases from Keap1. The protein 
Keap1 is present in the cytosol as a homodimer in a cherry-bob conformation, in which the 
homodimer binds to the Nrf2 protein sequence in two sites inside the Neh2 domain located at 
the N-terminal of the protein, one in high affinity ETGE the “hinge” and the lower affinity DLG 
the “latch”. DLG corresponding to aspartic acid, leucine and glycine and ETGE to glutamic acid, 
threonine, glycine and glutamic acid according to the one letter amino acid code. Both binding 
sites of Keap1 with DLG and ETGE facilitate the proteasomal degradation of Nrf2 by allowing the 
ubiquitination in the seven lysine (K) residues in the protein sequence. However, cysteine 
modification of Keap1 leads to a conformational change of Keap1, destabilizing the DLG binding 
(latch) and results in the accumulation and stabilisation of Nrf2, several kinases might also 
activate Nrf2 for complete dissociation from Keap1 (Suzuki et al. 2013). 
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2.2.3 NRF2 FUNCTIONS  
Nrf2 is considered the key controller of the redox homeostatic gene regulatory network and is 
therefore one of the important systems protecting against oxidant and electrophile-induced 
damage in the cells (Ishii 2000; Sandberg et al. 2014). Other systems involved in protection 
against oxidative stress are the pentose phosphate pathway (Kuehne et al. 2015), mitochondrial 
antioxidant pathways such as peroxiredoxin (Prx) and cAMP response element-binding 
protein/cAMP response element (CREB/CRE) transcriptional pathway (Lee et al. 2009; Perkins 
et al. 2015). Over the last few years it has been demonstrated that Nrf2 regulates the expression 
of a wide range of detoxification, antioxidant and conjugating enzymes, as well as proteins that 
enhance the export of xenobiotics and enzymes important in protection of inflammation 
induced damage. These protective enzymes and proteins include, for example, glutathione S-
transferases (GSTs; Chanas et al. 2002), NAD(P)H:quinone oxidoreductase 1 (NQO1; Hong et al. 
2010), brain derived neurotrophic factor (BDNF; Sakata et al. 2012), anti-apoptotic B-cell 
lymphoma 2 (BCL-2; Niture & Jaiswal 2012), anti-inflammatory interleukin IL-10 (Boyle et al. 
2011), the mitochondrial transcription co-factor NRF-1 (Piantadosi et al. 2011) and heme 
oxygenase 1 (HO-1; Hong et al. 2010).   
The importance of this protective system is demonstrated by the fact that Nrf2 knockout mice 
demonstrate a deficiency in the production of phase II detoxification antioxidant enzymes that 
are that are indispensable against oxidative and xenobiotic stress (Sandberg et al. 2014). Phase 
II detoxification enzymes are responsible for the conjugation reactions of xenobiotics in the 
biotransformation metabolism, usually these enzymes are transferases that transfer a functional 
group from one molecule to another to facilitate the elimination of drugs in the metabolism 
(Jancova et al. 2010).  These mice with deficiency of phase II detoxification enzymes are also 
more sensitive to toxic electrophiles, leading to elevated neurotoxicity and resulting in acute 
and severe pathological effects in brain (more severe damage in stroke and traumatic brain 
injury), liver (cancer and liver toxicity) , lungs (hyperoxic lung injury) and intestine (intestinal 
ischemia reperfusion; Ishii 2000; Motohashi & Yamamoto 2004; Sandberg et al. 2014). 
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2.2.4 NRF2 AS A MULTI-ORGAN PROTECTOR AGAINST DISEASE 
A relationship between the activation of Nrf2-ARE pathway with anti-inflammatory effects has 
been suggested, one hypothesis is an interaction with the nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-кB), a protein complex important for the transcription control 
of DNA, cytokines and cell survival. This relationship is not yet understood but NF-кB binding 
sites in the Nrf2 gene have been identified suggesting a similar role for inflammatory processes 
(Nair et al. 2008; Sandberg et al. 2014). Antioxidant response studies in animal models 
demonstrate that genetic disruption (gene silencing or gene deletion) of Nrf2 increased brain, 
liver, and pulmonary injury due to the decreased levels of ARE-driven cellular protection systems 
and overexpression of Nrf2 can protect these organs from induced toxicity response (Fig.2.5; 
Lee et al. 2005). Below are some examples of diseases related to Nrf2 dysfunction in different 
organs. 
 
Figure 2.5. Nrf2 has a protective effect in a variety of different tissues and organs. Nrf2 increases 
the expression of ARE-driven detoxification and antioxidants genes (Lee et al. 2005). 
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2.2.4.1 LUNGS  
Nrf2 is  highly expressed in lungs and it is associated with protection against inflammatory agents 
and oxidants (Chan & Kan 1999). Nrf2 knockout (KO) mice displayed acute respiratory distress 
syndrome with the administration of toxic butylated hydroxytoluene (BHT) compare with wild 
type, suggesting an important role of Nrf2 in the defence against oxidants in the lungs (Chan & 
Kan 1999). Oral administration of BHT is used for the induction of lung damage and alveolar 
epithelial cells destruction (Chan & Kan 1999). Nrf2 protects lungs against hyperoxic injury in 
mice, macrophage inflammation and epithelial injury were increased by 47% and 43% in Nrf2 
deficient compared to wild type mice after 72 hours of hyperoxia exposure (Cho et al. 2002). 
Also, in a Nrf2 KO experiment showed that wild type Nrf2 mice displayed protection from lung 
injury and fibrosis induced by bleomycin administration in a pulmonary fibrosis animal model 
(Cho et al. 2004).  
Chronic obstructive pulmonary disease (COPD), a progressive condition characterised by lung 
damage, emphysema and breathing disorders, is associated with cigarette smoking. Cigarette 
smoke-induced emphysema studies showed greater bronchoalveolar inflammation and 
apoptotic alveolar cells in Nrf2 KO compared with the wild type mice (Rangasamy et al. 2004; 
Iizuka et al. 2005; Ishii et al. 2005). The Nrf2-ARE driven genes have an important role in 
protection in pulmonary emphysema by regulating the oxidant/anti-oxidant balance, 
inflammation and protease/anti-protease balance in alveolar macrophages (Ishii et al. 2005; 
Boutten et al. 2011).  
 
2.2.4.2 LIVER AND GASTROINTESTINAL TRACT 
The liver plays an important role in metabolizing xenobiotics, such as, chemicals, drugs and 
toxins. It performs the break down and elimination of chemical compounds with the help of 
phase I (oxidation, reduction and hydrolysis reactions) and phase II (conjugation reactions) 
metabolism. Hence, the liver is vulnerable to oxidative stress and liver diseases related with 
oxidants are hepatitis, fibrosis, cirrhosis and hepatocellular carcinoma (Fig. 2.6). Nrf2 is known 
to activate the phase II antioxidant enzymes that help balance the redox homeostasis and 
therefore Nrf2 has an important role in preventing liver  and gastrointestinal tract disease (Shin 
et al. 2013).  Studies in mice have showed that Nrf2 gene deletion increases the sensitivity to 
xenobiotics. For example, it has been shown that Nrf2 knockout mice have an increased 
sensitivity to acetaminophen toxicity relative to wild type animals (Enomoto et al. 2001). 
Similarly, treatment of carcinogen benzo(a)pyrene showed more severe damage (gastric 
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neoplasia and liver toxicity) in mice with Nrf2-deficient compared to wild type animals (Ramos-
Gomez et al. 2001). These studies indicate that Nrf2 is important in regulating drug metabolizing 
enzymes and antioxidant genes in the liver and gastrointestinal tract (Aleksunes et al., 2007 & 
Klaassen & Reisman 2010).  
 
Figure 2.6. The protective role of Nrf2 expression in liver disease. The schematic representation 
of the Nrf2 activation to help prevent liver diseases by controlling the reactive oxygen species 
levels in cells (Shin et al. 2013). GCLC, glutamate-cysteine ligase catalytic subunit; GCLM, 
glutamate-cysteine ligase modifier subunit; GST, glutathione s-transferase; UGT, uridine 5’-
diphospho-glucuronosyltransferase; HO-1, heme oxygenase; MRPs, multidrug resistance 
proteins and NQO-1, NAD(P)H quinone dehydrogenase 1.  
 
2.2.4.3 SKIN 
Studies in mice have also shown that Nrf2 has an important role in the protection of skin against 
UV rays. Hence, compared to wild type mice, UVB-irradiated Nrf2 knockout animals showed 
increased skin ageing, deeper coarse wrinkle formation, skin flexibility diminution, epidermal 
thickening and higher skin reactivity; the same mice demonstrated lower levels of glutathione 
levels in the skin (Hirota et al. 2011; Saw et al. 2011). In a fibroblast study, primary human skin 
fibroblasts displayed better resistance to ionizing radiation when treated with antioxidant and 
Nrf2-activator sulforaphane, however this resistance was dependent on Nrf2 activation, nuclear 
translocation and induction of antioxidant enzymes (Mathew et al. 2014).  
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2.2.4.4 HEART 
Recent studies suggest that Nrf2 deficiency increases the earlier onset of cardiac dysfunction 
and the development of heart failure (Wang et al. 2014a; Sandberg et al. 2014). In Nrf2 knockout 
mice treated with the anticancer drug doxorubicin (Dox), the absence of Nrf2 amplified the 
adverse effects associated with Dox, such as cardiomyocyte necrosis, protein aggregation and 
cardiac dysfunction relative to wild type animals. In the same study the overexpression of Nrf2 
in cultured rat neonatal wild type cardiomyocytes suppressed Dox cytotoxicity, suggesting that 
Nrf2 ameliorates Dox-induced damage by triggering expression of antioxidants (Li et al. 2014a).  
 
2.2.4.5 BRAIN AND NERVOUS SYSTEM  
Subarachnoid haemorrhage (SAH) is caused by the rupture of a cerebral aneurysm and is 
characterised by bleeding in the space between the brain and the tissues that cover the brain 
(pia mater). In animal models, Nrf2 over-expression has been shown to reduce the secondary 
complications of SAH, such as vasospasm and neuronal injury. A SAH mouse model has been 
developed by injecting blood into the prechiasmatic cistern in the brain, this model has shown 
to cause cerebral vasospasm in the mouse. Deletion of Nrf2 in knockout mice resulted in more 
severe brain injury with increased brain edema, blood-brain barrier disruption and neural 
apoptosis after injection of blood into the prechiasmatic cistern (Li et al. 2014b). Induced 
activation and over-expression of Nrf2 protects neurons against stressors and insults and 
consequently the Nrf2-ARE pathway is an important potential target for neurodegenerative 
diseases and CNS disorders (Calkins et al. 2009).  
 
2.2.5 NRF2 IN NEURODEGENERATIVE DISEASES 
The pathogenesis of various neurodegenerative diseases such as Parkinson´s disease, 
amyotrophic lateral sclerosis, and Alzheimer´s disease have all been linked with oxidative stress 
and mitochondrial dysfunction (Perry et al. 2002; Jenner 2003; Barber et al. 2006).  
It has been shown, for example, that free radicals and reactive oxygen species (ROS) 
accumulation from redox imbalance leads to neuronal death and possible neurodegeneration 
(Dawson & Dawson 1996; Abramov et al. 2007). Astrocytes have several functions for the correct 
maintenance of neurons, it have been suggested that astrocytes can perform nervous system 
repair due to their relative high amount of key proteins and antioxidants (such as glutathione) 
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involved in neutralizing damaging free radicals (Aschner 2000; Kimelberg & Nedergaard 2010).  
Data from studies in animal models suggests that Nrf2 can rescue neurons and astrocytes from 
glutamate toxicity, ischemic insults and mitochondrial complex II inhibition (Kraft et al. 2004; 
Lee et al. 2005; Ramsey et al. 2008). Furthermore, overexpression of Nrf2 in astrocytes reduces 
chemical-mediated neurotoxicity in Parkinson´s and Huntington´s diseases and increases motor 
neuron survival in mouse models (Chen et al. 2009; Calkins et al. 2010; Gan et al. 2012). 
Malonate is used in animal models to induce neuron degeneration simulating Huntington’s 
disease. For example, a genetic model of astrocyte-specific Nrf2 overexpression showed greater 
neuroprotection against malonate toxicity in mice in comparison to wild type mice (Calkins et al. 
2010). Similarly, a study in mice in which 1-methy-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) 
was used to produce neurotoxicity of neurons in the substantia nigra, and consequently 
Parkinson’s disease-like symptoms, showed that Nrf2 overexpression eliminates MPTP toxicity 
and help prevent neuronal death (Chen et al. 2009). In an amyotrophic lateral sclerosis (ALS) 
animal model using transgenic mice with mutation in Cu/Zn-superoxide dismutase (SOD1), 
overexpressing Nrf2 resulted in delayed disease development, increased overall survival and 
lower glial reactivity (Vargas et al. 2008). If the Nrf2-ARE pathway is able to rescue cells against 
these insults and oxidative stressors, then the Nrf2 pathway might have an important role in 
neuroprotection as many studies have shown (Kraft et al. 2004; Vargas et al. 2008; Calkins et al. 
2009; Chen et al. 2009; Gan et al. 2012).  
 
2.2.6 MODULATORS OF THE NRF2/ARE PATHWAY 
There are several compounds or substances such as; sulforaphane, quercetin, tert-
butylhydroquinone (tBHQ) and 5,6-dihydrocyclopenta-1,2dithiole-3-thione (CPDT) that can 
induce and activate the Nrf2-ARE pathway (Gharavi et al. 2007; Kimura et al. 2009; Li et al. 2012). 
This activation has been measured by different approaches, including measurement of Nrf2 
nuclear translocation and induction of downstream antioxidant genes (i.e. NAD(P)H, GST and         
HO-1).   
As discussed previously, Keap1 is a cysteine rich protein, the cysteine residues are highly reactive 
and have the potential to sense modulators of Nrf2 forming disulphide adducts with them. These 
modulators activate the Nrf2/ARE pathway indirectly by directly modifying the sulfhydryl groups 
of Keap1 cysteines by oxidation, reduction, or alkylation, thereby avoiding the further 
ubiquitination of Nrf2 and releasing it from Keap1. Cysteine residues of Keap1 involved in Keap1-
Nrf2 degradation are Cys-151, Cys-273 and Cys-288 and small molecules that mimic ROS 
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(electrophiles) interact with these cysteine residues to change the conformation of Keap1, 
resulting in dissociation of Nrf2 from Keap1 and thereby inhibits Nrf2 ubiquitination and 
degradation (Fig. 2.7; Hong et al. 2005; Kobayashi et al. 2006; 2009). 
 
 
Figure 2.7. Keap1 cysteine residues involved in chemical inducers. Some electrophiles and heavy 
metals are able to modify the cysteine residues of Keap1, consequently this redox cysteine 
modifications induce conformational changes in Keap1 resulting in dissociation from Cul3, 
thereby inhibiting Nrf2 degradation. tBHQ, tert-butylhydroquinone; SFN, sulforaphane; DEM, 
diethyl maleate; DMF, dimethylformamide; 15d-PJ2, 5-deoxy-Delta(12,14)-prostaglandin J2; 
PGA2, prostaglandin A2; 4HN3, 4-hydroxynonenal; OA-NO2, nitro-oleic acid and 8-nitro-cGMP,  
8-nitroguanosine 30,50- cyclic monophosphate (Suzuki et al. 2013).  
 
One of the most studied Nrf2/ARE modulators is tert-butylhydroquinone (tBHQ), a 
hydroquinone derivative that protects neuroblastoma cells from glutamate toxicity and 
hydrogen peroxide (H2O2)-induced apoptosis (Lee et al. 2005) by binding with the cysteine 
residue Cys-151 of Keap1, followed by Keap1 change conformation to Nrf2 release, escaping 
ubiquitination and degradation (Zhang 2006).  tBHQ induces the Nrf2-ARE pathway by indirectly 
stimulating the dissociation of Nrf2 from Keap1 and Nrf2 then can be translocate to the nucleus 
and activate ARE gene expression. Additional studies used tBHQ and sulforaphane to induce 
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Nrf2-ARE pathway cellular protection by translating antioxidants proteins against oxidative 
insults such as dopamine, hydrogen peroxide and glutamate (Murphy et al. 1991; Li & Johnson 
2002; Houghton et al. 2016). In a mouse primary cortical neuronal culture study, overexpression 
of Nrf2 via adenovirus infection in Nrf2-deficient neurons restored ARE genes expression and 
conferred neuroprotection from H2O2 and glutamate (Kraft et al. 2004). Further, in astrocytes, 
the overexpression of Nrf2-sMAF made neurons more resistant to glutamate toxicity (Lee et al. 
2005). A microarray analysis showed the increase in expression of 97 genes and decrease of 37 
genes in astrocytes by tBHQ treatment, many of which included detoxifying genes involved in 
the Nrf2/ARE pathway (Calkins et al. 2009). However, there are concerns about the safety and 
toxicity of long-term administration of tBHQ with studies suggesting that long-term exposure 
might induce carcinogenicity in mice. For example, administration of tBHQ for several days to 
rodents was shown to induce more neoplastic lesions in the stomach, kidney and urinary bladder. 
However the specific mechanism, whether or not these effects are specifically related to the 
Nrf2 mechanism of this toxicity is not well understood, some alternatives are the indirect 
formation of reactive GSH-conjugates, activation of caspase and apoptosis, and the formation 
of reactive species (Li et al. 2002; Gharavi et al. 2007).  
Sulforaphane, a compound extracted from broccoli, has been shown to activate Nrf2 by 
modifying the Cys-151 of Keap1 protein (Kobayashi et al. 2009).  This compound has been shown 
to induce the activation of the Nrf2/ARE pathway in animal models of intracerebral 
haemorrhage and traumatic brain injury (Fig. 2.8). Accordingly, Nrf2 pathway activation after 
oxidative stress could help to restore or protect cells against toxicity, moreover Nrf2-deficient 
animals showed more severe damage against oxidative insults (Zhao et al. 2007a;  Zhao et al. 
2007b). For example, primary neurons  from Nrf2-decifient embryos and in vivo Nrf2-knockout 
mice increased toxicity after exposure to a mycotoxin 3-nitroproprionic acid (3-NP); a neurotoxin 
which induces brain mitochondrial dysfunction (selective loss of striatal neurons), simulating 
Huntington’s disease pathology (Fig. 2.9; Calkins et al. 2009). Similarly, experiments in animals 
of traumatic brain injury using the controlled impact surgery model showed that Nrf2 knockout 
mice displayed higher levels of oxidative markers such as, 4-hydroxynonenal (4-HNE) and the 8-
Oxo-2'-deoxyguanosine (8-OHdG) in brain after injury compared with the wild type mice, 
suggesting Nrf2 as a key role in oxidative stress response against brain injury (Hong et al. 2010).  
These same authors also treated mice with sulforaphane and it reduced contusion, neurological 
dysfunction and neuronal death after traumatic brain injury (Hong et al. 2010).  
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Sulforaphane is under clinical evaluation for schizophrenia, autism disorders and cancer; there 
are 52 different clinical studies for sulforaphane, which 28 are terminated or completed, 9 
recruiting, 2 enrolling, 8 not yet recruiting and 5 suspended or unknown (www.clinicaltrials.gov). 
An open study in ten patients with schizophrenia suggests sulforaphane as a potential 
therapeutic drug in improving cognitive functions in schizophrenia; trial number NCT01716858 
(Shiina et al. 2015). Two other clinical trials in phase II and III are currently enrolling to investigate 
if sulforaphane can improve clinical symptoms and cognitive functions in schizophrenia patients; 
trials NCT02880462 and NCT02810964.   
A randomised, double-blind, placebo-controlled phase II single-site trial of sulforaphane-rich 
broccoli sprout extract in autism patients showed that sulforaphane significantly improved 
social interaction, abnormal behaviour and verbal communication; however more further 
studies need to be perform to investigate the specific mechanism of action in autism disorder; 
trial number NCT01474993 (Singh et al. 2014). However, the toxicity and reactivity of the 
molecule might cause the termination of clinical trials and research investigations. Consequently, 
Evgen Pharma developed Sulforadex (SFX-01), an orally stable powder composed by 
sulforaphane encapsulated within α-cyclodextrin. Sulforaphane is normally an unstable oily 
liquid but in complex with α-cyclodextrin can be stabilized by encapsulating it in the hydrophobic 
interior of the core structure and making it available for pharmaceutical delivery for possible 
therapeutic effects. Two clinical trials to investigate the safety and tolerability of single and 
multiple doses of SFX-01 in healthy males have concluded but results have not been released 
(NCT01948362 & NCT02055716). Currently, another two clinical trials are recruiting for the 
study of safety, tolerability and efficacy of SFX-01 in breast neoplasm and spontaneous 
subarachnoid haemorrhage (NCT02970682 & NCT02614742, respectively).  
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Figure 2.8. Sulforaphane-induced activation of the Nrf2 pathway. A, Detection of Nrf2 protein 
by Western blot in nuclear fractions of hematoma-affected striata 24 hours after induction of 
intracerebral haemorrhage. Sulforaphane treatment increased Nrf2 in the nuclear fraction, 
consistent with a hematoma-induced translocation of Nrf2 from the cytoplasm to the nucleus. 
B, Study of the Nrf2 DNA binding activity to the antioxidant response elements (ARE). For the 
electrophoresis mobility shift assay (EMSA) experiments Nrf2 nuclear protein was incubated 
with 32P-labeled, double stranded oligonucleotides. Intraperitoneal injection of sulforaphane (5 
and 10 mg/kg) increased Nrf2 ARE DNA binding activity. 10 mg of nuclear protein extracts were 
run from 0, 5 and 10 mg/kg of sulforaphane treatment in animals. C, The expression of Nrf2 
antioxidant genes (measured by RT-PCR) in rodent brain following intracerebral haemorrhage 
and the administration of either vehicle or sulforaphane (5 mg/kg). Data clearly shows a SF-
induced increase in the expression of catalase, superoxide dismutase (SOD), glutathione S-
transferase (GST) and NAD(P)H:quinone oxidoreductase 1 (NQO1). D, Image of the data 
quantified in panel C showing the RT-PCR products of the downstream genes (catalase, SOD, 
GST, NQO1) of Nrf2/ARE pathway with GAPDH used as a loading control. Figure and legend 
adapted from Zhao et al. 2007b. 
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Figure 2.9. Nrf2 plays a role in 3-NP-mediated neurotoxicity. A, There was an increase in the 
toxicity of 3-NP in primary neurons (2 days of culture in 0.5, 1.0 and 2.0 mM 3-NP) from Nrf2 
knockout compared to wild type mice as measured using lactate dehydrogenase (LDH) activity 
in the media as an index of neurotoxicity. B, Striatum lesion volume was quantified in coronal 
sections of the brain and stained with cresyl violet and with fluorojade-B for detection of 
degeneration in neurons (Figure and legend adapted from Calkins et al. 2009). 
 
 
In mice the administration of the Nrf2 activator 3H-1,2,-dithiole-3-thione (D3T) prior to the 
injection of MPTP protected glial cells from neurotoxicity whereas this protective effect of D3T 
was lacking in Nrf2 knockout mice (Burton et al. 2006), consistent with D3T have a 
neuroprotective effect that is mediated via the Nrf2 pathway, possibly as a consequence of D3T 
binding with the cysteine reactive residues of the Keap1 protein and thereby producing Nrf2 
activation (Kwak et al. 2003).  
Other small molecules that are claimed to be Nrf2 activators include; curcumin, spirulina, some 
planar aromatic compounds, β-napthoflavone, 3-methylcholanthrene, triterpenoids, some 
flavonoids, isothiocyanates, organosulfur, indoles and diterpernes (Boutten et al. 2011; 
Sandberg et al., 2014). Moreover, small molecules that have a predisposition to react with 
sulfhydryl groups can interact with the keap1 protein and activate Nrf2-ARE pathway. For 
example, curcumin induces oxidation or alkylation of the cysteine residues in Keap1 and releases 
Nrf2 which translocates to the nucleus and produces a consequent increase in the expression of 
antioxidant enzymes (González-Reyes et al. 2013). However, the mechanism of action by which 
these molecules activates the Nrf2 pathway is not yet clear but most of them are hypothesised 
to modify cysteine reactive residues of Keap1.  
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Bardoxolone methyl (CDDO-Me) is a synthetic triterpenoid antioxidant inflammation modulator 
that activates the Keap1-Nrf2 pathway by binding with Keap1 cysteine residues (Wang et al. 
2014b). In a kidney injury model, the administration of CDDO-Me increases renal Nrf2 and heme 
oxygenase-1 (HO-1) mRNA expression and protein levels (Wu et al. 2011). Additionally, knockout 
mice demonstrated acute kidney defects caused by increased inflammation and oxidative stress 
(Pergola et al. 2011). For example, a study shown that CDDO-Me treatment in wild type mice 
prevents the increased concentration of urea nitrogen in blood characteristic in acute kidney 
injury (Wu et al. 2011). 
In a phase 2, double blind, randomized trial with chronic kidney disease associated with type 2 
diabetes patients, the administration of CDDO-Me significantly improved kidney functions 
relative to placebo-treated patients (Pergola et al. 2011). However, the phase III clinical trial in 
the late state of disease, patients developed severe renal dysfunction or cardiovascular failure 
in a higher rate with CDDO-Me treatment than with placebo; therefore the trial was terminated 
due to safety concerns (Pergola et al. 2011; de Zeeuw et al. 2013; Sandberg et al. 2014).  
Cardiovascular adverse events related with CDDO-Me were investigated and were suggested to 
have off-target effects in modulating the endothelin pathway by promoting acute sodium and 
volume retention and increasing blood pressure in patients with severe chronic kidney disease 
(Chin et al. 2014).  
There are some clinically used drugs that appear to activate the Nrf2 pathway, such as melatonin 
and valproate. Melatonin, which is used in sleep disorders in children, suppresses the 
degradation of Nrf2 by inhibiting the proteasome activity (Vriend & Reiter 2015). Valproate, 
which is used clinically as an anticonvulsant in epilepsy, as well as in anxiety disorders, migraine 
and bipolar disorders, has been demonstrated to increase cellular levels of reactive oxygen 
species (ROS) and activate the Nrf2/ARE pathway indirectly. In cellular and animal experiments  
the treatment of valproate increased the association of transcription factors, such as Nrf2 and 
nuclear factor-кB (NF-кB), as well as the levels of heme oxygenase-1 and human 
NAD(P)H:quinone oxidoreductase 1 genes (Kawai & Arinze 2006; Sandberg et al. 2014; Liao et 
al. 2016). However, the full mechanism of action is not well understood. 
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Table 2.1 Summary of Nrf2 activators and their therapeutic utility.  
Activator Pre-clinical/Clinical 
significance 
Comments Reference 
Sulforaphane  
Antioxidant, 
schizophrenia, autism, 
aging, asthma, cystic 
fibrosis and cancer  
Toxic, reactive and unstable.  
48 clinical trials to investigate 
specific mechanism of actions.  
 
www.clinicaltrials.gov 
(Singh et al. 2014; 
Alumkal et al. 2015; 
Shiina et al. 2015; 
Singh & Zimmerman 
2016) 
 
CDDO-Me 
Chronic kidney 
disease & type 2 
diabetes 
Serious adverse effects (heart 
failure, muscle spasms, etc)  
(Pergola et al. 2011; 
de Zeeuw et al. 2013) 
tBHQ Late-life Depression  
Dietary supplement (fish oil) 
High doses or chronic exposure 
link to carcinogenesis  
(Gharavi & El-Kadi 
2005) 
Quercetin  
Antioxidant and anti-
inflammatory 
properties. 
Obtained from plants 
(flavonols), used as a dietary 
supplement  and additive in 
food products  
(Harwood et al. 2007; 
Boots et al. 2008; Jin 
et al. 2010) 
 
D3T 
Chemopreventive and 
anti-inflammatory 
properties  
Cytotoxicity is not well 
understood 
(Kuo et al. 2016; Li et 
al. 2016) 
Curcumin 
Antioxidant and anti-
inflammatory 
properties 
 
Dietary supplement. Current 
clinical trials to study the effect 
and safety in the treatment of 
neurological diseases such as 
schizophrenia, Alzheimer’s 
disease, epilepsy and 
depression. 
(Kulkarni & Dhir 
2010) 
www.clinicaltrials.gov 
 
Spirulina  
Source of vitamins, 
minerals and 
phytonutrients 
Glucose metabolism 
in Diabetes.  
Dietary supplement (green 
algae).  
If contaminated can be unsafe 
for use (toxins and heavy 
metals). 
More research is needed for 
establish therapeutics benefits.  
(Gilroy et al. 2000; 
Gershwin & Belay 
2008; Marcel et al. 
2011) 
 
DMF 
Psoriasis, necrobiosis 
lipoidica, granuloma 
annulare, sarcoidosis 
and  
multiple sclerosis  
Drugs containing DMF have 
adverse side effects, such as 
gastrointestinal disorders and 
progressive multifocal 
leukoencephalopathy.   
(Nowack et al. 2002; 
Kreuter et al. 2005; 
Roll et al. 2007; 
Weber et al. 2009; 
Bovenschen et al. 
2010; Fox et al. 2012; 
Gold et al. 2012) 
Bardoxolone methyl (CDDO-ME), tert-butyhydroquinone (tBHQ), 3H-1,2,-dithiole-3-thione (D3T) 
and Dimethyl fumarate (DMF)  
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2.3 AIMS 
As described in the preceding sections, Nrf2 is an important transcription factor for redox 
homeostasis in cells and has a therapeutic potential in disorders associated with oxidative stress 
such as cancer and neurodegenerative disorders. Recently, several groups have reported a 
variety of small molecule Nrf2 activators that can enhance the function of the Nrf2/ARE pathway. 
However, these molecules, for example sulforaphane, valproate and others, are relatively 
unselective, which not only makes the interpretation of their effects within the central nervous 
system difficult but also can result in off-target side effects (i.e., non-Nrf2-related). 
The aim of this work is to identify novel and specific small activators of this pathway which will 
be expected to have an improved selectivity and safety profile relative to existing activators. The 
approach is to exploit X-ray crystallographic structural information regarding the Nrf2-Keap1 
protein-protein interaction to conduct a virtual screen of molecules that might interrupt the 
protein-protein interface and thereby cause Nrf2 to dissociate from or prevent the association 
with Keap1, resulting in an increase in free cytosolic protein that is then available to translocate 
to the nucleus. Compounds selected from the virtual screen will then be purchased and 
evaluated in a DiscoverX PathHunter enzyme fragment complementation cellular assay 
designed to measure the translocation of Nrf2 from the cytoplasm into the nucleus.  
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2.4 MATERIALS AND METHODS  
2.4.1 MATERIALS 
Description Use for 
Supplier and Catalogue 
Number 
Select U2OS cell culture kit Cell culture DiscoveRx  (92-0018GL3) 
Cell plating 0 reagent Cell plating DiscoveRx (93-0563R0A) 
Revive U2OS medium Cell thawing DiscoveRx (92-0016RM5S) 
Preserve U2OS freezing reagent Cell freezing DiscoveRx (92-0017FR3S) 
Cell detachment reagent Cell detachment DiscoveRx (92-0009) 
Hydrogen peroxide solution Cell oxidant reagent  Fluka  (Sigma Aldrich, 88597) 
DL-Sulforaphane  Cell oxidant reagent Sigma Aldrich (S4441) 
PBS Assay buffer Sigma Aldrich (79382) 
DMSO Assay buffer Fisher chemical (10080110) 
Corning® 384 Well flat clear 
bottom white polystyrene TC-
treated microplates 
Cell seeding for assay  Corning (3707) 
96-V well microplate translucent 
polypropylene 
Source dilution plate 
MIC9050, Scientific 
Laboratory Supplies 
 
 
2.4.2 METHODS  
 2.4.2.1 VIRTUAL SCREENING STRATEGY 
In the protein data bank (PDB) there are eighteen crystal structures relating to Keap1-Nrf2 
binding interface, some structures display the apo state of the protein (with no ligand) and 
others are in the holo state (with ligand). The SDDC’s computational chemist, Dr. Ben Wahab, 
performed the structural superpose and alignment of sixteen crystal structures from the PDB 
(Table 2.2) resulting in a root-mean-square deviation (RMSD) of 0.451 Å over 285 residues 
(alignment results shown in Appendix I). The RMSD value was used to study the similarity 
between structures, the low RMSD obtained demonstrated a similar conformation between the 
PDB structures of Keap1 (given that the structures were both holo and apo, it indicates a 
reasonably rigid protein). The alignment and super-positioning results were used for the 
investigation of interactions between the sixteen structures and the ones displaying the Keap1-
Nrf2 interactions were used as a guide for pocket analysis and pharmacophore design.  
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PDB 1X2R displays Keap1 as a forked-stem dimer structure in a large globular conformation 
(known as a multiple tryptophan-aspartic acid (WD)-40 β-propeller structure) in which the Neh2 
ETGE sequence region of Nrf2 binds with high affinity in the homodimer. The structures of Keap1 
with Nrf2 or similar peptides were used as a reference for the modelling and virtual screening 
experiments (Fig.2.10).  
 
Figure 2.10. Nrf2-Keap1 protein-protein interface. A. Nrf2 peptide LDEETGEFL from the Neh2 
region in green and Keap1 protein in pink from 1X2R structure. B. Keap1-Nrf2 binding pocket 
with surface with Nrf2 like-loop of known structures Cpd15 (yellow and cyan) and Cpd16 (red) 
from PBD 4IN4 and 4IQK. Surface in green is hydrophobic, purple is hydrophilic and white/grey 
is neither. Structures generated by Maestro Schrödinger 11.1 (Maestro, Schrödinger, LLC, New 
York, NY, 2017).  
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Table 2.2. Keap1/Nrf2 crystal structures used for modelling.  
PDB 
ID 
Resolution 
(Å) 
Comments Reference 
 
1U6D 
 
1ZGK 
 
1X2J 
 
1X2R 
 
2DYH 
 
2Z32 
 
 
3ADE 
 
3VNG 
 
 
3VNH 
 
 
3ZGD 
 
4IN4 
 
4IQK 
 
3WDZ 
 
4IFL 
 
4IFN 
 
3WN7 
 
1.85 
 
1.35 
 
1.60 
 
1.70 
 
1.90 
 
2.00 
 
 
2.80 
 
2.10 
 
 
2.10 
 
 
1.98 
 
2.59 
 
1.97 
 
2.60 
 
1.80 
 
2.40 
 
1.57 
 
Apo of human Keap1   
 
Apo of human Keap1 
 
Apo of mouse Keap1  
 
Mouse Keap1 with Neh2-ETGE peptide  
 
Mouse Keap1 with Neh2-DLG peptide 
 
Mouse Keap1 in complex with 
ProTalpha 
 
Mouse Keap1 with Sequestosome-1 
 
Human holo Keap1 with small 
molecule 
 
Human holo Keap1 with small 
molecule 
 
Apo of human Keap1 
 
Human Keap1 in complex with Cpd 15 
 
Human Keap1 in complex with Cpd 16 
 
Mouse Keap1 in complex with p62 
 
Apo of human Keap1 
 
Human holo Keap1 with peptide  
 
Mouse Keap1 with Nrf2-DLG region 
 
 
(Li X. et al. 2004)  
 
(Beamer et al. 2005) 
 
(Padmanabhan et al. 2006) 
 
(Padmanabhan et al. 2006) 
 
(Tong et al. 2007) 
 
(Padmanabhan et al., 2008) 
 
 
(Komatsu et al. 2010) 
 
(Satoh et al. 2015) 
 
 
(Satoh et al. 2015) 
 
 
(Hörer et al. 2013) 
 
(Marcotte et al., 2013) 
 
(Marcotte et al., 2013) 
 
(Ichimura et al. 2013) 
 
(Pan et al. 2012) 
 
(Pan et al. 2012) 
 
(Fukutomi et al. 2014) 
Sixteen structures were used for modelling. 3ZGC (Hörer et al. 2013) structure was not used due 
to mutations with the crystal contacts with Nrf2 for blocking binding interactions. 2FLU (Lo et al. 
2006) structure was not used because there were already enough crystals structures for virtual 
screening.  
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Pocket analysis and pharmacophore design 
The Keap1-Nrf2 interactions to disrupt by ligands are between Glu-79 of Nrf2 with Arg-415, Arg-
486 and Ser-508 of Keap1; and also Glu-82 from Nrf2 with Arg-380, Asn-382 and Ser-363. The 
pocket analysis was based on five holo structures (with Nrf2 or similar peptide): 1X2R, 3VNG, 
3VNH, 4IN4 and 4IFN.  Dr. Ben Wahab investigated the key interactions between Keap1 and Nrf2 
binding interface which resulted in the following interactions. It is important to note that 
sequence numbering is based on the Keap1 1X2R structure, corresponding to sequence Q9Z2X8 
from the UniProt Knowledgebase (UniProtKB). Structure 4IN4 has multiple conformations; three 
biological assemblies generated by protein interfaces, surface and assemblies (PISA) software 
(Marcotte et al., 2013). 
 
1X2R: Keap1 in complex with Nrf2 peptide from Leu-76 to Leu-84 (LDEETGEFL) from sequence 
Q60795 of UniProtKB (Padmanabhan et al. 2006). 
 
Key interactions 
Water 35, 27, 90 
Asn 382 
Arg 380 
Ser 363 
Ser 602 
Arg 415 
Arg 483 
Ser 508 
Glu 530 
 
3VNG & 3VNH: Keap1 in complex with small molecule that mimics the ETGE Nrf2 motif (Satoh 
et al. 2015). 
 
Key interactions 
3VNG: Asn382 , Arg 380 
3VNH:  Arg 483, Arg 415, 
Water 723 
     
4IN4: Keap1 in complex with a benzenesulfonyl-pyrimidone compound (Cpd15) (Marcotte et 
al., 2013).  
 
Key interactions 
1: Ser 363, Gly 603, Arg 
380,  Arg 415  
2: Arg 483, Ser 555  
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       4IFN: Keap1 in complex with compound (Pan et al. 2012). 
 
Key interactions 
 
Ser 602 
Arg 415 
Asn 414 
Diagram and results generated by Dr. Ben Wahab and modified for the purposes this thesis.  
 
 
Part of the pocket analysis was to study the conserved water molecules involved in the binding 
pocket, with a total of fifteen conserved molecules around the binding space and four under the 
pocket (Appendix I). Conserved water molecules are believed to be important for binding 
interactions between both proteins. A set of 22 pharmacophores were designed around the 
known interactions from the documented binders with each pharmacophore having at least 
three features of the binding pocket (pharmacophore list in detail generated by Dr. Ben Wahab 
in Appendix I).  
1.8 million compounds from the SUNScreen internal database were pre-screened with the 
designed pharmacophores using the Molecular Operating Environment (MOE) software. This 
pre-screening identified 1901 unique hits, from which 1,000 were docked into the 1X2R 
structure using MOE. The compounds were filtered by structural and physicochemical criteria 
and 250 compounds were analysed for medicinal chemistry appraisal. A total of 122 compounds 
were purchased from preferred suppliers for testing (Fig. 2.11). 
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Figure 2.11. Summary of the virtual screening strategy. SUNScreen is the Sussex University NICEr 
database of materials from reliable preferred suppliers, filtered by structural and 
physicochemical criteria. 1.8 million compounds were subjected to pharmacophore screening, 
resulting in 1901 unique hits that were subjected to docking analysis based on a score system 
that measured the energy of the binding, surface dynamic, impact of the pocket, etc. Next steps 
included assessment and analysis to filter compounds by structural and physicochemical criteria. 
The medicinal chemistry appraisal was used to select the compounds with best features for 
design and synthesis of compounds. Finally 122 compounds were purchased for screening assay 
(35 compounds were not available).  
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2.4.2.2 NRF2 ENZYME FRAGMENT COMPLEMENTATION ASSAY  
The assay is based on enzyme fragment complementation technology (from DiscoveRx, 
PathHunter). In this approach, the complementing fragments of β-galactosidase are expressed 
in different compartments of stably transfected U2OS cells (Fig. 2.12). Upon nuclear 
translocation of the Nrf2 from the cytosol within the cells, the two β-gal fragments complement 
forming a functional enzyme that hydrolyses substrate and generate a chemiluminescent signal.  
 
 
 
 
 
 
 
 
 
 
Figure 2.12. PathHunter Nrf2 nuclear translocation assay mechanism.  A small inactive fragment 
of β-gal (enzyme donor, ED) was fused into the Nrf2 protein in U2OS cells. Another inactive 
fragment termed enzyme acceptor (EA) is located in the nucleus. Nrf2 dissociation from Keap1 
results in Nrf2 nuclear translocation and complementation of both β-gal fragments (ED+EA), 
forming a functional enzyme. Enzyme activity is then quantitatively detected as 
chemiluminescent signal (active substrate).  
 
 
Figure 2.13. Summary strategy followed for compound characterisation methodology. Single 
point assay compound hits were followed up by measuring EC50 in a biological assay, then 
verification of cellular viability and ROS generation to finally characterise the Nrf2 nuclear 
expression by western blotting.   
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2.4.2.2.1   ASSAY DEVELOPMENT  
U2OS cells were harvested from a T75 flask and seeded into a 384-well microplate (final 
concentration of 5,000 cells per well) and incubated overnight at 37°C in 5% CO2. Next day a 
series of ten 3-fold serial dilutions of sulforaphane in dimethyl sulfoxide (DMSO) were prepared, 
final top concentration of 5 μM in a 96-well plate. The concentration of each dilution was 
prepared at 5X the final screening concentration (5 μl compound + 20 μl of cells). The same 
procedure was followed for control wells PBS/DMSO. 5 μl of sulforaphane (5X) was transferred 
into the 384-well microplate (cells) and incubated for 90 minutes at 37°C in 5% CO2, following 
the addition of detection reagent (12 μl) to each well, for a final well volume of 37µl. Plates were 
then incubated at room temperature in the dark for 1 hour after which luminescence was read 
using the plate reader Pherastar FS from BMG Labtech (Optic module LUM plus, Gain 3600 and 
optic used measurements from top).  
 
 
Figure 2.14. General procedure of the PathHunter kit for assay development and screening 
compound.  
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DMSO Tolerance 
Dimethyl sulfoxide (DMSO) is used as a solvent to solubilise and dilute compounds that are 
difficult to dissolve in water of other assay buffers. Solvents can affect the assay performance, 
thus a DMSO tolerance curve was performed to ensure cell tolerance to DMSO. The cellular 
assay was tested at different concentrations of DMSO: 0.03%, 0.1%, 0.3%, 0.7%, 1.0% and 2.0%.  
Incubation Conditions  
To validate the assay different incubation conditions were tested. The incubation of cells 
exposed with compounds was tested at two different temperatures: room temperature and 
37°C. In order to observe the optimal incubation time the luminescence signal was read every 
hour up to 6 hours. A control of DMSO/PBS was performed to observe the basal values.   
 
2.4.2.2.2 ASSAY VALIDATION (LITERATURE COMPOUNDS) 
U2OS cells were harvested from a T75 flask and seeded into a 384-well microplate (final 
concentration of 5,000 cells per well) and incubated overnight at 37°C in 5% CO2. The next day 
a 96-well plate with compounds and controls was prepared, the compounds were tested in a 
final maximal concentration of 30 µM (for single point experiments) and 88 µM (for assay 
experiments, EC50 determination, compound concentration was determined by the maximum of 
DMSO allowed in the assay) diluted in DMSO, final DMSO concentration 0.3% and 1% 
respectively. Sulforaphane was included in each plate as a positive control. 5μl of testing 
compound (5X) was transferred into the 384-well microplate (cells) and incubated for 90 
minutes at 37°C in 5% CO2, following which detection reagent (12 μl) was added to each well. 
Plates were then incubated at room temperature in the dark for 1 hour after which 
luminescence was read using a BMG Pherastar FS reader.  
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2.4.2.2.3 COMPOUND SCREENING  
A library of 122 compounds were screened for activity on Nrf2 nuclear translocation, using the 
PathHunter Keap1-Nrf2 assay (DiscoverX). The compounds were prepared in stocks of 10 mM 
with DMSO. From the compound library, the compounds were screened for single point 
detection at 30 μM final concentration (0.3% DMSO). Sulforaphane at 5 μM and DMSO/PBS at 
0.3% were used as positive and negative controls respectively.  
After the detection of hit compounds from single point assay, an EC50 assay was performed using 
a FluidX Xpp-721 robot for compound addition. The compounds were tested with a series of ten 
1:3 serial dilutions in DMSO, top concentration of 88μM this maintained the DMSO percentage 
in 1%, as recommended by the assay supplier. 
384-well assay plate map format for FluidX Xpp-721 robot:  
 
Numbers indicate each different compound, for example all wells in number 1 corresponding to 
the same compound in different serial dilutions.   
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2.4.2.3 VIABILITY ASSAY  
Compounds that were active in the EC50 assay were assayed to ensure they were not toxic in 
cells. To confirm the toxicity of the compounds, an ATP viability assay (CellTiter-Glo® 
Luminescent cell viability assay, Promega) was performed. The assay measures the viable cells 
in culture based on the quantitation of the ATP in the cells by adding a single reagent that causes 
the formation of oxyluciferin and a luminescent signal (luciferase reaction) in the presence of 
ATP from viable cells (Fig. 2.15).  
U2OS Nrf2 cells were seeded into a 384-well plate, compounds at 88 µM were added and 
incubated for 2 hours at 37°C, 5% CO2. The cells were then equilibrated at room temperature 
for 30 min. CellTiter-Glo reagent was added (25 μl) and incubated for 10 minutes at room 
temperature. The ATP concentration was detected as relative light units (RLU) using a 
luminometer reader.  
 
 
Figure 2.15. CellTiter-Glo® luminescent cell viability assay principle. Viable cells generated ATP, 
upon lysis of cells, mono-oxygenation reaction of luciferin is catalysed by luciferase recombinant 
reagent with the help of ATP, Mg2+ and O2.  (Figure adapted from https://www.promega.co.uk/-
/media/images/resources/figures/9100-9199/9155ma-mod.jpg). 
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2.4.2.4 DETECTION OF REACTIVE OXYGEN SPECIES (ROS)  
In order to confirm if the compounds were non-specifically disrupting the protein-protein 
interaction the production of free radicals was measured. If compounds are highly reactive and 
react with the cysteine residues of Keap1 it will produce a large amount of free radicals, 
suggesting that the activation of Nrf2 pathway is non-specific. Consequently, the ROS-Glo™ H2O2 
Assay from Promega was used to measure the levels of H2O2 directly in U2OS cell culture.  
5,000 U2OS Nrf2 cells in 20 µl were seeded into 384-well plates. The compounds, sulforaphane 
and Menadione (a free radical generator that induced cell death was recommended by supplier 
Cat. No. M5625, Sigma Aldrich) controls in combination with the H2O2 substrate solution (20 µl) 
were added and incubated for 2 hours at 37°C, 5% CO2. A volume of 40 µl of ROS-Glo detection 
solution was then added and left at room temperature for 20 minutes to equilibrate the plate. 
The luminescence signal was then detected using a BMG Pherastar FS reader.  
 
 
Figure 2.16. Ros-Glo H2O2 assay reaction. Luciferin H2O2 substrate incubated with sample reacts 
directly with H2O2 to generate a luciferin precursor. After the addition of a second reagent with 
recombinant luciferase, ATP and D-cysteine, the precursor is converted to luciferin to produce a 
light signal. The signal is proportional to the levels of H2O2 in the sample.  
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2.4.2.5 COMPOUND CHARACTERISATION  
 
2.4.2.5.1 CELL CULTURE 
U2OS-Nrf2, U2OS WT and HEK293 cells were cultured as a monolayer using Dulbecco`s modified 
eagle medium Life Technologies, Gibco™) supplemented with 10% fetal bovine serum (Life 
Technologies, Gibco™)  and 5% penicillin-streptomycin (Life Technologies, Gibco™) at 37oC and 
5% CO2. 
 
2.4.2.5.2 CELL FRACTIONATION 
The cells were cultured for 3 days in T75 flasks, then washed with PBS and harvested with trypsin. 
Cells were pelleted by centrifugation (500g for 3 min) and the pellet was washed 3x with PBS, 
and then resuspended in 300µl of lysis buffer (20 mM Tris-HCl, 101 mM NaCl, 1 mM EDTA, 0.5% 
Triton X-100, protease and phosphatase inhibitor cocktail, Roche). After incubation on ice for 15 
min, with vortexing every five minutes, cells were centrifuged at 1,000g for 10 min. Supernatants 
(cytosolic extract) were collected and nuclear pellet was washed 3x with PBS and resuspended 
in 50µl of lysis buffer. The nuclear fraction was sonicated for 30s (Sonics, Vibra cell sonicator). 
The protein levels in both fractions were quantified using the Bicinchoninic acid protein (BCA) 
assay kit from Sigma-Aldrich.  Both the supernatant (cytosol) and pellet (membrane and nuclei) 
fractions were used for Western blot analysis to measure the levels of Nrf2 protein expression.  
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2.4.2.5.3 WESTERN BLOTTING  
The cellular fractions were diluted with 10 μl of SDS sample buffer.  30-60 µg of protein content 
were separated using SDS-PAGE gel (NUPAGE 4-12%, 140V for 1 hour) and transferred onto a 
PVDF membrane (Amersham Hybond™-P 0.45, Cat. No.10600023, GE). The membrane was 
blocked overnight with 5% non-fat dry milk in PBST at 4oC. The membrane was then probed with 
primary antibodies* overnight at 4oC. The next day the membrane was washed 1x15 minutes 
and 3x5 minutes with PBST and then incubated with HRP secondary antibody for 45 minutes at 
room temperature. Blots were washed 1x15 minutes and 3x5 minutes with PBST, and then 
developed using a Pierce ECL detection reagent and exposed to X-ray film (CL-Xposure film, Cat. 
No. 34089 Thermo Scientific).  
The Nrf2 protein has a predicted molecular weight of 68 KDa; the Nrf2 antibody was validated 
from supplier Abcam to detect a band of approximately 110 kDa in western blot experiments 
(http://www.abcam.com/nrf2-antibody-ab137550.html). The antibody had been used for 
detecting Nrf2 protein in western blot experiments in published literature (Yamashita et al. 2014; 
Grootaert et al. 2015; Yamada et al. 2016 & Sun et al. 2017).  
*The following antibodies were used: 
Primary antibodies  
Antibody Type Dilution Supplier Cat. No. 
Nrf2 Rabbit polyclonal 1:1000 Abcam ab137550 
GAPDH Mouse monoclonal  0.5µg/ml Novus biological NB600-502SS 
H2B Rabbit polyclonal 1:10,000 Abcam ab1790 
 
Secondary antibodies  
Antibody Type Dilution Supplier Cat. No. 
HRP-Ab Anti-rabbit IgG 1:30,000 GE Healthcare Life Sciences NA934 
HRP-Ab Anti-mouse IgG 1:10,000 Dako P0260 
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2.5 RESULTS  
2.5.1 NRF2 ENZYME FRAGMENT COMPLEMENTATION ASSAY 
2.5.1.1 ASSAY DEVELOPMENT  
In the Nrf2 cellular assay sulforaphane was used as a control because it is well known that 
sulforaphane induces the nuclear translocation of Nrf2 by reacting with the cysteine residues of 
Keap1. The general methodology recommended by the supplier was performed. Hence, 
sulforaphane was added into cells at 5 µM (3-fold serial concentrations) with 0.3% of DMSO. As 
shown in Fig. 2.17, increase of sulforaphane concentration results in a proportional increase of 
chemiluminescent signal, indicating the nuclear translocation of Nrf2 by this compound. EC50 of 
400 nM was obtained, similar to the manufacturer’s value of 506 nM (from supplier validation 
results, DiscoveRx). Control wells with PBS/DMSO gave a baseline in the graph.  
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Figure 2.17. Effect of DL-Sulforaphane on Nrf2 nuclear translocation in the U2OS Nrf2 assay. 
Sulforaphane tested at a maximal concentration of 5 μM gave an EC50 of 400 nM. Error bars 
represent the mean ± SD of n=3 individual experiments performed within one week. Signal-to-
noise ratio S/N = 3.28, in which S is the average of the higher values and N is the average of the 
control values (PBS/DMSO). Experiments performed at 37°C for 90 minutes and DMSO final 
concentration of 0.3%. Y-axis in relative luminescence units (RLU) and X-axis is the concentration 
of compound in molar units.  
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DMSO Tolerance  
Different percentages of DMSO in the assay were tested, the results are the following: 
DMSO % 
Average 
EC50  (nM) 
S/N 
0.03 % 570.5 4.0 
0.1 % 385.6 4.4 
0.3 % 450.6 3.9 
0.7 % 415.5 3.8 
1.0 % 376.6 4.0 
2.0 % 596.8 4.3 
  
The EC50 values and signal-to-noise ratios were similar at different DMSO percentages. The assay 
demonstrated good tolerance up to 2.0 % of DMSO, indicating that compounds can be dispensed 
at 2% DMSO with a final assay concentration of 200 µM. Percentage of DMSO is the final 
concentration in the assay. The potency of sulforaphane was slightly higher with 1.0% this could 
be for the better solubility of the compound in the solvent.  
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Figure 2.18. DMSO tolerance curve. Sulforaphane tested at different concentrations of DMSO. 
Error bars (SD) represent the mean ± SD of n=3 individual experiments. S/N was calculated with 
the average of the higher and lower values. Experiments performed at 37°C for 2 hours to test 
the maximal incubation time of 90 minutes.  Y-axis in relative luminescence units (RLU) and X-
axis is the concentration of compound in molar units. 
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 Incubation Conditions 
In order to obtain the optimal incubation time and temperature conditions for the test 
compounds, the signal and S/N from the control compound sulforaphane were compared at 
room temperature (RT) and 37°C. The plate was read every hour for 6 hours (Fig. 2.19). The 
optimal incubation time was 2 hours at 37°C, reaching the highest intensity with sulforaphane 
control and highest S/N value of 3.9. To summarize, the optimal conditions for the assay test 
with sulforaphane was to incubate plates at 37°C for 2 hours, followed by further incubation 
with the detection reagent for 1 hour at room temperature in the dark. With a range of final 
DMSO concentrating in the assay from 0.03% to 2.0%. These conditions will be used for the 
compound screening single point and EC50. 
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Figure 2.19. Comparison of incubation times at 37°C vs RT at 6 hours with sulforaphane 
compound. Sulforaphane optimal EC50 value at room temperature was at 6 hours with 204.1 nM. 
The EC50 values at 37°C incubation for 6, 2 and 1 hour were 314.7 nM, 341.7 nM and 216.7 nM 
respectively. The S/N values are displayed in the table below the graphs. Y-axis in relative 
luminescence units (RLU) and X-axis is the concentration of compound in molar units, n = 1 
experiment.  
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2.5.1.2 ASSAY VALIDATION (LITERATURE COMPOUNDS) 
Previous studies (Kanno et al., 2012; Marcotte et al., 2013) using virtual screening and confirmed 
with luciferase cell assay, suggest that these novel small molecules disturb the protein-protein 
interaction between Keap1-Nrf2. Three such compounds were synthesised in-house and tested 
with the Nrf2 assay: N-(4-(2-pyridyl)(1,3-thiazol-2-yl))-2-(2,4,6-trimethylphenoxy) acetamide 
(CPN-9) (Kanno et al., 2012), and two benzene-disulfonamide compounds (Marcotte et al., 2013) 
named in-house as compound 13545 and 13546.  
 
Figure 2.20. Chemical structure of literature compounds. Novel Nrf2 activators CPN-9 (Kanno et 
al. 2012), compounds 13545 and 13546 (Marcotte et al. 2013). These compounds have been 
shown to protect cells against oxidative stress and cell death in vitro experiments.  
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Figure 2.21. Activity of testing compounds by Nrf2 cellular assay. Cells U2OS were tested with 
each compound at maximum concentration of 70 μM and sulforaphane at 8 μM. Y-axis in 
relative luminescence units (RLU) and X-axis the concentration of compound in molar units,          
n = 1 experiment.  
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It was expected that the three compounds would give a high signal of Nrf2 induction. Only the 
compound 13546 produced Nrf2 translocation into the nucleus with an EC50 of 9.4 µM (literature 
EC50 of 2.7 µM) and the sulforaphane control of EC50 0.87 µM (Fig. 2.21).  
 
2.5.1.3 COMPOUND SCREENING  
122 compounds were screened in a single point assay of which 11 hit compounds were detected 
with at least 15% activity normalized relative to the sulforaphane control. EC50 values were 
obtained to confirm the Nrf2 activity. From the 11 compounds only 5 compounds showed 
activity in the Nrf2 assay (Table 2.3, Fig. 2.23).   
Table 2.3. Compounds with Nrf2 activity. Compounds that showed activity in the Nrf2 
translocation assay, % normalised with sulforaphane control at 5 µM.  
 
Compound % activity 
UOS-00014231-001 25 % 
UOS-00014239-001 20 % 
UOS-00014262-001 ˃100 % 
UOS-00014265-001 15 % 
UOS-00014266-001 40 % 
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Figure 2.22. Compounds with a possible Keap1-Nrf2 activity. The compounds were tested with 
a final concentration of 88 μM, using a sulforaphane control of 5 μM. Data and graphs analysed 
with the Domatics Studies Notebook analysis package. Red dots are automatically excluded data 
points that are distant from the mean (error points, away from the standard deviation) 
generated by Domatics Studies.  Y-axis is % of response normalized with control and X-axis is the 
concentration of compound in nanomolar, n = 2 experiments.  
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Figure 2.23. Chemical structure of the hit compounds for Nrf2 activity. 
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2.5.2 VIABILITY ASSAY 
The five novel compounds, plus the literature compound 13546 were not toxic to U2OS cells 
during a 2 hour exposure time. After 2 hours the cell viability decreases by only ~5% in all 
compounds and the control sulforaphane. This shows that the compounds are not toxic and do 
not cause cell death when incubated for 2 hours. Hydrogen peroxide (H2O2) is well known to 
induce cell death (Whittemore et al. 1995), for that reason it was used as a control in the viability 
assay. It was observed that higher concentration of H2O2 decrease significantly the 
concentration of ATP (Fig. 2.24) in cells indicating cell death and toxicity, the levels of ATP are 
directly proportional to the number of viable cells present in the well. The low concentrations 
of H2O2 displayed higher levels of RLU, the possible reason for this is that the dose-curve of H2O2 
was performed in a different plate from the compounds, the number of cells might vary from 
plate to plate increasing the RLU detection.  
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Figure 2.24. U2OS viability assay with test compounds. Compounds and control hydrogen 
peroxide were tested at 88 µM, 1:3 serial dilutions, n = 1 experiments. Plate incubated at 37°C 
for 2 hours. RLU is proportional to the concentration of ATP from cells, only hydrogen peroxide 
displayed a significant decrease of ATP in cells suggesting cell death.  
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2.5.3 DETECTION OF REACTIVE OXYGEN SPECIES (ROS)  
As previously discussed, compounds with Nrf2 assay activity can either interact by specifically 
disrupting the protein-protein interaction or non-specifically by causing ROS, which results in a 
change in Keap1 conformation as a result of interacting with cysteine residues of Keap1 protein. 
The purpose of this experiment was to measure the generation of ROS by test compounds. If 
compounds increase ROS levels it suggests interaction with Keap1 cysteine residues.  
The ROS-Glo H2O2 assay was used to measure the increase of ROS generated in cells, after 2 
hours exposure of test compounds. Menadione was used as a control, since it is well known to 
induce reactive oxygen species and sulforaphane is well known to interact with Keap1 cysteine 
residues.  
As can be seen in Fig. 2.25, the majority of the compounds induced reactive oxidant reagents as 
indicated by an increase in the luminescence signal. These results suggested that the compounds 
affect the Keap1-Nrf2 protein interaction by indirectly causing stress or reacting with the 
cysteine residues of Keap1, but not interacting at the protein-protein interface pocket. The 
compounds UOS-00014231 and UOS-00014239 showed a decrease in ROS, suggesting a possible 
Nrf2-Keap1 direct interaction. The decreasing level of ROS can be due to the production of 
antioxidants by the nuclear translocation of Nrf2. The next step was to observe the translocation 
activity of the compounds by western blot analysis.  
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Figure 2.25. ROS induction in U2OS-Nrf2 cultured cells. The cells were treated with increasing 
concentrations of compounds with a maximum concentration of 88 μM. Controls: Menadione 
and Sulforaphane. The response values in the Y-axis correspond to the relative luminescence 
units (RLU) and X-axis correspond to the concentration of compound in nanomolar, n=1 
experiments, red dots in the graph are being excluded automatically by the program. Data and 
graphs analysed with the Domatics Studies Notebook analysis package. The compounds 
displayed an increase in ROS generation, except compounds 14231 and 14239 that showed a 
reduction in ROS generation suggesting a regulated balance induced by Nrf2-ARE pathway 
activation.  
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2.5.3 WESTERN BLOT 
2.5.3.1 NRF2 DETECTION IN WILD TYPE U2OS CELL LINE  
In order to observe nuclear translocation of Nrf2, the effects of oxidative stress were studied in 
wild type (WT) U2OS cells. Sulforaphane has been shown to activate the Nrf2-Keap1 pathway 
and induce the phase II antioxidant genes (i.e. GSTs, NQO1, HO-1 and TXNRD1) by reacting with 
the cysteine residues of Keap1 protein (Bryan et al. 2013; Baird et al. 2014). Accordingly, 
sulforaphane was chosen as a positive control in U2OS for inducing the nuclear translocation of 
Nrf2. Sulforaphane has been tested in the literature at different concentration from 5-50 µM in 
different cell lines such as, HEK-293, HeLA, COS1, MDA-MB-231 and CaCO2 (Traka et al. 2005; 
Juge et al. 2007; Kanematsu et al. 2010; Lau et al. 2013; Kemmerer et al. 2015; Ullah 2015). From 
the different concentrations tested in the literature it was decided to exposed U2OS cells with a 
high concentration of sulforaphane (40 µM) to be able to observe an Nrf2 nuclear translocation 
induction. Nrf2 is predicted to display a band of ~65 kDa, however the antibody supplier (Abcam) 
and the literature had found evidence that the biologal relevant species of Nrf2 migrates at ~110 
kDa in a denaturing gel (SDS-PAGE) (Lau et al. 2013 & Grootaert et al. 2015). It had been 
suggested that in the nucleus Nrf2 is bound to ubiquitin so the molecular weight would be higher 
than cytoplasm, other suggested reasons are; post-translational modifications, splice variants 
and the relative charge of the composition of amino acids. Additionally, different commercially 
available antibodies were able to only detect a band of Nrf2 ~100 kDa, such as; NovusBio (NBP1-
32822), Cell signaling technology (12721), Abcam (ab62352) and R&D systems (AF3925 & 
MAB3925). A comparison of commercially available Nrf2 antibodies in a 7.5% SDS-PAGE with 
sulforaphane treatment displays a band at ~100 and 72 kDa (Lau et al. 2013). In these 
experiments the Nrf2 protein band was also detected at ~100 kDa in the nuclear fractions.  
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Figure 2.26. Wild type U2OS cells vs U2OS with sulforaphane treatment. U2OS cells were 
incubated with 40 µM of sulforaphane (SFN) or 0.4% DMSO in PBS for 2 hours. Cell fractions 
were subjected to western blot analysis.  The controls for the cytosolic and nuclear fractions 
were GAPDH and H2B respectively and were used to verify the differential centrifugation 
experiments. GAPDH is an enzyme that catalyses several steps of glycolysis in the cytosol of cells 
and is highly expressed in all cells; H2B is a histone involved in the chromatin production and is 
localised only in nuclear cells.  
 
The differential centrifugation fractionation protocol worked since GAPDH and H2B were 
preferentially enriched in the correct cellular fractions (cytosolic and nuclear respectively). 
Increased translocation of Nrf2 from the cytoplasm to the nucleus was not observed in cells 
treated with sulforaphane, cytoplasmic Nrf2 was observed in relative low levels in the control 
conditions, indicating none or low levels of Nrf2 to translocate.  This could be due to U2OS cells 
being a cancer cell line (osteosarcoma) and as a consequence alternative defence pathways 
against oxidative stress are highly upregulated. For example including those using oxidation 
resistance 1 protein (Oxr1; Oliver et al., 2011), heat shock proteins (Hsps; Jolly et al. 2000) or 
activating transcription factor 4 (ATF4; Lange et al., 2008)  instead of activation of the Nrf2 
pathway as evidenced by the similar Nrf2 nuclear protein levels in the treated and untreated 
cells (Fig. 2.26 & 2.27). The cytosolic fraction of Nrf2 was detectable but not in a higher intensity, 
therefore it was not possible to make a cytosolic quantification. These results indicate that 
untreated cells have slightly higher Nrf2 protein in the nucleus measured by densitometry 
relative to H2B control, however this is not significant compared to cells treated with 
sulforaphane (Fig. 2.27). Due to the cytosolic fraction not being completely detectable it was not 
possible to establish a measurement of the nuclear translocation of Nrf2.  
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Figure 2.27. Densitometry analysis of Western Blot from U2OS cells with and without 
sulforaphane treatment. Cells were treated with sulforaphane or with control PBS/DMSO for 
two hours. Nrf2 levels were normalised against histone H2B antibody and quantified by 
densitometry with ImageJ. Three different gels were used for western blot and for densitometry 
analysis, the relative density was calculated using the H2B band relative to each sample to 
eliminate the effects of the different exposure times. Values are the mean ±SD of three 
independent experiments.   
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2.5.3.2 NRF2 DETECTION IN U2OS-NRF2 CELL LINE (DISCOVERX)  
The commercial kit PathHunter® U2OS Keap1-Nrf2 was used to analyse the Nrf2 nuclear 
translocation with 122 compounds from virtual screening (as described in compound screening 
section 2.4.2.2.3). The commercial cell line U2OS-Nrf2 was used to test selective compounds for 
western blot analysis.  This cell line is engineered to co-express two enzyme fragments of β-
galactosidase that in the presence of Nrf2 nuclear translocation will produce a detectable 
chemiluminescent signal.  Therefore, it was important to examine Nrf2 protein in nuclear and 
cytosolic fractions when it is incubated with test compounds by western blotting.  
The compounds tested for Nrf2 nuclear translocation for western blot, chemical structures in 
shown in Fig. 2.20 & 2.23: 
 UOS-00014239-001 
 UOS-00014231-001 
 UOS-00013634-001 (CPN-9) 
 UOS-00013546-001 
 Sulforaphane (positive control)  
 DMSO/PBS (control negative) 
 
In this experiment it was decided to increase the concentration of sulforaphane from 40 µM to 
90 µM to observe a more significant induction of Nrf2 expression as a control and exposure time 
in cells from 2 to 4 hours, incubation times similar to the literature (Sakao & Singh 2012; Zhuang 
et al. 2014). The purpose was to find compounds that disrupt Keap1-Nrf2 protein interaction 
and induce the nuclear translocation of Nrf2. Compounds 14239 and 14231 were selected based 
upon their respective EC50 values of ~0.469 M and ~3.491e-5 M, viability assays and ROS-GLO 
assay. Compound 13634 is a novel small molecule (CPN-9) which has been reported to 
upregulate the Nrf2 pathway and increase the expression of antioxidants and phase II 
detoxification enzymes by inducing Nrf2 nuclear translocation (Kanno et al. 2012). Compound 
13546 is a small compound closely related to a tested compound  N,N’-1,4-naphthalenediylbis 
4-methoxybenzenesulfonamide (named as compound Cpd16 in the literature), which was 
shown to interact with the cysteine residues in Keap1 and stimulates Nrf2 nuclear translocation 
(Marcotte et al. 2013). Sulforaphane was used as a positive control for Nrf2 nuclear translocation.  
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Figure 2.28. Nrf2 nuclear accumulation in U2OS-Nrf2 cells. Cells were treated with 90 μM of test 
compounds for 4 hours.  Nuclear and cytosolic fractions were subjected to western blot analysis. 
GAPDH and H2B antibodies were used as loading control and to verify the differential 
centrifugation experiments.  
 
These results indicate that some compounds increase the levels of Nrf2 in the nuclear fraction 
compared to the control (Fig. 2.28), however Nrf2 protein was not observed in any of the 
cytosolic fractions. Nrf2 protein levels were enhanced with compounds 14239, CPN-9, 13546 
and sulforaphane. It appears from these results that compound CPN-9 has a more pronounced 
effect on Nrf2 expression in the nuclear fraction. However, CPN-9 compound did not show 
nuclear translocation in the PathHunter Keap1-Nrf2 assay (Fig. 2.21), suggesting that CPN-9 
might indirectly activate Nrf2 pathway, instead of interacting with Nrf2 and Keap1. For example, 
CPN-9 might induce the activation of Nrf2 by increasing kinases activity, however the mechanism 
of action between CPN-9 and Keap1-Nrf2 pathway is not known.  
Nrf2 expression in cytosolic fraction could not be detected by this method. This might be due to 
a reduced level of protein expression in cytosolic fraction, making it more difficult to detect by 
western blot analysis. Similarly, studies in gastric cancer cell lines have showed only detectable 
levels of Nrf2 in the nucleus, suggesting that some cell lines express higher levels of Nrf2 in the 
nucleus depending on their antioxidant rate activity as part of a cancer cell line behaviour 
(Kawasaki et al. 2015).  
70 
 
 
Figure 2.29.  Nrf2 densitometry analysis of Western Blots from U2OS-Nrf2 cell line with test 
compounds. Nrf2 levels were normalised against histone H2B antibody and quantified by 
densitometry with ImageJ. For densitometry the relative density was calculated using the H2B 
band relative to each sample to eliminate the effects of the different exposure times. Values are 
the mean of two different cellular samples treated in separate individual experiments*.  
*This cell line is part of a commercial kit assay, the use of which was limited to a specific period of time, 
there was not enough cells for a third repeat due to license expiration.   
 
The densitometry analysis (Fig. 2.29) showed that CPN-9 compound has the most effect on 
nuclear expression of Nrf2, followed by 14239 and sulforaphane, however these results are not 
significant due to only having two replicas of the experiments. Therefore, these results suggest 
a higher Nrf2 expression on the nuclear fraction by compound CPN-9. Compound 14239 
increased the expression of Nrf2 in the nuclear fraction compared to compound 14231, 
consequently, the next experiments were decided to be focused on the study of compound 
14239 as a potential target for Nrf2 signalling. 
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2.5.3.3 NRF2 DETECTION IN HEK-293 CELL LINE  
Since the results displayed no significant effect in the U2OS cells, it was sought to examine 
whether the compounds had an effect on Nrf2 nuclear translocation in an alternative cell line, 
HEK-293 again using sulforaphane, CPN-9, compound 14239, hydrogen peroxide and PBS/DMSO 
as control with western blot analysis. Human embryonic kidney (HEK)-293 cells were chosen 
because they are easy to grow and widely used for biology research. A study in this cell line using 
immunohistochemistry demonstrated Nrf2 expression and nuclear translocation with 5μM of 
sulforaphane treatment (Wen. et al. 2014). It was decided to verify the nuclear translocation of 
Nrf2 protein triggered by compound 14239. These results showed that test compounds failed to 
demonstrate an increased induction of Nrf2 nuclear translocation (Fig. 2.30). One possibility is 
the high viscosity of nuclear fractions for HEK-293 cells, this was reduced with sonication but it 
was still difficult to maintain equal protein content into the gel, H2B control was used as a 
loading control for this matter. The results using this cell line are more variable than U2OS cell 
lines. Therefore, the possibility of compound 14239 as a potential inducer of Nrf2 nuclear 
translocation cannot be dismissed. Cytosolic Nrf2 expression was not detectable in HEK-293 cells, 
consistent with previous experiments with the wild type U2OS and U2OS-Nrf2 (DiscoveRx) cell 
lines.   
 
Figure 2.30. Effect of compounds on Nrf2 levels in HEK-293. Cells were treated with 90 µM of 
compounds for 4 hours. Nuclear and cytosolic fractions were subjected to western blot analysis. 
GAPDH and H2B were used as loading and differential centrifugation controls.  
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Figure 2.31. Densitometry analysis of Western Blot HEK-293 cell line with compounds. Nrf2 
levels were normalised against histone H2B antibody and quantified by densitometry with 
ImageJ. Three different gels were used for western blot and for densitometry analysis the 
relative density was calculated using the H2B band relative to each sample to eliminate the 
effects of the different exposure times. Values are the mean ±SD of 3 independent experiments.  
 
Densitometry analysis of the western blot experiments (Fig.2.31) showed that sulforaphane 
slightly increased the Nrf2 in the nuclear fraction, however the control of PBS/DMSO showed 
similar levels of expression to H2O2 treatment. In conclusion, HEK-293 cell line western blot 
experiments failed to demonstrate an effect on Nrf2 by test compounds.   
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2.6 DISCUSSION 
Structure-based virtual screening was used to identify compounds that disrupt the interaction 
of Keap1-Nrf2. The strategy was to use 16 of the 18 crystal structures of the protein data bank 
(PDB) that show the Keap-Nrf2 interaction interface, resolution of crystal structures from        
1.35 Å to 2.80 Å. The other two structures 3ZGC (Hörer et al. 2013) and 2FLU (Lo et al. 2006) 
were not used due to having mutations in the binding pocket and already having enough crystals 
structures for the virtual screening. From the crystal structures selected a pocket analysis was 
performed of Keap1 in complex with the N-terminal region of Nrf2 and other ligands (i.e., Cpd15, 
ProTalpha and p62; Table 2.2).  Pharmacophore design was used with at least three features of 
the binding pocket for further docking analysis based on score system using MOE and medical 
chemical appraisal selection. The interface between the two proteins is relatively small, which 
is a challenge for compounds that can bind and disrupt the protein-protein interaction. The 
virtual screen (VS) approach was similar to other literature studies for identifying novel small 
inhibitors of the Keap1-Nrf2 protein-protein interaction (Kanno et al. 2012; Marcotte et al. 2013; 
Zhuang et al. 2014). Three compounds (CPN-9, Cpd16 and analogue) were tested in the Nrf2 
translocation assay in which only compound Cpd16 (internally named 13546) displayed activity 
for Nrf2 nuclear translocation. One of the VS approaches found in the literature was a 
structured-based virtual screening followed by docking studies using 1X2R as a reference of the 
protein-protein interaction, similar to the virtual screen approach performed in this thesis 
(Marcotte et al. 2013). A second approach by Zhuang et al. used the same structure-based VS 
integrated with hit-based substructure search for finding compounds with similar structure for 
clustering analysis (Zhuang et al. 2014). In contrast, a ligand-based VS using a quantitative 
structure-activity relationship (QSAR) technique for predicting the biological activity of 
compounds was published (Kanno et al. 2012).  
In order to study the activation of Nrf2, the in vitro cell-based Keap1-Nrf2 pathHunter® assay 
from DiscoveRx was used. The advantage of an in vitro assay is that it can be automatized for 
high-throughput screening in a simpler and more convenient way than in vivo experiments. The 
majority of publications have utilized in vitro cellular assays to study the activation of the Nrf2-
Keap1 pathway followed by further studies using in vivo models. Another way to study Nrf2 
activation in neurons is by using neuronal models derived from induced pluripotent stem cells 
(iPSCs), this in vitro method has been used in Nrf2 signalling activation in drug discovery and cell 
therapy research (Pistollato et al. 2016). Neurons derived from iPSCs can generate specific 
disease models, patient specific cells can be used for the generation of an in vitro assay.  This 
technology has been used with various models of neurodegeneration such as Parkinson’s 
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disease (PS), Alzheimer’s disease (AZ) and Amyotrophic lateral sclerosis (ALS). The main 
advantage of this method is that the cells generated can be used for cell-based assay and drug 
screens (Borger et al. 2017).  
In these studies sulforaphane was demonstrated to induce the nuclear translocation of Nrf2 
according to literature, our EC50 values ranging from 0.37 µM to 0.87 µM are similar to supplier 
value of 0.50 µM (DiscoveRx); another literature value of sulforaphane EC50 is 33 µM obtained 
from a ARE luciferase reported assay measured with Steady-Glo (Promega) incubated in AREc32 
cells for 24 hours (Wu et al. 2014). The significant differences between EC50 values can be due 
to the difference of both methods, they used a cell line with copies of the GST ARE promoter 
linked to a luciferase gene to quantify the ARE induction by luciferase activity. In contrast, this 
research used a commercial assay method based on β-galactosidase enzyme fragment-
complementation to measure the Nrf2 nuclear translocation in U2OS-Nrf2 cells. The same Nrf2 
nuclear translocation assay was used to identify (3S)-1-[4-[(2,3,5,6-tetramethylphenyl) sulfo-
nylamino]-1-naphthyl]pyrrolidine-3-carboxylic acid (RA839), a small compound that shown to 
bound to the Keap1 protein and disrupted the interaction with Nrf2 (Winkel et al. 2015).  
Reference compounds recommended by manufacturer for Nrf2 nuclear translocation assay 
were sulforaphane (EC50 0.50 µM), bardoxolone methyl (CDDO-Methyl; EC50 0.16 µM), quercetin 
(EC50 4.3 µM), iodoacetamide (EC50 2.3 µM) and tert-butylhdroquinone (tBHQ; EC50 71.1 µM), 
values obtained from DiscoveRx assay validation experiments. The preferred reference 
compounds were sulforaphane and CDDO-Methyl based on the EC50 values, hence sulforaphane 
was chosen due to price and availability from supplier (Sigma Aldrich). In the cellular assay 
sulforaphane increased Nrf2 nuclear translocation in a concentration-dependent manner, it was 
also used as a control in the cellular assay and western blot experiments.   
Literature Nrf2 activators such as sulforaphane (Ullah 2015), CPN-9 (Kanno et al. 2012) and 
Cpd16 (Marcotte et al. 2013) were tested in the Nrf2 pathHunter nuclear translocation assay. 
Compound CPN-9 and compound 13545 (analogue to Cpd16) did not display Nrf2 activity in the 
assay, in contrast with sulforaphane and Cpd16 (compound 13546) that displayed an EC50 of 0.37 
to 0.87 µM and Cpd16 EC50 of 9.4 µM (literature value of 2.7 µM). Published data of CPN-9 
measured the Nrf2 activation by the upregulation of ARE downstream genes but there is no 
evidence of the direct interaction with the protein-protein interface. Interestingly, ARE-driven 
luciferase reporter assays were performed in the literature to confirm the activity on Nrf2 
activation and results showed that only Cpd16 displayed  dose-response activity in Nrf2-ARE 
genes (Marcotte et al. 2013).  
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According to the virtual screening and cellular screening results, there are compounds that 
appeared to induce the Nrf2-ARE pathway, however further studies showed that most 
compounds induce the Nrf2 translocation by inducing high ROS levels and reacting with the 
Keap1 cysteine residues. Only two compounds were not interacting by inducing this oxidative 
stress mechanism. After testing the compounds 14239 and 14231 with western blotting the 
results suggest that compound 14239 increases Nrf2 levels in the nucleus in U2OS-Nrf2 cell line, 
the suggested mechanism of action is by disrupting the protein-protein interaction of Nrf2-
Keap1, however this was not confirmed in the western blot experiments or any other technique. 
One way to study this theory is by fluorescent polarisation binding assay (Hancock et al. 2012), 
the purified fluorescein-labelled peptides display a fluorescence polarization response when 
bound to Keap1 protein.  
Nonetheless, these results are not conclusive; the sulforaphane treatment in U2OS wild type 
cells did not show an increase of Nrf2 levels in the nuclear fraction. It was decided to test 
sulforaphane, compounds 14239, 14231, CPN-9 and compound 13546 in the U2OS-Nrf2 cell line 
and interestingly the results suggest some overexpression of Nrf2 in the nucleus by CPN-9, 
compound 14239 and sulforaphane against the PBS/DMSO control treatment. This result 
suggests that the lack of Nrf2 expression in the cytosolic might be due to a higher rate of 
oxidative response in the nucleus for a cancer cell line or the rapid degradation of cytosolic 
protein by Keap1 protease complex. The results obtained with HEK-293 indicate a similar 
mechanism to the U2OS cell line (altered pathways). HEK-293 cells are immortalized by sheared 
human adenovirus type 5 DNA and these resulted in an altered and dysregulated p53 and 
retinoblastoma protein (pRB) that are important for stress response, DNA replication, tumour 
suppression, cell division and cell cycle control (Harris & Levine 2005; Giacinti & Giordano 2006; 
Kavsan et al. 2011).  
Importantly Nrf2 protein needs other proteins to bind the DNA, suggesting that even when the 
Nrf2 is overexpressed other proteins stayed at basal levels. This could prevent Nrf2 to induce 
any response in the nucleus and possibly the free protein could be exported naturally to the 
cytosol to trigger the Keap1-ubiquitination and degradation processes. For example, the normal 
basal levels of sMAF proteins might not be enough for the over induced levels of Nrf2 in the 
nucleus, nevertheless there is no evidence and this is just a hypothesis. However, further 
experiments need to be performed to confirm this data. Compounds were then tested with a 
general cell line HEK-293 in which a slight increase of nuclear Nrf2 levels with sulforaphane and 
CPN-9 was observed, however the controls were  invalid, being  the same  levels as hydrogen 
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peroxide, making the results inconclusive and invalid. In addition, the nuclear samples were not 
completely soluble and this could make the data difficult to interpret.   
In contrast to the Keap1-Nrf2 strategy, sMAF proteins play a critical role in the inducible 
expression of ARE-driven genes becoming a potential modulator of Nrf2-ARE pathway. Nuclear 
levels of MAF proteins are essential for the heterodimerization with Nrf2 protein, however this 
approach requires Nrf2 being localized in the nucleus and previously dissociated from Keap1 
protein. There is no current research publications using MAF proteins to modulate Nrf2-ARE 
pathway, but future work can be a potential mechanism of study.  
Both compounds found to activate Nrf2 activity in the nuclear translocation assay displayed 
relatively low activity and there was insufficient evidence of Nrf2-Keap1 robust interaction, it 
was therefore decided not to continue further experiments. The necessity to find other methods 
to confirm the Nrf2 nuclear translocation by test compounds is essential, such as, 
immunofluorescence, mRNA expression of downstream genes, etc. It has been decided to 
conclude this project, due to unclear and inconclusive results.  In research discovery groups it is 
important to be able to distinguish when to terminate research when results are not significant 
to continue. However, Nrf2 protein is still relevant for future research in neurodegenerative 
diseases and in oxidative stress injury.   
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CHAPTER 3 
INTRODUCTION OF GLUTAMATE RECEPTORS 
3.1 GLUTAMATE NEUROTRANSMISSION  
L-Glutamate is the principal excitatory neurotransmitter in all vertebrate mammalian central 
nervous systems (CNS). Glutamate is synthesised in the brain and plays an important role in 
information processing, memory and neuronal plasticity (McEntee & Crook 1993; Huber et al. 
1998; Riedel et al. 2003).  
The glutamate neurotransmission is an excitatory synapse process that involves a range of 
different glutamate receptors in neurons. Glutamate is able to bind to different ionotropic 
(Kainate, AMPA and NMDA) or metabotropic receptors. In glial cells, glutamate is broken down 
to glutamine by glutamine synthetase and is exported extracellularly (Niciu et al. 2012); the 
extracellular concentration of glutamate is normally low ~1 µM (Anderson & Swanson 2000; 
Platt 2007). The sodium-coupled neutral amino acid transporter 7 (SNAT7) takes the 
extracellular glutamine into neurons (presynaptic axon; Fig.3.1). Inside the presynaptic neuron 
glutamine is converted into Glutamate by glutaminase enzyme, another source of glutamate 
inside neurons comes from glucose in the Krebs cycle that converted α-ketoglutarate to 
glutamate by glutamate dehydrogenase (GLDH; Newsholme et al. 2003). The vesicular 
glutamate transporter (VGluT) proteins encapsulate glutamate into synaptic vesicles from the 
cytoplasm. An action potential in the presynaptic axon activates calcium channels in a voltage-
dependent manner, glutamate is then released into the synaptic cleft (Niciu et al. 2012). The 
soluble N-ethylmaleimide-sensitive factor activating protein receptor (SNARE) are proteins that 
help the fusion of the vesicle into the membrane for glutamate release. Glutamate then binds 
to different transmembrane receptors, such as G-protein coupled metabotropic receptors 
(mGluRs) or ionotropic glutamate receptors (iGluRs) to induce the depolarization of the neuron. 
Glutamate receptors can be found on glial cells, presynaptic and postsynaptic neurons. The 
released glutamate can be recycled from the synaptic cleft into glial cells and neurons by 
excitatory amino acid transporters (EAAT; Niciu et al. 2012). In addition, the cystine-glutamate 
antiporter called system Xc ̶  exchanges extracellular cysteine for intracellular glutamate in a 1:1 
ratio to regulate the extracellular levels of glutamate. This antiporter is critical in the formation 
of the antioxidant glutathione for oxidative protection (Bridges et al. 2012; Niciu et al. 2012).  
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Figure 3.1. Excitatory glutamate synapse. The release of glutamate from the presynaptic neuron 
into the synaptic cleft activates several glutamate receptors mGluRs and iGluRs. The glutamate 
from the synaptic cleft is transported into glial cells by glutamate transporters (EAAT), glutamine 
synthetase converts glutamate into glutamine inside glial cells. Glutamine is further released 
into the extracellular space to be transported into the presynaptic neuron by SNAT7. 
Glutaminase converts glutamine into glutamate and VGluT package glutamate into synaptic 
vesicles. Vesicles are further fused into the membrane by SNARE proteins to release 
neurotransmitter into the synaptic cleft to initiate synapsis. The antiporter Xc ̶ regulates the 
levels of extracellular glutamate by exchanging extracellular cystine for intracellular glutamate. 
Ionotropic glutamate receptors Kainate, AMPA and NMDA in brown, pink and blue respectively. 
Metabotropic glutamate receptor in blue with red.  EAAT- Excitatory amino acid transporter; 
SNAT7 – Sodium-coupled  neutral amino acid transporter 7; VGluT – Vesicular Glutamate 
transporter; SNARE – Soluble N-ethylmaleimide-sensitive factor activating protein receptor; 
GPCR – G-protein-couple receptors (Adapted from Tulane University, Medical Pharmacology 
TMedWeb. 
http://tmedweb.tulane.edu/pharmwiki/doku.php/overview_of_cns_neurotransmitters). 
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3.2 GLUTAMATE NEUROTRANSMISSION IN DISEASE  
Glutamate is the principal excitatory neurotransmitter however high concentrations of 
glutamate could be toxic for neurons and cause cell death (Lau & Tymianski 2010). Glutamate 
activates two types of receptors; the ligand gated ion channels (ionotropic) and G-protein 
coupled (metabotropic) receptors (Traynelis et al. 2010). These receptors are distributed in 
several areas of the brain and CNS and therefore important for normal development and correct 
function of the nervous system. In general dysregulation and dysfunction of glutamate receptors 
is linked to several neurological disorders and degenerative diseases such as Parkinson’s 
(mGluRs such as mGluR5), Schizophrenia (NMDA receptors), Alzheimer’s disease (Kainate, 
AMPA and NMDA receptors), epilepsy (kainate receptors), stroke, brain damage and many more 
(Serafimoska & Johansen 2011; Matute 2011; Fritsch et al. 2014; Anggono et al. 2016).  
Intellectual disability (ID) is a neurodevelopmental disorder characterised by limitations in the 
intellectual functioning and adaptive behaviour such as, learning, reasoning, problem solving, 
social and practical skills. The symptoms originate before the age of 18 and ID patients often 
have additional abnormalities such as epilepsy, autism and dysmorphic features (Volk et al. 
2015). The ID affects 1% to 3% of the general population in North America (Volk et al. 2015; The 
Arc 2016). More than 450 genes that are linked to ID and autism have been identified (van 
Bokhoven 2011), a large number of these genes had association with the glutamate 
neurotransmission (van Bokhoven 2011; Soto et al. 2014; Bonnet-Brilhault et al. 2016). Gene 
mutations in iGluRs AMPA (GRIA2 and GRIA3) and NMDA (GRIN1 and GRIN2A) have been linked 
to ID, epilepsy and neurodevelopmental phenotypes (van Bokhoven 2011; Soto et al. 2014).  
Down syndrome (DS), is a genetic condition characterised for having three copies of the 
chromosome 21 instead of the normal two and displays symptoms of ID, weak muscle tone 
(hypotonia) and dysmorphic facial features in infancy. Post-mortem brain tissues of DS patients 
showed endosome abnormalities suggesting an altered endocytic pathway in DS pathology 
affecting glutamate receptors endocytosis (Cataldo et al. 2000). More specifically, the synaptic 
endosomal protein sorting nexin 27 (SNX27) involved in endocytosis, trafficking and degradation 
of membrane receptors such as AMPA and NMDA was significantly reduced in DS patients (Wang 
et al. 2013). Deletion of SNX27 gene (mice knockout) showed reduction in glutamate synaptic 
transmission, increasing the degradation of AMPA and NMDA receptors and avoiding the 
recruitment of glutamate receptors in long-term potentiation (LTP) and synaptic plasticity 
suggesting a deficiency in learning and memory processes (Wang et al. 2013; Hussain et al. 2014; 
Volk et al. 2015). Restoring SNX27 gene in Ts65Dn mice completely rescued synaptic dysfunction 
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and cognitive deficits, suggesting an important role in glutamate synapsis in DS (Wang et al. 
2013). 
22q11 deletion syndrome (22q11DS) is a genetic disorder caused by the deletion of a small piece 
of chromosome 22, this syndrome has a wide range of symptoms including heart abnormalities, 
cleft palate, immune system deficiency and higher risk of developing psychiatric disorders and 
schizophrenia (Evers et al. 2015). 22q11DS displays abnormalities in glutamate metabolism, it is 
suggested that patients with this syndrome lack or have reduced levels of proline 
dehydrogenase (PRODH), the enzyme that converts proline to glutamate. Patients with 22q11DS 
display high levels of proline and reduced levels of PRODH, however more studies need to be 
conducted in order to understand the specific mechanism with glutamate neurotransmission 
(Goodman et al. 2000; Evers et al. 2015).  
The fragile X syndrome (FXS) is a genetic condition characterised by the mutation of FMR1 gene, 
the loss of FMR1 causes a lack of expression of the fragile X mental retardation protein (FMRP). 
FXS affects more males than females, the symptoms include; learning disabilities, cognitive 
impairment, anxiety and hyperactive behaviour. One in three patients with the syndrome 
develop autism spectrum disorders (ASD) defined as a neurodevelopmental set of disorders 
characterised by impairment in social interactions, communication, interests and behaviours 
(Volk et al. 2015) . FMRP is a RNA-binding protein that regulates protein production in cells, it 
has an important role in development of synapses in neurons and is required for normal 
glutamate synapse control. More specifically FMRP have shown to bind and interact with 
glutamate receptors mGluR5 and NMDA (subunits NR1, 2A, 2B and 3A); currently there is no 
cure for this syndrome however new approaches for targeting mGluR5 are promising for a novel 
treatment  (Darnell & Klann 2013; Pop et al. 2014; Scharf et al. 2015).  
Previous research has suggested glutamate neurotransmission involved in the pathophysiology 
of ASD. A group of sixty patients with ASD were studied to confirm significant elevated levels of 
glutamate in blood plasma, a smaller study of fourteen autistic children was reproduced using 
high-performance liquid chromatography (HPLC) to confirm the same results, glutamic acid 
levels were higher compared to control subjects (Moreno et al. 1992; Moreno-Fuenmayor et al. 
1996). Similarly, elevated glutamate levels in plasma have been found in patients with 
Asperger’s syndrome a disorder included in ASD and their families (Aldred et al. 2003; Cai et al. 
2016). A study with adults, eighteen male patients with autism and nineteen healthy male 
subjects found higher glutamate serum levels in autism patients 82.2 µM versus 61.1 µM in 
healthy controls using HPLC (Shinohe et al. 2006).  
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Hassan et al. studied glutamate levels in blood plasma and four regions of the brain in ten 
children with autism versus ten healthy patients using HPLC and proton magnetic resonance 
spectroscopy (1HMRS) respectively. The results were similar to others, levels of glutamate were 
significantly higher than control subjects in blood serum and the four brain regions tested: 
bilateral anterior cingulate, left striatum, left cerebellar hemisphere and left frontal lobe (Hassan 
et al. 2013). In a similar way, a small pilot study using magnetic resonance spectroscopy found 
that seven adolescent males with autistic disorders displayed a significantly higher level of 
glutamate in the anterior cingulate cortex, a part of the brain located in the medial surface of 
the cerebral cortex and important for learning, processing, emotion formation and memory 
compared to the control group (Joshi et al. 2013). Similarly, patients with ASD displayed 
significantly higher concentration of glutamate and glutamine in the brain region amygdala-
hippocampal involved in processing, behaviour, learning and memory using in vivo 1HMRS (Page 
et al. 2006).  
Higher levels of glutamate/glutamine were found in obsessive-compulsive disorder (OCD) 
patients using proton magnetic resonance spectroscopy (1HMRS) in the orbitofrontal cortex 
(OFC) which is part of cognitive processing in decision-making (Whiteside et al. 2006). Ten 
patients diagnosed with social anxiety displayed higher glutamate levels relative to creatinine in 
the anterior cingulate complex, these glutamate levels are positively correlated with the 
intensity of social anxiety symptoms (Phan et al. 2005).  Whereas, a NMR brain scanning in major 
depressive disorder (MDD) patients showed that depressed patients had reduced levels of 
glutamate/glutamine and γ-aminobutyric acid (GABA) in prefrontal brain regions (Hasler et al. 
2007). There is strong evidence demonstrating that glutamate neurotransmission plays an 
important role in autism, OCD, depression, anxiety disorders and decision making, however, the 
exact mechanism of dysregulation of glutamate levels in serum and brain are not yet established. 
In schizophrenia, the “glutamate hypothesis” correlates glutamate receptors with mental 
conditions by detecting reduced levels of glutamate, glutamine and n-acetylaspartate in the 
dorsolateral prefrontal cortex suggesting a dysfunction in the glutamate neurotransmission in 
the brain (Ohrmann et al. 2005; Stone 2011). More specifically, it is believed that schizophrenia 
is caused by hypofunctional glutamate NMDA receptors in view of the fact that antagonists 
ketamine and phencyclidine (PCP or angel dust) are used for pharmacological models of 
schizophrenia. Both antagonists gave conditions that mimic the positive (hallucinations and 
delusions), cognitive (memory problems), negative (apathy and lack of emotion) and affective 
(anxiety and depression) symptoms of schizophrenia (Lahti et al. 2001; Konradi & Heckers 2003; 
Morris et al. 2005; Morrissette & Stahl 2011).  
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There are a few studies suggesting an important role of kainate receptors in psychiatric disorders. 
For example, GluK1 and GluK2 expression were reduced in limbic cortices of post-mortem brains 
from bipolar and schizophrenia patients using in-situ hybridization histochemistry (Beneyto et 
al. 2007). More interestingly, PCP chronic treatment was found to decrease GluK1 and Gluk2 
expression in rat prefrontal cortex (Barbon et al. 2007; Woo et al. 2007). In Schizophrenia 
patients, a GRIK3 polymorphism study found an association between GluK3 receptor 
polymorphism (T928G) and the mental disorder (Begni et al. 2002).  A chromosomal analysis 
study found a link between polymorphism on the GRIK4 gene (KA-1) in Schizophrenia and bipolar 
disorder (Pickard et al. 2006). In contrast, a study in Japanese population found that GRIK1 single 
nucleotide polymorphisms do not play a role in schizophrenia pathology (Shibata et al. 2001). 
The research suggests a link between glutamate receptors NMDA and kainate with 
Schizophrenia and bipolar disorder, more research needs to be conducted to elucidate the exact 
mechanism of these receptors with the pathology.  
Alzheimer’s disease (AD), the most common cause of dementia, is a chronic neurodegenerative 
disease that is estimated to affect 850,000 people in the UK (NHS). In past years, various 
autoradiography studies have shown that AMPA, kainate and NMDA receptors are reduced in 
severe Alzheimer disease (AD) in areas of neuronal cell loss suggesting a dysregulation of 
glutamate receptors in AD (Jansen et al. 1989; Chalmers et al. 1990; Penney et al. 1990; Dewar 
et al. 1991; Carlson et al. 1993).  
Excitatory glutamate neurotransmission plays a role in the initiation and spread of seizure 
activity. In epilepsy the seizure episodes are caused by the sudden and disorderly discharges of 
neurons in the brain, these neurons are activated at the same time causing major excitatory 
signals. The long lasting activation of glutamate receptors such as NMDA and kainate are 
associated with epilepsy. For example, brain tissues from patients with temporal lobe epilepsy 
(TLE) showed high levels of expression of GluK1 receptors (Sperk et al. 1983; Olney et al. 1986; 
Matute 2011). Also, a tetranucleotide repeat polymorphism of the GluK1 gene (chromosome 
21q22.1) have been linked to juvenile absence epilepsy (JAE; Sander et al. 1997). There is strong 
evidence linking kainate and NMDA receptors with epilepsy and seizure pathology, targeting 
these receptors can provide a new potential for novel antiepileptic treatments.  
Finally, kainate receptors have also been linked to pain processing in the brain and some 
selective GluK1 antagonists have been shown to reduce chronic pain (Li et al. 1999; Guo et al. 
2002; Palecek et al. 2004; Zhuo 2017b). For example GluK1 antagonist LY-382884 reduces pain 
responses measured by electrophysiology in spinothalamic tract (STT) neurons in response to 
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mechanical and thermal stimuli in a peripheral neuropathy model in primates (Palecek et al. 
2004). In addition, a mouse model showed that responses to capsaicin or inflammatory pain 
were notably reduced in GluK1-deficient mice compared to GluK2 receptors (Ko et al. 2005).  All 
these findings can provide important information for the study of pain therapy. Glutamate 
neurotransmission is important for correct excitatory synapses, any dysregulation can cause a 
wide range of neurological disorders, their study and understanding is a promising target for 
novel treatments.  
 
3.3 GLUTAMATE RECEPTORS GENE FAMILIES  
3.3.1 METABOTROPIC GLUTAMATE RECEPTORS (mGluRs)  
mGluRs are members of the family of the G-protein coupled receptors (GPCRs). GCPRs are 
membrane-bound proteins that are activated by extracellular molecules such as 
neurotransmitters and peptides. Several metabolic steps involving G-protein signal transduction 
regulate the flow of ions across the membrane. mGluRs are members of the class C GPCRs which 
also include the calcium-sensing receptors, γ-amino-butyric acid (GABA) type B receptors, taste 
T1R receptors and vomeronasal type-2 receptors (Bräuner-Osborne et al. 2007; Chun et al. 2012). 
GPCRs can be classified into six families, A to F depending on the homology sequence of the 
conserved heptahelical transmembrane domain (7TM). Class A are the rhodopsin-like family, 
class B the secretin receptor family, class C metabotropic glutamate/pheromone family, class D 
fungal mating pheromone receptors, class E cyclic AMP receptors and Class F 
frizzled/smoothened family (Alexander et al. 2015; IUPHAR/BPS Guide to Pharmacology). The 
class C family is characterised as presenting two unique structural features, the large 
extracellular domain with the orthosteric site situated away from the 7TM and the ability to 
form dimers with unique activation modes compared to other GPCRs families (Chun et al. 2012).   
The structure of mGluRs (Fig.3.2) is formed by an extracellular bi-lobed N-terminal domain 
(glutamate binding site), followed by a cysteine-rich domain, seven spanning transmembrane 
alpha helices domains and an intracellular C-terminal domain (Kew & Kemp 2005; Niswender & 
Conn 2010). 
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Figure 3.2. Representation of a typical mGluR structure (Kew & Kemp 2005). 
 
The extracellular domain of mGluRs contains a ligand binding site and the intracellular domain 
binds to G-proteins subunits (α, β and γ). The α subunit binds to guanine nucleotides guanosine 
triphosphate (GTP) or guanosine diphosphate (GDP). In the inactive state, α subunit binds to 
GDP to form an inactive heterotrimer with β and γ subunits. The activation of the receptor by 
an extracellular signal causes the exchange of GDP with GTP. When GTP binds the α subunit the 
G-protein becomes activated and induces the dissociation of α subunit from the βγ complex, the 
dissociated subunits (α-GTP and βγ) can bind to effector proteins such as ion channels or 
enzymes to mediate a variety of responses in the target cell. This type of activation can induce 
the opening and closing of an ion channel (Fig. 3.3; Purves et al. 2004).  
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Figure 3.3. Metabotropic Glutamate Receptor. mGluRs activate G-protein  subunits (α,β and γ) 
which trigger several steps to induce the modulation of ion channels (Purves et al. 2004). 
 
mGluRs are classified into three main classes based on their sequence homologies, 
pharmacology and preferred agonist (Fig. 3.4). Group I (mGluR1 and mGluR5), Group II (mGluR2 
and mGluR3) and Group III (mGluR4, mGluR6, mGluR7 and mGluR8). Group I typically couple via 
Gq/G11 to induce the activity of phospholipase C (PLC), resulting in the hydrolysis of 
phosphotinositides and the formation of inositol triphosphate (IP3) and diacylglycerol. This 
pathway results in the binding of IP3 to calcium channels to induce intracellular calcium 
mobilization and further activation of protein kinase C (PKC; Niswender & Conn 2010). Group II 
and III couple via Gi/Go and both inhibit the activity of adenylyl cyclase (AC), avoiding the 
conversion of adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP) follow 
by reducing the activity of cAMP-dependent protein kinase  and turning off the cAMP pathway 
(Kew & Kemp 2005; Niswender & Conn 2010). 
mGluRs main functions are regulation of neuronal excitability, synaptic transmission and 
plasticity. Due to the extensive expression of mGluRs in the brain, it has potential therapeutic 
targets for drug discovery, however the purposes of this project are focused on ionotropic 
glutamate receptors exclusively.  
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Figure 3.4. Classification of mGluRs families. Group I, activates Phospholipase C (PLC), which 
results in the formation of inositol triphosphate (IP3) and the further activation of protein kinase 
C (PKC). Group II and III inhibit Adenylate cyclase (AC) activity thereby reducing the levels of 
cyclic adenoside monophosphate (cAMP) turning off the cAMP pathway and reducing cAMP-
dependent protein kinase levels (Adapted from Kew & Kemp 2005).  
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3.3.2 IONOTROPIC GLUTAMATE RECEPTORS (iGluRs)  
Ionotropic glutamate receptors (iGluRs) are ligand gated ion channels, meaning that binding of 
a ligand (usually a neurotransmitter) triggers the opening of the channel allowing the transport 
of ions such as Na+, K+ and  Ca2+ through the membrane (Purves et al. 2004). In humans iGluRs 
are encoded by 18 genes (Fig. 3.5) and they are classified by their selective agonists: α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), Kainate, N-methyl-D-aspartatic acid 
(NMDA) and delta (δ) receptors, the latter is not well characterised yet and no endogenous 
ligands have been identified. More recently it has been found that D-serine and glycine can bind 
and activate the delta receptor GluD2 (Khan 2016). AMPA receptors family is formed by four 
receptors GluA1 to GluA4, Kainate formed by five receptors GluK1 to Gluk5, NMDA comprises 
seven sub-types GluN1, GluN2A to D and GluN3A to D (Mayer 2016).  
 
 
Figure 3.5. The ionotropic receptor gene family. Protein names are shown according to the 
current nomenclature (with previous nomenclature in parenthesis) and gene names being 
shown in blue.  Genes nomenclature were obtained from UniProt.  
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3.4 iGluRs STRUCTURE  
3.4.1 GENERAL FEATURES  
Structural information on iGluRs from high-resolution X-ray crystallography has enabled 
researchers to explore and gather information of the structure-function relationship. In 1998, 
the X-ray crystal structure of the soluble LBD of rat GluA2  in complex with kainate provided at 
1.9 Å was the first atomic information of the binding site structure of iGluRs (Armstrong et al. 
1998). There are currently over one-hundred crystal structures of the LBD of GluA2 in complex 
with different ligands including kainate, glutamate, L-aspartate, fluoro-willardiine and more 
(Armstrong et al. 1998; Armstrong & Gouaux 2000; Ahmed et al. 2011; Krintel et al. 2014; 
Meyerson et al. 2014; Salazar et al. 2017).  
In 2009, Sobolevsky obtained the first crystal structure of the full-length rat GluA2 at 3.6 Å 
providing important information about the global structure and domain organisation of an iGluR 
(Sobolevsky et al. 2009). Also obtained in the same year was the soluble ATD GluA2 crystal 
structure at 2.33 Å (Jin et al. 2009). For kainate receptors, in 2005 the first LBD structure of GluK1 
and Gluk2 was published (Nanao et al. 2005; Naur et al. 2005), currently there are 84 high-
resolution crystals of kainate receptors LBD and ATD with agonist, antagonist and ions (Møllerud 
et al. 2017). In 2014, the full-length of GluK2 was determined at low resolution 7.6 Å using cryo 
electron microscopy (Meyerson et al. 2014). For NMDA receptors the first ATD of GluN2B 
subunit at 3.21 Å was reported in 2009 (Karakas et al. 2009) and in 2011 the same research 
group published the ATD of GluN1 subunit at 2.0 Å (Karakas et al. 2011). Finally, in 2014 two full-
length structures of NMDA GluN1/GluN2B were published (Lee et al. 2014; Karakas & Furukawa 
2014). All these high- and low-resolution structures have given important information in the 
structure and topology of iGluRs, several crystal structures will be described in more detail in 
the following sections.  
iGluRs form tetramers assembled as dimer-dimer conformation. Each subunit is formed of four 
main domains (Fig. 3.6), an extracellular amino terminal domain (ATD), an extracellular ligand-
binding domain (LBD), a transmembrane domain (TMD), and an intracellular carboxyl-terminal 
domain (CTD; Traynelis et al. 2010).  
89 
 
 
 
Figure 3.6. Ionotropic glutamate receptor domains. A. Subunit of a monomer structure, amino 
terminal domain (ATD) in green, ligand binding domain (LBD) formed of segment S1 and S2 
ligand binding core (also called D1 and D2) in orange and blue, the transmembrane domain (TMD) 
formed of three membrane spanning segments (M1, M3 and M4) and a re-entry pore loop (M2) 
in grey and the C-terminal domain (CTD) in black. B. Representation of the dimer conformation 
of the ATD, LBD, TM and CTD. ATD and LBD show the clamshell-like structure (Adapted from 
Mayer 2006b). C. For the CTD of iGluRs there are no structural details in the PDB, the sequence 
of the CTD of GluA2 is shown, P42262-1 UniProt (Traynelis et al. 2010; Henley & Wilkinson 2016).  
 
The Amino terminal domain (ATD) of iGluRs are allocated in the extracellular region away from 
the membrane and have a bi-lobed clamshell like structure composed of two lobes (lower and 
upper). The structural form of the ATD allows a binding site for allosteric modulators. ATD has 
the most divergent sequence identity of 20-25% comparing other subunits (Furukawa 2012).  
ATD have an important role in subtype-specific receptor,  receptor assembly and trafficking 
(Garcia 2004; Traynelis et al. 2010; Yelshanskaya et al. 2014; Díaz-alonso et al. 2017).  
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Figure 3.7. Gluk1 LBD S1S2 clamshell-like structure. GluK1 LBD (2F36, PDB accession code; Mayer 
2006a) in complex with glutamate in orange, LBD forms clamshell-like structure formed of S1 
and S2, in light cyan and dark cyan, respectively (Møllerud et al. 2017). 
 
The extracellular ligand binding domain (LBD) is formed of two extended amino acid segments 
usually named as S1 and S2 (Fig.3.7), both segments form a ligand-binding cavity core where the 
ligand/neurotransmitter binds (Yelshanskaya et al. 2014; Mayer 2006b). The LBD structure 
forms a clamshell-like conformation, in which segments S1 (N-terminal of M1 transmembrane 
spanning domain) and S2 (between M3 and M4 regions) form the two-domain clamshell-like 
structures for ligand binding, the opening and closing of the clamshell will depend on gating 
binding and unbinding  activities (Traynelis et al. 2010; Hammond 2015). As Fig. 3.6 shows, the 
ATD also has a clamshell-like structure formed by two lobes (upper and lower lobe). The LBD of 
glutamate receptors is attached to the TMD with three small linkers, these linkers connect S1-
M1, S2-M3 and S2-M4. The TMD forms an ion channel pore by three transmembrane helices 
M1, M3 and M4 and a re-entrant loop M2 and contributes to receptor tetrameric stability 
(Balannik et al. 2005; Yelshanskaya et al. 2014; Traynelis et al. 2010). Sequence homology is 
found in the ATD, LBD and TM, with higher homology in the ligand binding core (up to 80-90% 
within similar groups), in contrast the CTD has not shown any sequence homology between 
glutamate receptors (Traynelis et al. 2010; Furukawa 2012). However, the CTD contains several 
different phosphorylation sites and binding sites for intracellular binding proteins giving it an 
important role in receptor regulation, synaptic localisation, trafficking, targeting for degradation 
and post-translational modifications (Traynelis et al. 2010). 
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Tetramer conformation 
iGluRs assemble as four subunits to form tetramers either by different subunits 
(heterotetramers) or identical subunits (homotetramers). There are two proposed pathways for 
tetramer assembly “preferential” and “obligatory” (Herguedas et al. 2013). The formation of 
heterotetramers is obligatory for function of some receptors but preferential for other receptor 
families. The subunits ATD, LBD and TMD form dimers between them to initiate the assembly of 
further tetramers. In the preferential route, the subunits (ATD, LBD and TMD) will form 
homodimers to then form tetramers, a reequilibration step will induce the formation of 
heterodimers between subunits to obtain a functional heterotetramer (Fig.3.8). For example, 
AMPA and kainate (GluK1-GluK3) usually forms functional homotetramers, but also has the 
ability to form native functional heterotetramers. In obligatory assembly the subunits do not 
form homodimers and directly form functional heterotetramers, NMDA and kainate (GluK4 and 
GluK5) are examples of this pathway (Sobolevsky et al. 2009; Herguedas et al. 2013).  
 
Figure 3.8. iGluR tetramer assembly representation. A. Phylogenetic tree of the main iGluRs (δ 
has not been fully characterised) divided into preferential and obligatory assembly pathways.    
B. Schematic representation of the assembly pathway for obligatory or preferential tetramers 
formation, tetramer structure represents GluA2 (3KG2 PBD code; Herguedas et al. 2013).  
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3.4.2 AMPA RECEPTORS 
α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) is the specific agonist that 
activates AMPA receptors (Fig. 3.10). As previously described the AMPA receptors are composed 
of four subunits GluA1 to GluA4. AMPA receptors mediate the fast excitatory synaptic 
transmission in the central nervous system (CNS). Earlier published high-resolution data of the 
LBD of  rat GluA2  (Armstrong et al. 1998) described a bilobed structure formed by two domains 
S1 and S2, the domain closure was induced by kainate binding and interdomain contacts were 
found between the two domains including the formation of a disulphide bond to stabilize the 
formation of dimers.  
X-ray crystallography experiments have confirmed the agonist binding site in the clamshell-like 
structure in the LBD.  As previously discussed the LBD is formed of two segments S1 and S2 that 
are connected to the TMD; Armstrong and Gouaux were able to design a soluble construct of 
the LBD (S1 and S2) that was easily expressed in E. coli bacteria for protein purification and 
crystallography experiments. This construct contains the ligand binding domain from N392 to 
S775 and a GT linker between S1 and S2 (Fig.3.9), sequence numbered according to M36419 
flop GluA2 (GenBank-EMBL; Keinänen et al. 1990; Armstrong & Gouaux 2000). This new 
construct was able to offer better understanding of the binding interactions of various ligands 
in the LBD pocket. They successfully crystallised and obtained X-ray data for the rat GluA2 LBD 
in complex with glutamate, DNQX, AMPA and kainate; PDB accession codes 1FTJ, 1FTL, 1FTM 
and 1FW0 respectively (Armstrong & Gouaux 2000).  
In 2009 homotetrameric rat GluA2 subunit was the first full-length crystal structure 
characterised at 3.6 Å resolution in complex with competitive antagonist ZK200775  (Sobolevsky 
et al. 2009). The full-length structure of homotetrameric rat GluA2 (Sobolevsky et al. 2009) 
agrees with the previously described data, however, it provided more detailed information 
about the full membrane symmetry and tetrameric conformation in glutamate receptors.   
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Figure 3.9. Construct of the LBD (S1S2) design. Domain configuration of GluA2 LBD, S1 in blue 
and S2 in pink, the construct was isolated by cutting above the ATD and before the TMD M4, a 
Glycine-Threonine was used for linking S1 and S2 between M1 and M2 (Adapted from Armstrong 
& Gouaux 2000). 
 
The full-length GluA2 rat receptor (PDB accession code, 3KG2) appears as a “Y” shape type 
structure, with the ATD at the top, the LBD at the middle and the TMD at the bottom to form 
the ion channel (Fig. 3.11; Sobolevsky 2015). In the paper they used the full-length rat GluA2i 
(flip variant, from two alternative splicing variants in the LBD) sequence (NP_058957), 36 
residues were removed from C-terminus, 6 residues were eliminated from the ATD and the LBD 
segment, as well as four residues substituted by alanine to stabilize the tetrameric conformation 
and facilitate crystallography experiments (Sobolevsky et al. 2009). The full-length rGluA2 
receptor displayed a 2-fold axis symmetry for the full tetrameric structure, and 4-fold symmetry 
in the ion channel pore (Sobolevsky et al. 2009).  
In addition, they found that the GluA2 tetrameric receptor can form two different subunit 
conformations, amino acid sequences of each subunit are identical however they fold into A/C 
(proximal) and B/D (distal) type subunits (Fig. 3.12A). The type A subunit formed a dimer with 
the B subunit in the ATD, however the A type subunit formed a dimer with D subunit in the LBD, 
this interaction is called subunit “crossover” or domain “swapping” (Fig.3.12B; Sobolevsky et al. 
2009; Hansen et al. 2010; Traynelis et al. 2010).  
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Structural conformational changes due to the domain swapping might have an important role 
for tetramer assembly. Domain swapping allows conversion of 2-fold symmetry from LBD to 4-
fold symmetry formation in the pore channel. The property of domain swapping results in strong 
interactions between dimers (disulphide cross-linking) which maintains the stability and 
flexibility of the tetramer formed by the four subunits (Herguedas et al. 2013; Gan et al. 2015; 
Sobolevsky 2015).   
Crystal structure of rGluA2 (PDB accession code, 3KG2; Sobolevsky et al. 2009) in complex with 
the competitive antagonist ZK200775 (Fanapanel or MPQX), the antagonist was previously 
defined by Turski and co-workers (Turski et al. 1998). Fanapanel is a quinoxalinedione drug (Fig. 
3.10) which was in phase II clinical trials (Bayer) for the treatment of acute ischemic stroke, 
however the study was terminated due to intolerable side effects (high levels of sedation, drop 
of consciousness and transient neurological deterioration) and glial cell toxicity (Elting et al. 
2002). Consequently, this first crystal structure of a full-length AMPA GluA2 provided important 
information about the structure, symmetry, architecture of the ion channel and tetrameric 
assembly in other families of the ionotropic glutamate receptors. 
 
Figure 3.10. AMPA agonists and antagonist. Top, (RS)-AMPA agonist chemical structure, a 
synthetic analogue of glutamate (Kew & Kemp 2005) and other established agonist of GluA2, 2-
methyl-tetrazolyl-[2-amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propanoic acid (2-Me-Tet-
AMPA), (S)-2-amino-3-(3-Carboxy-5-methylisoxazol-4-yl)propionic acid (ACPA) and (S)-2-amino-
3-(4-bromo-3-hydroxy-isoxazol-5-yl)propionic acid (Br-HIBO) (Serafimoska & Johansen 2011). 
Bottom, AMPA competitive antagonist ZK200775, also known as Fanapanel and MPQX, a highly 
selective AMPA/kainate antagonist. Figure obtained from MedChemExpress (Source 
https://www.medchemexpress.com/ZK200775.html).  
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Figure 3.11. Structural architecture and symmetry of rGluA2. Homotetrameric receptor, each 
subunit is defined in different colours, rGluA2 in complex with antagonist ZK200775. Antagonist 
inside the LBD clamshell pocket in grey space-filling representation.  Open and narrow view of 
the receptor A and B, respectively. N-acetyl-D-glucosamine (NAG) and beta-D-mannose (BMA) 
binding the ATD, shown in green (Sobolevsky et al. 2009). 
 
 
Figure 3.12. Tetrameric distinct conformations. A. Two different structural conformations form 
A/C type and B/D type subunits. B. Dimer-dimer conformation of the ATD and LBD form 2-fold 
symmetry and TMD 4-fold symmetry (Hansen et al. 2010). 
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3.4.2.1 Alternative splicing (Flip/Flop) and RNA editing site (Q/R) 
The four AMPA subunits (GluA1-4) can exist in two different alternative splicing versions, 
commonly named as a “flip/flop”. Exon 14 (flip) and 15 (flop) are RNA segments of ~38 amino 
acids before the transmembrane domain M4, only nine amino acids are different between them 
(Fig. 3.13). These two different variants result in different pharmacological and kinetic 
properties such as channel gating, desensitization and activation (Dingledine et al. 1999; 
Sommer et al. 1990; Penn & Greger 2009). For example, the flip/flop variants alter the channel 
opening kinetics of AMPA receptors. They found that the flop variant of GluA2 desensitize faster 
than the flip variant, this finding suggests an important structural role of the flip/flop sequence 
in stabilizing the open channel conformation and could be due to the location of the sequence 
near the transmembrane domain M4 (Pei et al. 2009).  The flip/flop segment is located inside 
the ligand binding domain (S2) and before M4 (TMD), this location might give a structural role 
to the flip/flop variants for opening/closing the ion channel (Fig. 3.13). In GluA2, GluA3 and 
GluA4 a selective nuclear RNA editing-site determines the codon change from Arginine to 
Glycine (conserved site R/G) to regulate receptor assembly and control the speed of recovery 
from desensitization (Dingledine et al. 1999; Gan et al. 2015). 
The regulation of calcium (Ca2+) permeability of the GluA2 subunit is determined by a RNA 
editing site Q/R located in the transmembrane M2 region of the protein (Fig. 3.13). This post-
transcriptional modification changes the amino acid 607 glutamine (Q) to arginine (R) only in the 
GluA2 mRNA subtype. The GluA2 subtype that contains the R edited residue will be impermeable 
to Ca2+. In contrast, the other AMPA subtype receptors GluA1, GluA3 and GluA4 maintain the 
glutamine (Q) residue and therefore they will be permeable to Ca2+ (Carlson et al. 2000; Greger 
et al. 2002; Wright & Vissel 2012). In addition, there are a number of polyamine derivatives and 
toxins, such as; spermine, spermidine, argiotoxin, Joro spider toxin and philanthotoxin that act 
as channel blockers in AMPA receptors lacking GluA2 subtype. These spider toxins and 
polyamines are attracted by the negative charges on the glutamine (Q) residue in GluA1, GluA3 
and GluA4 and modify the calcium permeability and voltage-dependent of the receptor. The 
GluA2 subtype modified by RNA editing has a positive charged residue arginine (R) instead of 
glutamine (Q) resulting in the repulsion of positive charged polyamides and toxins (Pellegrini-
Giampietro 2003 & Isaac et al. 2007).  
 
 
 
97 
 
 
 
Figure 3.13. Schematic representation of the location and sequence comparison of the Flip/Flop 
AMPA subunit variations. Top, AMPA receptor structure, ATD in grey, LBD in green (S1 and S2 in 
blue and pink), TMD in yellow, NTD in light blue. Glutamate in orange, Q/R RNA editing site in 
TM2 re-entrant loop in dark blue circle and Flip/Flop region in red. Bottom, Flip/Flop sequence 
alignment in pink and purple, respectively. R/G editing site is indicated in bold for GluA2 receptor 
(Adapted from Zhang et al. 2008; Pei et al. 2009). 
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3.4.2.2 Activation and Inactivation of Ion Channel (Gating)  
The term gating refers to the opening and closing of ion channels caused by conformational 
changes upon ligand binding/unbinding. This activation and inactivation can be measured 
electrophysiologically. The three steps involved in gating changes are; 1) activation (agonist 
binding and channel opening), 2) desensitization (clamshell closure to avoid agonist dissociation) 
and 3) inactivation (conformational change to induce ion channel closure) (Sobolevsky 2015). 
Gating might be disturbed at different sites along the receptor by small molecule inhibitors.  
 
 
 
Figure 3.14. Gating steps in glutamate receptors. Top, electrophysiological measurement of the 
whole-cell current in HEK-293 rGluA2 at holding potential of -60 mV, displaying activation, 
desensitization and deactivation; 500 ms application of glutamate 3 mM, miliseconds (ms) and 
picopascal (pA). Bottom, representation of conformational changes involved in gating process; 
rest, open and desensitized in the LBD formed by domains 1 and 2 (D1 and D2) (Adapted from 
Perrais et al. 2010; Sobolevsky 2015). 
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3.4.2.3 AMPAR Auxiliary Proteins 
 AMPA receptors are able to form complexes with auxiliary proteins that are able to regulate 
receptor trafficking, channel activity, gating, synaptic transmission and pharmacology (Coombs 
& Cull-Candy 2009; Henley & Wilkinson 2016).  Some of these auxiliary proteins are the AMPA 
receptor regulatory proteins (TARPs), cornichon homologues (CNIHs), germ cell-specific gene 1-
like protein (GSG1L) and cysteine-knot AMPAR modulating proteins (CKAMPs) (Schwenk et al. 
2009; Schwenk et al. 2012; Shanks et al. 2012 & Klaassen et al. 2016). These proteins are able to 
regulate the function of the receptor with both positive and negative gating modulation, in 
addition to controlling permeation and blockade of the channel (Riva et al. 2017). The most 
studied and characterized of these AMPAR auxiliary proteins are the TARPs family. There are 
seven types of TARPs; γ2 (stargazin) and γ3-8 (Henley & Wilkinson 2016). TARPs control the 
expression of receptors (postsynaptic membrane) and modulate the gating and pharmacology 
of AMPA receptors (Carbone & Plested 2016). For example, the TARP stargazin (γ2) functions as 
a chaperone for AMPA receptors and has an essential role in receptor expression in cell surface. 
A study using in-vitro experiments showed that the absence of stargazin results in retention of 
the AMPA receptors in the endoplasmic reticulum and the lack of expression in cell surface of 
cerebellar granule cells (Chen et al. 2000). Recently, a forebrain-selective AMPA receptor 
antagonist was found to target GluA2-γ8 complexes exclusively and might have potential for 
antiepileptic properties (Kato et al. 2016).  This antagonist (LY3130481) prevented seizure types 
in rodents without presenting motor side effects, hence AMPA receptors auxiliary proteins could 
be used as potential drug targets (Kato et al. 2016).  
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3.4.2.4 Agonist Binding  
Glutamate, kainate and AMPA shared similar interactions in the binding pocket of the LBD of 
GluA2.  The three agonists showed conserved interaction with LBD residues in Arg-485 and Thr-
480, however weak interactions between residues Glu-705, Ser-654 and Pro-478 are similar 
between agonists  (Fig. 3.16; Armstrong & Gouaux 2000).   
GluA2 LBD in complex with glutamate displayed specific interactions with Pro-478, Thr-480 and 
Arg-485 from the S1 domain and Ser-654, Thr-655 and Glu-705 from the S2 domain of the 
protein (Fig.3.16A). The α-carboxylate and α-amino group of glutamate have a key role in ligand 
recognition, the carboxylates and amino groups bind to the protein because they become 
desolvated. In addition, a mutation of the residue Arg-485 led to complete loss of the channel 
function suggesting the key role of this residue in ligand binding (Speranskiy & Kurnikova 2005; 
Serafimoska & Johansen 2011).  
Kainate in complex with GluA2 displays hydrogen bond interactions with Pro-478, Thr-480, Arg-
485, Ser-654 and Thr-655. Glu-705 was not observed to interact with kainate however it might 
form inter protein interactions with other residues inside the binding pocket (Fig. 3.16B).  AMPA 
displayed similar interactions in the binding pocket with Thr-480, Arg-485 and Glu-705 (Fig. 
3.16C).  For all three agonist residues Arg-485 and Thr-480 bind to the structure forming strong 
hydrogen bonds with the α-carboxyl group of agonists (Armstrong & Gouaux 2000; Serafimoska 
& Johansen 2011). 
 
Figure 3.15. GluA2-LBD in complex with glutamate. Glutamate in green ball and stick 
representation, S1 and S2 in blue and brown respectively. A disulphide bond was observed 
between S1 domain and S2 domain, 1FTJ PBD accession code (Armstrong & Gouaux 2000; Naur 
et al. 2005). 
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Figure 3.16. Glutamate, kainate and AMPA binding interactions. A) Left, chemical structure of 
glutamate with carboxyl group designated by α, β, γ and δ. Right, interaction binding pocket of 
GluA2 with glutamate, 1FTJ accession code. B) Left, chemical structure of kainate with carboxyl 
group designated by α, β, γ and δ. Right, interaction binding pocket of GluA2 with kainate, 1FW0 
accession code. C) Left, chemical structure of AMPA with carboxyl group designated by α, β, γ 
and δ. Right, interaction binding pocket of GluA2 with AMPA, 1FTM accession code (Armstrong 
& Gouaux 2000). Diagrams were generated using Maestro Schrödinger. 
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3.4.2.5 AMPA Antagonist  
There are two main classes of antagonists, competitive and non-competitive (Fig. 3.17). Both 
block and reduce the activation of the channel upon binding. Competitive antagonists compete 
with the agonist (orthosteric) binding site and the non-competitive antagonists bind to an 
allosteric site which is different from the agonist, both reduce or interfere with the activation of 
the channel (Gill & Pulido 2005).   
AMPA antagonists will be described in detail in section 3.5.1.2 Antagonist and pharmacology.  
 
Figure 3.17. Competitive and non-competitive antagonist. Schematic representation of the 
mechanism of action of antagonist effect in membrane receptors. Image obtained from 
Biochemistry Online (http://employees.csbsju.edu/hjakubowski/classes/ch331/transkinetics/ 
TK_6C6_Agonist_Anta_Lig_Bind_Recept.html).  
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3.4.3 KAINATE RECEPTORS 
Kainic acid (Kainate) is a natural amino acid derived from the Japanese seaweed Digenea simplex 
(Coyle 1987) and is the preferred agonist for kainate receptors, it has also been shown to 
activate AMPA receptors. Kainate receptors assemble in five different subunits: GluK1, GluK2, 
GluK3, GluK4 and GluK5, they assemble as tetramers to form ion channels.  GluK1-GluK3 can 
form functional homomeric and heteromeric receptors, however GluK4 and GluK5 can only form 
heteromeric receptors with other GluK1-GluK3 subunits to form the ion channel (Fig. 3.8; Lerma 
& Marques 2013).  Compared to AMPA and NMDA receptors kainate receptor physiology is less 
understood. Kainate receptors are classified into low-affinity (GluK1-3) and high affinity (GluK4-
5) receptors based on their affinity for kainate (Kristensen et al. 2016).  
 
3.4.3.1 Kainate Receptor Structure 
There are no crystal structures available for a kainate full-length receptor, however in 2014 a 
cryo-electron microscopy (EM) full-length GluK2 in complex with 2S,4R-4-methylglutamate at 
7.6 Å resolution was published, PDB accession code 4UQQ (Meyerson et al. 2014). This full-
length structure of a desensitized kainate receptor displays the formation of a tetramer formed 
by ATD, LBD, TMD and CTD subunits (Fig. 3.18). This full-length GluK2 EM structure displayed 
drastic conformational changes in the LBD and ion channel assemblies in the TMD (Fig. 3.19); 
these LBD symmetry changes complement the 4-fold symmetry of the ion channel in the TMD, 
inducing the closure of the channel (Meyerson et al. 2014; Møllerud et al. 2017). The general 
conformation of the characterised EM full-length GluK2 displays similarities with AMPA and 
NMDA general structure subunits, however the low-resolution of the structure makes it difficult 
to study the specific similarities or differences between both receptor families. 
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Figure 3.18. Electron microscopy structure of full-length GluK2. A. Full GluK2 structure in surface 
representation, different subunits are shown in blue, fuchsia, green and turquoise, PDB 
accession code 4UQQ with 7.6 Å resolution. B. Comparison of the amino terminal domain (NTD) 
dimer from EM with the soluble dimer construct, PDB accession code 3QLT. C.  Comparison of 
the EM LBD dimer and a soluble construct, PDB accession code 2XXR (Møllerud et al. 2017). 
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Figure 3.19. Conformational changes in the GluK2 gating process. Structural changes of the 
receptor in the transition from resting to activated to desensitized state. Circles representing 
the two-fold and four-fold symmetry of the ATD and the LBD (Adapted from Meyerson et al. 
2016).  
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3.4.3.2 Ligand Binding Domain  
There is a vast amount known about the specific structural differences of the ligand binding 
properties of AMPA, kainate and NMDA receptors, however X-ray crystallography has played an 
important role in defining the mechanism of binding between different ligands and receptors.  
Table 3.1. Crystal structures of the LBD in complex with different ligands  
PDB code Ligand Resolution Å Origin Reference 
Gluk1     
1TXF Glutamate 2.1 Rat (Mayer 2005) 
1YCJ Glutamate 1.95 Rat (Naur et al. 2005) 
2F36 Glutamate 2.11 Rat (Mayer 2006a) 
2PBW Domoate 2.5 Rat (Hald et al. 2007) 
3C31 Kainate 1.49 Rat (Plested et al. 2008) 
2ZNS Glutamate 2.0 Human (Unno et al. 2011) 
3FUZ Glutamate 1.65 Human (Unno et al. 2011) 
GluK2     
1S50 Glutamate 1.65 Rat (Mayer 2005) 
1S7Y Glutamate 1.75 Rat (Mayer 2005) 
1SD3 * 1.80 Rat (Mayer 2005) 
1TT1 Kainate 1.93 Rat (Mayer 2005) 
1S9T Quisqualate 1.80 Rat (Mayer 2005) 
1YAE Domoate 3.11 Rat (Nanao et al. 2005) 
3G3F Glutamate 1.38 Rat (Chaudhry et al. 2009) 
2XXR Glutamate 1.6 Rat (Nayeem et al. 2011) 
GluK3     
3S9E Glutamate 1.6 Rat (Venskutonytė et al. 2011) 
3U93 Glutamate 1.88 Rat (Veran et al. 2012) 
3U94 Glutamate 1.96 Rat (Veran et al. 2012) 
4MH5 Glutamate 1.65 Rat (Venskutonytė et al. 2011) 
3U92 Kainate 1.90 Rat (Veran et al. 2012) 
GluK4   No crystal structures available 
GluK5   No crystal structures available 
*2S,4R-4-methylglutamate 
 
In 2005 the LBD of the GluK1 in complex with glutamate was crystallised for the first time (Naur 
et al. 2005) see Table 3.1 for list of PDB accession codes. Shortly after, the crystal structures of 
the LBD of GluK2 in complex with glutamate, 2S,4R-4-methylglutamate, kainate and quisqualate 
were solved (Mayer 2005). In the same paper they also reproduced the crystal structure of the 
GluK1 LBD in complex with glutamate (Mayer 2005). These X-ray structures revealed similarities 
in the binding core between kainate and AMPA receptors, with glutamate binding in the cavity 
interface between domain one and two (S1 and S2) having the same clamshell-like structure in 
the LBD (Fig.3.7 & 3.20A). 
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Figure 3.20. LBD binding pocket Gluk1 and GluK2 in complex with glutamate. A) LBD formed by 
S1 and S2 in blue and mustard, loop 1 and 2 in green, helices are numbered alphabetically. 
Glutamate and conserved amino acids arginine (R), threonine (T) and glutamic acid (E) are 
displayed in ball and stick representation. B) 3-dimensional view of the binding core with 
glutamate, conserved amino acids GluK2 (GluK1); R492 (R508), T659 (T675), and E707 (E723). 
Solvent accessible surface area of the binding cavity with glutamate is displayed as a transparent 
surface. Black dashes represent hydrogen bonds and ion interactions and green dashes are 
trapped water molecule interactions (Adapted from Mayer 2005). 
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Glutamate binding in both GluK1 and GluK2 was conserved between amino acids arginine, 
glutamate and threonine similar to GluA2 AMPA (Fig. 3.20; Armstrong & Gouaux 2000; Mayer 
2005). In one crystal structure of GluK2 Mayer found a conserved disulphide bond between Cys-
773 in the extending end of helix K and Cys-719 in the loop linking C terminal of helix I (Fig. 3.20) 
similar to observed in GluA2 AMPA LBD (Armstrong et al. 1998; Mayer 2005). However the 
presence or absence of disulphide bond did not modify the structure in both crystal forms 
(orthorhombic and hexagonal) (Mayer 2005). The importance or function of this conserved 
disulphide bond formed in the hexagonal crystal form of GluK2 is still not understood. Altogether 
it was demonstrated that the mechanism of binding between glutamate α-carboxyl and α-amino 
groups is almost the same between GluK1, GluK2 and GluA2 forming interactions with conserved 
residues arginine and glutamic acid (Mayer 2005).  
The binding mechanism of GluK2 LBD in complex with kainate displays the same binding mode 
to  glutamate with the exception of kainate pyrrolidine ring replacing the water W1 atom and 
separating the solvent hydrogen bond network, linking the side chain of Thr-710 to the α-amino 
group of kainate (Fig. 3.21; Mayer 2005).  
GluK1 to GluK3 receptors shared several structural similarities in the LBD ligand pocket. A LBD 
alignment of the three receptors in complex with glutamate reveals the same clamshell-like 
structure and same binding core for glutamate in the interface between domain 1 and domain 
2 (Fig. 3.22; Møllerud et al. 2017).  Currently there are five crystal structures of the LBD of GluK1, 
four structures of GluK2 and four of GluK3 all in complex with glutamate (Table 3.1). All these 
structures shared similar binding mechanism with glutamate agonist, more specifically the α-
carboxylate group of glutamate forms a salt bridge interaction with residue Arg-523 from 
domain 1 and then will form hydrogen bonds with residues Thr-518 from domain 1 and Ser-689 
from domain 2. The α-ammonium group interacts with Glu-738 forming a salt bridge, as well as 
hydrogen bonds with Pro-516, Thr-518 and a water molecule W1. The γ-carboxylate of 
glutamate will form hydrogen bonds with Ser-689, Thr-690 and three water molecules W2, W3 
and W4 (Fig. 3.21A; Møllerud et al. 2017).   
Interestingly glutamate binding pocket shared the same residues in GluK1 rat and human within 
4 Å of glutamate. From the ten residues found within 4 Å of glutamate in Gluk1, only Thr-518 
and Ser-689 are different between GluK1-GluK3 structures (Fig. 3.22).  Thr-518 of GluK1 is 
conserved in GluK3 but changed to alanine for GluK2. Additionally Ser-689 of GluK1 changes to 
alanine in GluK2 and GluK3. These few differences create a larger binding pocket for glutamate 
in GluK2 compared to GluK1 (Møllerud et al. 2017).   
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In summary, the agonist ligand binding pocket of kainate GluK1-GluK3 receptors displayed 
similarities, suggesting a similar binding mode of action. Ligand binding can induce some small 
changes in the secondary structure, these differences might be key for understanding selectivity 
between glutamate receptors and aid in drug design research for therapeutic purposes.  
 
Figure 3.21. GluK2 structure in complex with glutamate and kainate. A) Glutamate binding 
interactions, previously described in Fig. 3.20. B) 3-dimensional view of the GluK2 in complex 
with kainate, domain one and two are in blue and mustard. Kainate molecule in yellow ball stick 
representation, kainate interactions in black dashes, water molecules in green, water atoms 
forming hydrogen bond are in red (Adapted from Mayer 2005). 
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Figure 3.22. Glutamate binding site pocket for kainate receptors GluK1, GluK2 and GluK3. A) 
Glutamate in orange, GluK1 residues that interact with agonist in cyan, hydrogen bonds in black 
dashes and water molecules in red spheres. B) Binding sites differences for glutamate binding in 
GluK1, GluK2 and GluK3 in cyan, purple and green respectively, accession codes 2F36, 2XXR and 
4MH5. Amino acids numbering correspond to GluK1 sequence (Møllerud et al. 2017). 
 
3.4.3.3 Kainate Agonists  
As previously discussed kainic acid is the natural agonist for kainate receptors, however other 
molecules such as domoic acid and 5-iodowillardiine can also activate kainate receptors. Domoic 
acid (domoate) was identified for the first time in a sample of Japanese red algae Chrondria 
armata (Daigo  1959) in a study focused on identifying novel anthelmintic compounds. In 1982, 
domoic acid was synthesised for the first time (Ohfune & Tomita 1982) but it was not discovered 
until 1987 that domoic acid was toxic for humans when in Canada hundreds of people 
experienced poisoning symptoms after eating contaminated mussels (Hynie et al. 1990). 
Domoate is an analogue of glutamate and shares structural similarity with kainic acid, this toxin 
is  responsible for causing amnesic shellfish poisoning (ASP; Pulido 2008).  Domoate activates 
AMPA and kainate receptors by binding in the orthosteric site and causes an uncontrolled influx 
of calcium in neurons inducing apoptotic and necrotic neuronal cell death; domoate prevents 
the channel from rapid desensitization in both AMPA and kainate receptors, in addition to 
synergistic effect with NMDA receptors that results in excitotoxicity (Pulido 2008; Hogberg & 
Bal-Price 2011). Crystal structure of GluK2 LBD in complex with domoate was solved in 2005 and 
two years later the GluK1 LBD in complex with domoate was characterised (PDB accession codes 
2PBW and 1YAE).   
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Both crystal structures show similar residue interactions to kainate (Nanao et al. 2005; Hald et 
al. 2007). Similar to domoate, kainate in high concentrations can cause neuronal cell death and 
neurotoxic effects (Zhang & Zhu 2011).  
A derivative of AMPA agonist results in (S)-2-amino-3-(3-hydroxy-5-ter-butylisoxazol-4-yl) 
propionic acid (ATPA) a potent and highly selective agonist for GluK1 kainate receptors, with low 
affinity in AMPA receptors (Goot 2002; Nielsen et al. 2003). Crystal structure of the LBD of GluK1 
in complex with ATPA has not been crystallised yet.  
(S)-5-Iodowillardiine a willardiine analogue with agonist properties for glutamate receptors, has 
shown strong selectivity for kainate receptors over AMPA receptors and no interaction with 
NMDA receptors (Jane et al. 1997; Swanson et al. 1998).  
Another selective agonist at kainate receptors is the (2S,4R) 4-methyl glutamic acid (SYM2081), 
this glutamate analogue displayed preferential selectivity for kainate receptors over AMPA 
receptors, and displayed similar potencies for GluK1 and GluK2 subtypes, this agonist also 
induced pronounced desensitization (Zhou et al. 1997; Jane et al. 2009; Traynelis et al. 2010).  
 
Table 3.2. Agonist affinities to AMPA, kainate and NMDA receptors 
Agonist 
iGluRs 
AMPA Kainate NMDA 
Glutamate  ++ ++ ++ 
Kainate + ++ + 
Domoate ++ ++ ++ 
(S)-5-Iodowillardiine + ++ - 
ATPA + ++ - 
SYM2081 + ++ + 
++ Strong affinity and + low affinity, – no affinity 
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Figure 3.23. Structures of kainate receptor agonists (Adapted from Jane et al. 2009). 
 
Kainate antagonists will be described in detail in iGluRs section 3.5.2.2, antagonist and 
pharmacology.  
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 3.4.4 NMDA RECEPTORS  
NMDA receptors have three different subunits GluN1-GluN3. Post-transcriptional RNA 
processing of GluN1 results in eight different variants (alternative splicing) of the gene GRIN1 
located in two sites of the structure (Fig. 3.24), the N-terminus of the ATD and the C-terminus 
of the CTD (Vance et al. 2012; Vyklicky et al. 2014; University of Bristol 2017).  GluN2 subunits 
are encoded by four subtypes GluN2A-D and GluN3 by two subtypes GluN3A and GluN3B 
(Vyklicky et al. 2014).  
 
 
Figure 3.24. RNA alternative splicing in NMDA receptor subunit. Structure of the NMDA 
receptors, in red boxes show the regions of splice variation (University of Bristol, NMDA 
receptors; Adapted from http://www.bristol.ac.uk/synaptic/receptors/nmdar/). 
 
 
NMDA receptors form functional heterotetramers containing two obligatory GluN1 subunits in 
association with two GluN2 and/or GluN3 subunits. This combination of different subunits 
results in a large number of different NMDA receptors with different pharmacological and 
biological processes.  
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The structure of NMDA receptors is similar to AMPA and kainate receptors, an extracellular 
amino-terminal domain (ATD) linked to a ligand binding domain (LBD) connected to a 
transmembrane domain (TMD) and an intracellular carboxyl-terminal domain (CTD) (Fig. 3.24 & 
3.25). The full heterotetrameric GluN1-GluN2B solved at 3.96 Å (accession code PBD 4PE5) 
displayed a similarity in the dimer-dimer conformation for tetramer arrangement compared to 
other iGluRs. One significant structural difference is the more compact structure in the ATD and 
LBD, compared to the “Y” shape observed with AMPA and kainate receptors  (Fig. 3.25; Karakas 
& Furukawa 2014).  
This full-length structure of GluN1-GluN2B was crystallised in complex with glutamate, glycine 
and an allosteric inhibitor ifenprodil, a highly selective inhibitor for NMDA GluN2B subunit 
binding in the ATD. The structure represents the allosterically inhibited state of the receptor 
(Karakas & Furukawa 2014). Interestingly, a recent study using single particle cryo-electron 
microscopy (cryo-EM) combined with double electron-electron resonance investigated the 
structures of heterotetramer GluN1-GluN2B in complex with agonists (glutamate and glycine), 
agonists and allosteric inhibitor (Ro25-6991) and antagonists 5,7-dichlorokynurenic acid (DCKA) 
and D-(-)-2-amino-5-phosphonopentanoic acid (D-APV) (PDB accession codes in Table 3.3;  Zhu 
et al. 2016). This study proposed a mechanism of NMDA receptor inhibition and activation; firstly 
the binding of agonist glutamate in combination with glycine helps stabilize the LBD 
heterodimers and retain the gating ring formed by a dimer-dimer configuration from the LBD. 
Binding of the allosteric inhibitor Ro25-6981 in the ATD then induces the strength of LBD dimer 
interactions and stabilizes the LBD layer with ATD. Finally, the binding of competitive antagonist 
induces the separation and turns over of the LBD disrupting the LBD interactions with ATD and 
disrupting LBD gating ring (Fig. 3.26). A brief summary of the structural information of NMDA 
receptors is provided, however the purpose of this research is to focus on AMPA and Kainate 
receptors in more detail.  
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Figure 3.25. Comparison of the heterotetrameric GluN1-GluN2B receptor and the 
homotetrameric GluA2 receptor. NMDA GluN1a and GluN2B subunits labelled as GluN1a (α), 
GluN1a (β), GluN2B (α) and GluN2B (β) in orange, yellow, blue and purple respectively. Ifenprodil 
(IF) situated at the ATD interfaces, glutamate (L-Glu) and glycine (Gly) in the LBD are in green. 
NT, N-terminal and CT, C-terminal (Karakas & Furukawa 2014).  
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Figure 3.26. Schematic representation of the proposed mechanism of NMDA receptor inhibition 
and activation. Top, conformational changes of the extracellular domains ATD and LBD with 
agonist glutamate + glycine, allosteric inhibitor Ro25-6891 and competitive antagonist 5, 7-
dichlorokynurenic acid (DCKA) and D-(-)-2-amino-5-phosphonopentanoic acid (D-APV). Bottom, 
top-down representation of LBD conformations. The Apo-state is shown in grey due to no 
currently publish structure being available (Zhu et al. 2016).   
 
Table 3.3. Cryo-EM structures of GluN1/GluN2B NMDA receptor 
 
 
 
 
 
 
5,7-dichlorokynurenic acid (DCKA); D-(-)-2-amino-5-phosphonopentanoic acid (D-APV). Six 
different classes (conformations) of the DCKA/D-APV antagonist using double electron-electron 
resonance (DEER; Zhu et al. 2016). 
 
 
 
Accession code In complex with 
Resolution  
Å 
5IOU Glutamate + glycine 7.0 
5IOV Glutamate + glycine + Ro25-6981 7.5 
5IPQ DCKA/D-APV (Class 1) 13.5 
5IPR DCKA/D-APV (Class 2) 14.1 
5IPS DCKA/D-APV (Class 3) 13.5 
5IPT DCKA/D-APV (Class 4) 14.1 
5IPU DCKA/D-APV (Class 5) 15.4 
5IPV DCKA/D-APV (Class 6) 9.25 
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 3.5 iGluRs FUNCTION AND PHARMACOLOGY 
3.5.1 AMPA RECEPTORS  
 
3.5.1.1 FUNCTION AND DISTRIBUTION  
AMPA receptor subtypes GluA1-GluA4 have been found in the CNS, specifically with high levels 
of expression in the brain cerebral cortex, basal ganglia, thalamus, hypothalamus, hippocampus, 
cerebellum and spinal cord measured using [3H] AMPA binding studies and in-situ hybridization 
histochemistry (Olsen et al. 1987; Insel et al. 1990; Keinänen et al. 1990; Sommer et al. 1990; 
Stone 1995; Ozawa et al. 1998; Catarzi et al. 2007). Futhermore, AMPA autoradiography studies 
have found high density of AMPA anatomical distribution in the hippocampus (CA1 stratum 
radiatum and dentate gyrus), neurocortex (outer layers) and molecular layers of the cerebellum 
(Davis 2002). The hippocampus is responsible for short and long-term memory while the 
neurocortex plays a role in memory, language, cognition, attention and perception. The 
cerebellum plays an important role in balance and motor control but is also involved in cognitive 
functions (such as language and attention) and processing of procedural memory (unconscious 
memory) (Kryukov 2008; Kumaran 2008; Mochizuki-Kawai 2008; Rakic 2009).  
AMPA receptors mediate the majority of fast excitatory synaptic transmissions in the CNS and 
have an important role in long-term potentiation (Joshi et al. 2012).  Long-term potentiation 
(LTP) is the outcome of the increased activity between two neurons and is important for learning 
and memory processes.  
Frequently AMPA and NMDA receptors are located closer to each other in the presynaptic 
neurons, the traveling of an action potential in neurons results in the release of 
neurotransmitter glutamate. Glutamate then binds to both AMPA and NMDA receptors, if a 
small amount of glutamate is released, only AMPA receptors will allow the influx of Na+ ions into 
the postsynaptic neuron to cause a depolarization event; NMDA receptors usually have Mg2+ or 
Zn2+ ion that block the transport of ions through the channel. For LTP to occur a high-frequency 
action potential is necessary to release a larger amount of neurotransmitter from presynaptic 
neurons. When glutamate binds to AMPA receptors a greater depolarization event causes the 
AMPA receptors to remain open for longer and increases the influx of Na+ into the neuron. The 
large amount of Na+ influx will cause a larger depolarization in the neuron and will cause the 
release of Mg2+ or Zn2+ from the NMDA channel pore by a process called electrostatic repulsion, 
allowing the entering of ions such as Ca2+ through the pore  (Offermanns & Rosenthal 2008).  
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The Ca2+ influx in the postsynaptic neuron causes the phosphorylation and activation of 
Ca2+/calmodulin-dependent kinase II (CAMKII), this protein kinase promotes the trafficking and 
membrane exocytosis processes of AMPA receptors (Fig. 3.27; Lisman et al. 2002; Herring & 
Nicoll 2016). Protein kinase A (PKA) is also activated by the Ca2+ influx and both kinases 
phosphorylate AMPA receptors to enhance the conductance of the receptor (Kim et al. 2010). 
The upregulation of AMPA receptors is necessary for the induction of LTP (Cull-Candy et al. 2006; 
Chater & Goda 2014).  
 
Figure 3.27. Mechanism of long-term potentiation (LTP). (Adapted from The Human Brain: 
From neuron to nervous system, 
http://neurones.co.uk/Neurosciences/Tutorials/M1/M.1.B.4%20Ionotropic.html). 
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3.5.1.2 Antagonists and Pharmacology 
AMPA receptors have been found to play an important role in epilepsy; prolonged activation of 
AMPA receptors results in high levels of excitability, also upregulated activation of AMPA can 
generate proliferation of seizures. Antagonists of AMPA receptors have been shown to protect 
against seizures in vitro and in vivo in animal models (Rogawski 2013; Hanada et al. 2014; Twele 
et al. 2015).  AMPA antagonists have shown remarkable reductions in epileptiform, as well as 
reducing epileptic discharges in human seizures and epilepsy models  (Kasteleijn-Nolst Trenité 
et al. 2015; Twele et al. 2015; Chen et al. 2016).  AMPA antagonists such as 2,3-dihydroxy-6-
nitro-7-sulfamoyl-benzo[f]quinoxaline-2,3-dione (NBQX), Selurampanel (BGG492) and 
Perampanel are a promising new target for epilepsy therapy.  
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Table 3.4. Summary of AMPA antagonist drugs. 
Drug Clinical 
stage  
Use/Treatment  Comments  Reference  
Competitive Antagonist 
Fanapanel  
 
Phase II  Acute ischemic 
stroke  
Halted for intolerable side 
effects: high levels of 
sedation, drop of 
consciousness and transient 
neurological deterioration 
(Elting et al. 
2002) 
Becampanel 
 
Phase II Epilepsy, 
anticonvulsant  
Discontinued, no more 
information published  
(Suter et al. 
2002) 
NS1209 Phase II Refractory 
status 
epilepticus  
Inconclusive and incomplete 
results 
(Sabers et al. 
2013) 
(Keppel 
2017) 
Tezampanel Phase II  Acute migraine FDA approved phase III but 
study has not started due to 
financial constraints  
(www.clinica
ltrials.gov) 
Negative allosteric modulators (NAMs)  
Talampanel Phase I & 
II  
Anticonvulsant Halted due to finding various 
drug interactions 
(Bialer et al. 
2007; 
Rogawski 
2013) 
Perampanel  Marketed Epilepsy  Commercial name Fycompa 
by Eisai Co. Adverse side 
effects: somnolence, 
dizziness, fatigue, irritability 
and nauseas.  
(Besag & 
Patsalos 
2016) 
Positive allosteric modulators (PAMs)  
Aniracetam Marketed  Dementia, 
supplement for 
cognitive 
function 
Nootropic drug not 
approved by the FDA, 
however it is a prescription 
drug in Europe 
(Nakamura 
2006; Koliaki 
et al. 2012) 
Piracetam  Marketed Myoclonus and 
supplement for 
cognitive 
function 
Nootropic drug not 
approved by FDA but sold in 
Europe, Asia and South 
America  
(Einstein & 
McDaniel 
2004) 
Cyclothiazide Marketed Diuretic and 
antihypertensive 
Currently discontinued for 
marketing by the FDA 
registry 
(Antlitz & 
Valle 1967; 
Fucile et al. 
2006) 
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AMPA Competitive Antagonists 
The group of quinoxaline compounds were the first selective and potent AMPA receptor 
antagonist that have been found to display neuroprotection and reduce seizures in epilepsy 
models (Joshi et al. 2012).  The discovery of 2,3-dihydroxy-6-nitro-7-sulfamoyl-
benzo[f]quinoxaline-2,3-dione (NBQX) and 6-cyano-7nitroquinoxaline-2,3-dione (CNQX)  as 
potent and selective antagonists of the AMPA receptor in 1988 (Honoré et al. 1988; Sheardown 
et al. 1990) has initiated the synthesis and study of several quinoxaline type compounds. NBQX  
and CNQX were found to have anticonvulsant activity in mouse seizure models (Chapman et al. 
1991; Namba et al. 1994; Maj et al. 1995; Szczurowska & Mareš 2013).  Other quinoxaline 
derivatives found with anticonvulsant activity are; DNQX, YM-872, YM-90K, ZK-200775 
(Fanapanel) and AMP397 (Becampanel)(Shimizu-Sasamata et al. 1996; Turski et al. 1998; 
Takahashi et al. 2002; Catarzi et al. 2007; Joshi et al. 2012; Rogawski 2013). Fanapanel was in 
phase II clinical trials in patients with acute ischemic stroke, however it was terminated due to 
intolerable side effects such as glial cell toxicity and neurological deterioration (Elting et al. 2002).  
Another selective AMPA antagonist pyrazine derivative 9-carboxymethyl-imidazo-[1-
2a]indenol[1-2e]pyrazin-4-one-2-carboxylic acid (RPR117824) has been discovered to be a 
potent compound with anticonvulsant activity in mouse models (Mignani et al. 2002).  
Isatin oxime compounds such as  NS1209 (SPD502), have also been shown to inhibit GluK1 
kainate receptors (Nielsen et al. 1999; Pitkänen et al. 2007). NS1209 was tested in humans in a 
phase II clinical trial for Refractory Status Epilepticus (RSE). The compound displayed good 
tolerability in humans, however the results were inconclusive (Sabers et al. 2013).  Tezampanel 
(LY293-558 or NGX-242) a drug developed by Eli Lilly is a competitive antagonist of AMPA 
receptors and also presents great antagonist potency against GluK1 kainate receptors (Rogawski 
2013). This drug has been approved by FDA to initiate phase III clinical trials for acute migraine 
(NCT00567086, www.clinicaltrial.gov).  
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AMPA Non-Competitive Antagonists 
The non-competitive (negative allosteric) antagonists of AMPA receptors are the most potent 
and have less toxic side effects compared to other antagonists (Tarnawa & Vize 1998; Donevan 
& Rogawski 1993). The first non-competitive AMPA receptor antagonist identified was 1-(4-
aminophenyl)-4-methyl-7,8-mehtyllenedioxy-5H-2,3-benzodiazepine (GYKI 52466) and was 
used as a model for the development of novel, more potent, less toxic and more selective 2,3 
benzodiazepines. Derivatives of GYKI 52466 include GYKI 53405, GYKI 53655 and GYKI 53773 
and have displayed a wide range of anticonvulsant activity in several animal models (Chapman 
et al. 1991; Szabados et al. 2001; Rogawski 2013; Dhir & Chavda 2016). GYKI 53773, also known 
as talampanel, displayed great efficacy in reducing seizure frequency in a clinical trial, however 
various drug interactions were found, specifically with carbamazepine (Bialer et al. 2007; 
Rogawski 2013).  
Other unrelated non-competitive AMPA antagonists include the phthalazine YM928, the 
imidazole GYKI 47264, the quinazolin-4-one CP-465,022 and the bipyridine benzonitrile 
Perampanel (Abrahám et al. 2000; Menniti et al. 2000; Ohno et al. 2003). The latter, 2-(2-oxo-1-
phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl) benzonitrile (perampanel)  is a selective non-
competitive AMPA receptor antagonist drug with the commercial name Fycompa (Eisa Co.). It 
was approved by the FDA in 2012 for the treatment of primary generalized tonic-clinic seizures 
(PGTCS) in patients with epilepsy; adverse effects include dizziness, somnolence, fatigue, 
irritability and nauseas (Besag & Patsalos 2016).  
Balannik and co-workers found using mutagenesis experiments that non-competitive 
antagonists (GYKI-53655 and CP-465,022) bind in an interface between S1 and S2 of the LBD and 
the transmembrane spanning regions, more specifically between S1-M1 and S2-M4 linkers (Fig. 
3.28; Balannik et al. 2005). In 2016 the full-length GluA2 in complex with the antagonist GYKI 
53655, CP 465,022 and Perampanel was successfully crystallised, PDB accession codes 5L1H, 
5L1E and 5L1F respectively (Yelshanskaya et al. 2016).  These findings confirmed the binding 
sites of the non-competitive antagonist between the S1-M1 and S2-M4 linkers (Yelshanskaya et 
al. 2016).  A possible model of action of the non-competitive antagonist is that it acts like a 
wedge between the transmembrane segments, immobilizing the movement towards each other 
and stabilizing the closure of the channel (Fig. 3.29; Yelshanskaya et al. 2016). These new 
findings of the antagonist binding pocket can give a new target for the designing of new drugs 
with improved efficacy and safety. 
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Figure 3.28. AMPA non-competitive antagonist binding site. Schematic representation of the 
AMPA receptor dimer and binding site of the non-competitive GluA2 inhibitors Perampanel 
(PMP), GYKI53655 (GYKI) and CP 465,022 (CP) in red squares with structures (Yelshanskaya et al. 
2016). Linker segments between S1-M1 and S2-M4 are binding sites for non-competitive AMPA 
antagonist (Adapted from Rogawski 2013). 
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Figure 3.29. Putative model of the mechanism of the non-competitive inhibitor in AMPA 
receptors. In absence of an inhibitor the glutamate binding domain closes the clamshell-like 
structure and induces the opening of the pore (red arrow). Inhibitor acts like a wedge (yellow) 
avoiding the opening of the channel (Yelshanskaya et al. 2016). 
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3.5.2 KAINATE RECEPTORS 
3.5.2.1 FUNCTION AND DISTRIBUTION  
Kainate receptors are expressed in postsynaptic and presynaptic neurons, with postsynaptic 
receptors being involved in excitatory neurotransmission and presynaptic receptors in inhibitory 
neurotransmission (Kristensen et al. 2016). In situ hybridization studies in the brain have found 
the expression of mRNA GluK1 subunit in dorsal root ganglion neurons and in the Purkinje cells 
of the cerebellum. GluK2 mRNA was highly expressed in the cerebellar granule cells, in the 
dentate gyrus, the striatum and the CA3 region of the hippocampus (Lerma et al. 2001). GluK3 
mRNA was detected at low levels of expression in the cerebral cortex, the striatum and in the 
inhibitory neurons of the molecular layer of the cerebellum (Lerma et al. 2001). In contrast, 
GluK4 was found almost exclusively in the CA3 region of the hippocampus, with relatively low 
levels of expression in amygdala and entorhinal cortex (Lerma et al. 2001; Darstein et al. 2003). 
The GluK5 mRNA was found in the striatum, the inner/outer layers of the cortex  and amygdala  
(Gallyas et al. 2003; Braga et al. 2004).  
Kainate receptors have been demonstrated to play an important role in synaptic transmission, 
presynaptic release of glutamate and γ-aminobutyric acid (GABA) and in the development of 
epileptogenesis. The function of kainate receptors depends on their cellular distribution. In 1999, 
kainate receptors (GluK1 subunit) were found to be involved in long-term potentiation in 
synaptic transmission in mossy fibre of CA1 region of the hippocampus by ligand binding studies 
and electrophysiology (Bortolotto et al. 1999). Similar to AMPA, kainate receptors function in 
synaptic plasticity in the postsynaptic cell, however their role is minor compared to AMPA 
receptors but aid in the influx of Na+ to induce LTP (Fig. 3.30a). Recently, kainate receptors have 
been implicated in regulating presynaptic LTP in hippocampus and amygdala.  More specifically 
GluK1 receptors have been associated with pre-LTP mechanisms in anterior cingulate cortex 
(ACC), pre-LTP in ACC have shown an important role in chronic pain, fear and anxiety  (Koga et 
al. 2015; Yamanaka et al. 2016).  In presynaptic neurons active GluK1 receptors allow the influx 
of Ca2+ that leads to the activation of type I adenylyl cyclase (AC1)/protein kinase A (PKA) 
pathway and hyperpolarization-activated cyclic nucleotide-gated (HCN) channels that result in 
the regulation of vesicular glutamate transport and in the long lasting increase of glutamate 
release (Fig. 3.30b; Huang & Trussell 2014; Yamanaka et al. 2016; Zhuo 2017a).  
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In addition, kainate GluK1 receptors play an important role in modulating the release of GABA 
neurotransmitter in the pre-synaptic neuron by action potential-dependent GABA release and 
the activation of voltage-dependent Ca2+ channel influx. However, the exact mechanism of 
kainate in GABA signalling it is not yet fully understood (Fig. 3.30c; Wu et al. 2007; Zhuo 2017a).   
 
Figure 3.30. Synaptic transmission and pre-synaptic LTP regulation by kainate receptors in the 
cingulate cortex.  a) Postsynaptic GluK1 and GluK2 is involved in mediating synaptic response in 
addition to AMPA receptors. b) Activation of GluK1 receptor in presynaptic neuron allows the 
influx of Ca2+ ions into the neuron and activates the type I adenylyl cyclase (AC1)/protein kinase 
A (PKA) pathway and the hyperpolarization-activated cyclic nucleotide-gated (HCN) channels to 
induce the increase of glutamate release. c) In presynaptic neurons  activation of GluK1 
receptors triggers action potential-dependent GABA release (Zhuo 2017a).  
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Seizure generation and epileptogenesis  
The first evidence of a link between kainate receptors and epilepsy was in 1998 when it was 
found that GluK2 receptors in the CNS of mice are important in synaptic transmission and in 
epileptogenesis induced by kainate (Mulle et al. 1998). In the study, GluK2-deficient mutant 
mice showed less susceptibility to develop seizures by kainate administration, suggesting the 
importance of the GluK2 kainate subtype in seizure onset induced by kainate administration 
(Mulle et al. 1998).  
Previous research has demonstrated that selective antagonists for AMPA and kainate can reduce 
seizure symptoms in animal models. For example, in a GluK1 study  antagonists LY-377770 and 
LY-382884 prevented and interfered with limbic seizures induced by pilocarpine in a rat model 
(Smolders et al. 2002). Also, the Gluk1 and AMPA antagonist NS1209 (discussed in AMPA 
antagonist section 3.5.1.2) alleviated refractory status epilepticus (RSE) in a small phase II study 
however no further research followed due to inconclusive results (Pitkänen et al. 2007; Sabers 
et al. 2013). 
Topiramate (Topamax), a current anticonvulsant drug approved by the FDA in 2012 for the 
treatment of epilepsy, has been shown to interact (antagonize) with AMPA and kainate 
receptors (Andreou & Goadsby 2011). For example, one study showed that Topiramate inhibits 
kainate-induced activation in cultured cerebellar granule neurons expressing AMPA and kainate 
receptors (Skradski & White 2000; Gryder & Rogawski 2003; Braga et al. 2009). In another study, 
Topiramate selectively inhibited GluK1 kainate receptor-mediated excitatory postsynaptic 
responses and protected against seizures induced by ATPA in rat neurons (Braga et al. 2009).   
In a chemoconvulsive status epilepticus (SE) model in rats, the administration of kainate 
increased the expression of Gluk1, GluK2/GluK3, GluK4 and GluK5 in the CA1 region of the 
hippocampus measured by immunohistochemistry and colocalization (fluorescence microscopy) 
studies (Vargas et al. 2013).  Higher expression of GluK1 was observed in astrocytes followed by 
GluK4, GluK2/3 and GluK5; these results demonstrate that after seizure onset astrocytes initiate 
the overexpression of kainate receptors, indicating a role in epilepsy (Vargas et al. 2013).  
There is strong evidence linking kainate receptors in seizure generation and epileptogenesis, for 
that reason novel antagonists of kainate receptors might be an alternative for the treatment of 
epilepsy. This thesis research was focused on structure-based studies of kainate receptors GluK1 
and GluK2 for the target of epilepsy treatment.  
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3.5.2.2 Antagonists and Pharmacology 
 Competitive Antagonists  
Quinoxalinedione derivative compounds such as CNQX and NBQX are relatively non selective 
competitive antagonists for kainate and AMPA receptors  (Kew & Kemp 2005; Jane et al. 2009).  
A number of tetrazole-substituted decahydroisoquinolines, including LY-293558 (Tezampanel), 
LY-294486, LY-37770 and LY-382884 have been shown to possess antagonist activity for AMPA 
and kainate receptors, more specifically with GluK1 receptors compared to AMPA subtypes 
(Bleakman et al. 1997; Dingledine et al. 1999; Jane et al. 2009; Rogawski 2013) . A willardiine 
analogue UBP302 selectively inhibits GluK1 receptors with low activity versus other kainate 
subtypes or AMPA receptors (More et al. 2004). Crystal structures of the LBD of Gluk1 in complex 
with UBP302 and UBP310 (PDB accession codes, 2F35 and 2F34) were characterised, both 
compounds were shown to bind in the orthosteric site using a new mechanism of binding and 
did not form direct contacts with Glu-723 residue resulting in 22 Å extension of the ligand 
binding core compared with other crystal structures (Mayer 2006a).  These crystal structures in 
complex with UBP compounds were important for the design of a new antagonist UBP316 
(ACET). ACET was found to be a highly potent antagonist for GluK1, and not for GluK2 and GluK3 
receptors by adding substituents to the thiophene ring and increasing the hydrophobic 
interactions with GluK1 receptor in Val-670 and Asn-705 (Dolman et al. 2007). ACET also displays 
antagonist activity with NMDA receptors, ACET reversibly blocked induction of NMDA receptor-
independent long term potentiation (LTP) in vitro experiments (Dolman et al. 2007; Dargan et 
al. 2009). There is a need for more detailed information on how exactly new antagonists interact 
with glutamate receptors and their possible effects in therapeutics.  Competitive antagonists 
that bind to the orthosteric site exhibit more side effects because they can also bind to 
homologous receptors with similar binding sites such as AMPA and NMDA. For that reason, non-
competitive antagonists are advantageous; however, a few of non-competitive antagonists have 
been reported. 
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 Non-Competitive Antagonists  
Although several AMPAR non-competitive antagonists have been described, relatively few non-
competitive antagonists have been discovered for kainate receptors. In recent years, efforts 
have been focused on studying kainate antagonists that bind to the orthosteric site (glutamate 
site). However, recent evidence shows new allosteric binding sites for AMPA and kainate 
receptors antagonists, these novel binding sites can have important clinical relevance 
(Yelshanskaya et al. 2016; Probst Larsen et al. 2017).  
5-carboxyl-2,4-di-benzamido-benzoic acid (NS3763), the first non-competitive antagonist for 
kainate receptors was characterised in 2004 (J. K. Christensen et al. 2004). NS3763 was shown 
to inhibit domoate-induced responses in homomeric GluK1 receptors expressed in HEK-293 cells 
but no inhibition was observed in heteromeric GluK1/GluK2 or GluK1/GluK5, AMPA or NMDA 
receptors (J. K. Christensen et al. 2004; Matute 2011).  
Two 2-arylureidobenzoic acids (AUBAs) identified as 1 and 2a (Fig. 3.31; named accordingly to 
original paper Valgeirsson et al. 2004) demonstrate to have non-competitive activity against 
kainate receptors, more specifically, compound 1 displayed higher affinity to GluK1 than GluK2, 
whereas compound 2a had the same potency for GluK1 and GluK2. Both compounds had no 
antagonist activity against AMPA subunits expressed in HEK-293 cells (Valgeirsson et al. 2003; 
Valgeirsson et al. 2004), thereby demonstrating high selectivity for kainate versus AMPA 
receptors, no studies have been done in NMDA receptors. A more recent study using homology 
modelling and molecular docking suggests a new non-competitive binding site for kainate 
receptors GluK1 and GluK2 for indol-derived antagonists. This allosteric site is suggested to occur 
between S1-M2 and S2-M4 in the transduction domain. However these results not have any X-
ray data to prove the exact binding site, they based this experiment on previously discussed 
AMPA allosteric site (Rogawski 2013; Kaczor et al. 2014). 
 
 
Figure 3.31. Chemical structure of kainate receptors allosteric antagonists (Adapted from 
Valgeirsson et al. 2004; Jane et al. 2009) 
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Kainate Allosteric Modulators  
Concanavalin A (Con-A) is a member of the sugar lectin family that has shown to block 
desensitization in kainate receptors by binding to a series of N-glycosylated residues on 
glutamate receptors extracellular domain. Con-A is a non-selective positive allosteric modulator 
(PAM) which can increase receptor agonist affinity in kainate, AMPA and NMDA receptors 
(Partin et al. 1993; Lerma et al. 2001; Bleakman et al. 2002; Mott et al. 2010).  
More recently, a new study was able to crystallize GluK1 LBD in complex with three positive 
allosteric modulators (PAMs) BPAM344, BPAM121 and BPAM521 (PDB accession codes 5MFQ, 
5MFW and 5MFV respectively). These kainate modulators (Fig. 3.32) are benzothiadiazine 
compounds that bind to a novel allosteric binding site in the lower area of the GluK1 LBD dimer 
interface, near the D1-D2 hinge area (Fig. 3.33; Probst Larsen et al. 2017). BPAM344 and 
BPAM521 display a potent positive modulatory effect on currents evoked by glutamate in 
homomeric GluK1b, GluK2a and GluK3a isoform receptors expressed in HEK-293. More 
specifically, BPAM344 showed a stronger potentiation effect of glutamate-evoked currents in 
GluK2a and GluK3a compared to AMPA GluA2 receptors. In addition, the allosteric effect showed 
no differences between GluK1b and GluA2. The three compounds displayed allosteric activity 
for GluA2 AMPA receptors, in which only BPAM121 significantly potentiates the peak current 
amplitude of AMPA receptors (Probst Larsen et al. 2017). In previous studies BPAM344 was 
identified as a strong positive allosteric modulator for AMPA receptors and more interestingly it 
displayed a specific binding site between the dimer interface of the LBD for all types of 
benzothiadiazine modulators. It is believed that allosteric modulators of AMPA receptors 
stabilize the dimer and agonist-bound opening channel conformation, thereby reducing rapid 
desensitization and deactivation (Nørholm et al. 2013; Krintel et al. 2016).  Positive allosteric 
modulators of iGluRs are promising targets for helping improve cognitive disorders like 
Alzheimer’s disease and schizophrenia in which glutamate transmission is deficient.  These new 
allosteric sites could give an opportunity to find new drugs with improved pharmacological 
properties and higher target specificity (Menniti et al. 2013; Krintel et al. 2016).  
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Figure 3.32. Chemical structures of BPAM344, BPAM521 and BPAM121 (Adapted from Probst 
Larsen et al. 2017). 
 
Figure 3.33. Binding interactions of BPAM344, BPAM521 and BPAM121 with LBD-GluK1. 
Antagonists BPAM344, BPAM521 and BPAM121 in green, cyan and orange respectively. 
Residues involved in antagonist interaction within 3.5 Å in domains one and two in beige and 
grey. Water molecules in red spheres and hydrogen bonds in black dashed lines (Probst Larsen 
et al. 2017). 
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Figure 3.34. GluK1-LBD in complex with BPAM344 and kainate. A) LBD of GluK1 dimer, domains 
one and two in beige and grey respectively. Kainate and BPAM344 are shown as black and green 
stick representations, chloride ion used for crystallography in green. B) Rotated view of the LBD 
in which the antagonist BPAM binds inside the lower part of the dimer interface (Probst Larsen 
et al. 2017).  
 
The PAM BPAM344 binds between the dimer interface of the GluK1 dimer, more specifically two 
BPAM344 molecules bind in a lower region of the interface. In addition, kainate agonist binds in 
the orthosteric site of the LBD between domains one and two (Fig. 3.34). The three PAMs bind 
with similar interactions, the main differences are residues Thr-535, Ser-761 and Gln-786 that 
adopt different binding conformations for each PAM (Fig. 3.33) and more specifically Thr-535 
side chain turned aside from modulator site in the presence of BPAM121 (Probst Larsen et al. 
2017).  This binding interface shares a similar binding mode to that previously observed with 
AMPA GluA2 in complex with other PAMs, such as cyclothiazide, piracetam, aniracetam, 
LY451646 and 3,4-dihydro-2H-1,2,4-benzothiadizine dioxide (Menniti et al. 2013; Nørholm et al. 
2013). To conclude, the kainate and AMPA receptors display a similar allosteric binding site at 
the LBD interface; these similarities allow the design of novel PAMs that can be selective for 
kainate receptors. 
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3.5.3 NMDA RECEPTORS  
3.5.3.1 FUNCTION AND DISTRIBUTION  
The N-methyl-D-aspartate (NMDA) receptor is a iGluR important for synaptic plasticity and 
memory function (Li & Tsien 2009). NMDA receptors are located in the cerebral cortex, the 
largest region of the brain responsible for information processing, memory, attention, 
perception, cognition, language, sensation and association (Vidyasagar 1996; Boundless 
Cerebral Cortex 2016). Immunocytochemistry studies found cortical NMDA receptors in 
dendritic spines, astrocytes and axon terminals (excitatory and inhibitory) suggesting a large 
distribution of NMDA receptors in neurons of the cerebral cortex (Conti 1997).  
NMDA agonist selectively and exclusively activates NMDA receptors and no other glutamate 
receptors. The property that differentiates NMDA receptors from other receptors is the 
requirement of the binding of an agonist (glutamate) and a co-agonist (Glycine or D-serine) for 
activation of the channel (Fig. 3.35). Extracellular ions such as Mg2+ and Zn2+ are able to bind 
inside the pore and block the channel, membrane depolarization results in the release of Mg2+ 
and Zn2+ from the pore channel allowing the voltage-dependent flow of ions Na+ and Ca2+ inside 
the cell and K+ outside the cell (Hashimoto 2017). The opening of the channel results in an influx 
of Ca2+ ions that triggers signal transduction cascades such as protein kinases, calcium-
dependent enzymes, second messengers and phosphatases that are important for 
neuroplasticity (Blanke & VanDongen 2009; Karakas & Furukawa 2014).  
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Figure 3.35. Diagram of the topology of activated NMDA receptors. The activation of the NMDA 
channel requires the binding of neurotransmitter glutamate and co-agonist Glycine or D-serine 
to allow the influx of Ca2+ and Na+ and the efflux of K+, membrane depolarization is necessary 
for the release of Mg2+ from the pore (Adapted from Tulane University, Medical Pharmacology 
TMedWeb. 
http://tmedweb.tulane.edu/pharmwiki/doku.php/overview_of_cns_neurotransmitters).  
 
NMDA receptors are important for a large amount of post-synaptic functions; more specifically, 
long-term potentiation (LTP), a mechanism of synaptic plasticity important for learning and 
memory, is controlled by NMDA receptors. As previously described in AMPA function section 
3.5.1.1; the activation of NMDA receptors in the postsynaptic neuron allows the influx of Ca2+ 
and results in the activation of Ca2+/calmodulin-dependent kinase II (CAMKII) and protein 
kinases (A and C). Both induce the synaptic insertion of AMPA receptors (Fig. 3.27 & 3.36) to 
ensure synaptic potentiation by LTP (Newcomer et al. 2000; Lisman et al. 2002; Kim et al. 2010; 
Herring & Nicoll 2016). In addition, NMDA receptors are also implicated with long-term 
depression (LTD), a mechanism that is characterised by the longer reduction of synaptic 
transmission. Once more, the influx of Ca2+ by NMDA receptors by low-frequency stimulation 
activates hippocalcin, a Ca2+ binding protein important for synaptic plasticity and learning 
(Dovgan et al. 2010). Hippocalcin forms a complex with adaptor protein 2 (AP2) to activate the 
receptor-mediated endocytosis (RME) to initiate the AMPA receptor internalization and as a 
result the neuron is less responsive to glutamate neurotransmitter (Palmer et al. 2005; Derkach 
et al. 2007; Dovgan et al. 2010). 
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Figure 3.36. NMDA dependent long-term potentiation (LTP) and long-term depression (LTD).  In 
long-term synaptic plasticity the activation of NMDA allows the influx of Ca2+ either by increasing 
the expression of AMPA receptors (high-frequency stimulation) or reducing the expression of 
AMPA receptors (low-frequency stimulation). (Boundless, Synaptic plasticity; 
https://www.boundless.com/biology/textbooks/boundless-biology-textbook/the-nervous-
system-35/how-neurons-communicate-200/synaptic-plasticity-765-11998/). 
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3.5.3.2 ANTAGONIST AND PHARMACOLOGY  
 
 Competitive antagonists  
These compounds will compete for the glutamate binding site in the LBD of the receptor. The 
2R-amino-5-phosphonopentanoate (AP5) is a selective competitive NMDA receptor antagonist 
first described in 1981  by Watkins and Evans (Watkins & Evans 1981). AP5 is able to block the 
induction of LTP and impairs spatial learning (Davis et al. 1992; Morris et al. 2013). One 
disadvantage of AP5 antagonist is the low selectivity (<10-fold) for other AMPA subunits 
(Vyklicky et al. 2014). Two phenanthrene compounds (2R*,3S*)-1-(phenanthrene-3-carbonyyl) 
piperazine-2-3-dicarboxylic acid (UBP141) and its 9-brominated homolog (2R*,3S*)-1-(9-
bromophenan- threne-3-carbonyl)piperazine-2,3-dicarboxylic acid (UBP145) have shown high 
selectivity for GluN2D subunits over GluN2B and GluN2A (Morley et al. 2005; Costa et al. 2009).  
 
 Channel blockers (Non-competitive antagonists) 
Some compounds have the ability to block the channel by binding at the Mg2+ site inside the 
channel pore acting as a non-competitive antagonist (Fig. 3.37). However, the blocking of the 
channel will require previous receptor activation, otherwise the drug will not be able to enter 
the open channel  (Vyklicky et al. 2014). The most potent NMDA blocker is a dizocilpine maleate, 
frequently named dizocilpine or MK-801; dizocilpine was discovered and patented by Merck and 
functions as an anticonvulsant and anaesthetic drug. Unfortunately drug administration in rats 
demonstrated the development of brain lesions (Olney’s lesions), it has also been associated 
with neurotoxicity and learning impairment (Olney et al. 1986; Kovacic & Somanathan 2010). 
Two other channel blockers with lower affinity antagonist effect are phencyclidine (PCP) and 
ketamine (previously discussed in section 3.2, glutamate neurotransmission in disease) both 
drugs are mainly used as anaesthetics however, both drugs display dissociative effects 
(hallucinogens) such as memory loss, sedation and delusions (Kapur & Seeman 2002; Sleigh et 
al. 2014; Vyklicky et al. 2014).  Medical use of PCP in humans was discontinued for the 
dissociative side effects; ketamine is used to treat chronic pain and as anaesthetic but only as a 
prescription and controlled drug. Memantine is another channel blocker, a drug approved by 
FDA and European medicines agency (EMA) for the treatment of Alzheimer’s disease (AD), it is 
a low-affinity voltage-dependent channel blocker of NMDA receptors and it has been shown to 
have better clinical tolerability.  
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The reduction of side effects of memantine is due to their low affinity for NMDA receptors, this 
drug rapidly binds to the Mg2+ binding site and quickly dissociates from the receptor (Kalia et al. 
2008; Vyklicky et al. 2014). The major challenge of these channel blockers is that they have low 
or no subtype selectivity causing large side effects (Dravid et al. 2007). 
 
 Polyamine site antagonists 
In the amino terminal domain (ATD) of NMDA receptors there is a region that shares homology 
to the leucine-isoleucine-valine binding protein (LIVBP), this region is an allosteric modulator 
domain that binds to zinc in GluN2A and polyamines in GluN2B (O’Hara et al. 1993; Masuko et 
al. 1999; Fayyazuddin et al. 2000; Monaghan & Jane 2009). Ifenprodil, a phenylethanolamine 
drug, is a selective antagonist of NMDA receptors containing NR2B subunit (Williams 2001). It is 
currently in clinical trial phase II for the treatment of post-traumatic stress disorder (PTSD) in 
adolescents, results to be completed in 2020 (NCT01896388, www.clinicaltrials.gov). The 
highest affinity antagonist for this site is Ro25-6981 which has binding affinity for NMDA 
receptors containing GluN2B subunit (Fischer et al. 1997).  Ro25-6981 has been reported to have 
antidepressant properties and studies are currently being conducted to determine the clinical 
actions of this drug in depression (Duman 2014).  Traxoprodil (CP-101,606) a drug characterised 
by Pfizer, displayed a selective antagonist for NMDA receptors containing the GluN2B subunit 
(Di et al. 1997). Traxoprodil has shown neuroprotective and analgesic properties, and phase II 
clinical trials were performed in Parkinson disease (PD) and major depressive disorder (MDD) 
patients (NCT00163085 & NCT00163059, www.clinicaltrials.gov).  Unfortunately, the studies 
were halted due to electrocardiographic abnormalities (QT prolongation) associated with 
potassium channel blockade (Wolfgang & Rogawski 2002).  In addition, traxoprodil was also 
associated with abnormal thinking and amnesia as undesirable side effects (Nutt et al. 2008).  
Subunit selectivity for competitive antagonist is necessary in the new antagonist of NMDA, to 
avoid adverse side effects; this research was not focused on NMDA receptors.  
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Figure 3.37. Chemical structures of several NMDA antagonists. 
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CHAPTER 4 
AMPA PROJECT 
 
4.1 ABSTRACT 
Epilepsy is a chronic neurological disorder and is characterised by recurrent unprovoked seizures. 
It is one of the most common neurological disorders worldwide; with the overall incidence of 
epilepsy in Europe and North America being 24 and 53 cases per 100,000 persons per year 
respectively, affecting 50 million people worldwide according to the World Health Organization 
(WHO). Epilepsy has a wide variety of phenotypes having more than 15 different seizure types 
and more than 30 epilepsy syndromes. Several anti-epileptic drugs (AEDs) such as, 
carbamazepine, perampanel, piracetam and diazepam are available currently, however 25% to 
30% of epilepsy patients do not respond to drug treatment (refractory patients; French 2006; 
Laxer et al. 2014). Additionally, the significant side effects of current AEDs such as fatigue, 
vertigo, headaches, sedation, drowsiness and nausea may result in treatment discontinuation in 
approximately 25% of patients (Perucca & Gilliam 2012). 
AMPA receptors are a type of ionotropic glutamate receptors (iGluRs), involved in excitatory 
neurotransmission and are a recent target for AEDs. Currently several anticonvulsant drugs such 
as Becampanel and Fanapanel can diminish the excitatory neurotransmission of glutamate by 
antagonising the binding site; however these antagonist drugs can cause significant side effects 
due to action in other iGluRs in the brain. Perampanel, an antiepileptic drug approved in 2012 
for the treatment of partial seizures and generalized tonic-clonic seizures in adults, was found 
to bind in a new allosteric site in AMPA receptors. This new binding site located in the 
transduction domain (between the ligand-binding domain and the transmembrane domain) 
gives great selectivity to negative allosteric modulators (NAMs) including perampanel. 
Unfortunately, this drug can cause a large number of adverse side effects including behavioural 
and psychiatric changes, irritability, nauseas, somnolence, fatigue and dizziness, for that reason 
its clinical use is limited (Besag & Patsalos 2016). Hence, we are interested in a different allosteric 
site than the transduction domain due to a large amount of side effects, as well as the difficulty 
of obtaining the isolated transmembrane domain with the LBD for purification and 
crystallography experiments.  
AMPA receptors play an important function in the process of synaptic plasticity and are known 
to be involved with the long-term potentiation mechanism. A group of positive allosteric 
modulators (PAMs) of AMPA receptors frequently known as AMPAkines have been shown to 
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improve cognitive function in a variety of pre-clinical assays (Lynch & Gall 2006; Beneyto et al. 
2007; Ward et al. 2011). In addition, a novel binding site for positive allosteric modulators (PAMs) 
located between the dimer interface of the ligand-binding domain of AMPA receptors has been 
targeted for drug discovery research focused on cognitive processes (learning and memory). 
Previous research has shown that AMPA PAMs can improve cognitive performance and be a 
potential target for Schizophrenia, a  chronic mental disorder that affects behaviour, thoughts 
and perception (Ward et al. 2011).  
This project was focused on finding novel negative allosteric modulators (NAMs) and positive 
allosteric modulators (PAMs) compounds in the LBD of AMPA receptors using fragment-based 
screening experiments. The experiments resulted in a successful protein production, purification 
and crystallography for the LBD of AMPA. More than 700 fragment compounds were screened 
with LBD AMPA crystals using the Diamond fragment screening (XChem) library. Eight fragments 
were identified, situated in three different sites in the LBD of AMPA, two sites within the dimer 
interface and one site near the Gly-Thr linker of S1 and S2 of the LBD. These fragment hits found 
in the dimer interface similar to the literature PAM site are promising for the novel AMPA PAMs 
characterisation with improved therapeutic properties. Similarly, fragments found near the Gly-
Thr linker situated near to the novel NAMs site found in published literature could be a potential 
target for improved antiepileptic form. These results give important information for the early 
development of drug discovery in epilepsy and Schizophrenia treatment.   
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4.2 AIMS  
 
The overall aim of the project was to obtain X-ray structural information about the AMPA 
receptors GluA2 LBD in complex with small compounds to aid future drug development in the 
treatment of disorders associated with a dysfunction of AMPA receptors, such as the cognitive 
deficit associated with schizophrenia as well as epilepsy. The initial aim was to express the LBD 
construct in E. coli bacteria and then purify the protein at a scale large enough to support 
crystallography method development and then X-ray crystallography to determine the structure 
of dimeric GluA2 in association with orthosteric ligand (glutamate) as well as small molecule 
binders. A construct with a sequence encoding a 6xHis-SUMO tag was chosen due to its ability 
to enhance protein folding (the SUMO sequence) and to purify the protein (the six-residue 
polyhistidine sequence). The main objective of the fragment screen (XChem, Diamond Light 
Source) was to identify novel binders of the AMPA protein binding in the dimer of the LBD of the 
protein.  
 
 
Figure 4.1. AMPA overall project plan. The large blue box with a dashed border represents the 
experiments covered in this thesis project research. The functional characterisation of hits and 
potential subsequent iterative medicinal chemistry is planned for future studies.  
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4.3 MATERIALS AND METHODS 
 
4.3.1 CLONING AND PLASMID VECTOR 
The plasmid used for protein expression and purification was the ligand-binding domain (LBD) 
of rat GluA2, kindly supplied by Dr. Antony W. Oliver from the Genome Damage and Stability 
Centre (GDSC; University of Sussex).  In the GDSC, they used their own pHis-SUMO-3C vector in 
which they cloned the proteins for purification purposes. Polyhistidine in combination with small 
ubiquitin-like modifier (SUMO) tags are frequently used due to the ability of increase the 
expression of recombinant proteins and enhance protein solubility (Costa et al. 2014).  
The LBD construct was designed according to previous published experiments (Armstrong & 
Gouaux 2000) using the segments S1 and S2 from the LBD (Fig. 4.2). The S1S2 construct was 
produced by deleting the ATD at the beginning of S1 and then link the end of S1 with proximal 
S2 using a Gly-Thr linker and finally cutting the ending of S2 before the transmembrane segment 
M4. This dipeptide Gly-Thr was sufficient to covalently join S1 and S2 without modifying the 
conformation and properties of the LBD of the protein (Reddy et al. 2013).  
 
Figure 4.2. Cartoon showing the strategy for the GluA2 ligand-binding domain construct design. 
The S1S2 construct is based on previous published experiments in which the amino terminal 
domain (ATD) was deleted at the beginning of S1; a Gly-Thr linker was used to join S2 and S1 and 
deleting the last segment of S2 closer to M4 (Adapted from Armstrong & Gouaux 2000).  
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In this case, the LBD of rat GluA2 was cloned into pHis-SUMO-3C vector and consequently sub 
cloned into pBR322 plasmid using a commercially available pET T7 expression system by 
Invitrogen (Thermo Fisher Scientific). Similar to previously published studies (Armstrong & 
Gouaux 2000) the LBD sequence was based on the Flop-splice variant UniProt P19491-1 (Fig. 
4.3), with three mutations in the N-terminus of S1 in G410R, L411G and E412A  with the purpose 
of facilitating crystallography experiments. Additionally, one mutation in S2 of N775 to serine 
corresponding to the flip isoform was designed because compounds such as cyclothiazide have 
preference to the flip isoform in this specific residue (Partin et al. 1996; Sun et al. 2002; Nørholm 
et al. 2013). The recombinant protein contains a 6xHis-SUMO tag to improve the solubility and 
purification experiments. The plasmid was provided by Invitrogen and contained an ampicillin 
resistance gene to control the production of recombinant protein (Fig. 4.4). Protein expression 
was induced by β-D-1thiogalactoryranoside (IPTG) under a T7 RNA polymerase/promoter 
system. In this system the T7 promoter site is located upstream of the recombinant gene and 
the expression of the gene is controlled by the addition of IPTG. This expression system is highly 
effective in producing large amounts of target protein.  
 
Figure 4.3. rGluA2 LBD sequence construct for protein expression and purification. rGluA2 
construct contains an N-terminal 6xHis-SUMO tag, a recognition SUMO cleavage site and the 
protein sequence consisted of S1 [406-NDTSRGAN….SIMIKK-527] and S2 [653-
PIESAEDL….YDKGECG-795], separated by a Gly-Thr linker. Sequence based on rGluA2 P19491-1 
Flop Isoform (Uniprot). Positive allosteric modulators (PAMs).  
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Rat GluA2 protein expression and purification was used because crystals of rat protein are, for 
whatever reason easier to express and purify and more readily forms crystals (Ward et al. 2011). 
In addition, there are more published structures of the LBD of GluA2 rat than human. 
 
Figure 4.4. Plasmid map of the inserted rat GluA2 LBD gene, of which 5µg of lyophilised plasmid 
was obtained by Invitrogen. The plasmid PBR322 commonly used as a cloning vector encoding 
an Ampicillin resistant gene, origin of replication, T7 promote site (control the levels of protein 
expression by IPTG), 6xHiS-SUMO tag, rGluA2 LBD and different restriction enzyme sites. Plasmid 
used for cloning by Invitrogen (Thermo Fisher Scientific).  
  
4.3.2 COMPETENT CELLS  
The competent cells used for transformation experiments were E. coli Origami™ B (DE3) by 
Novagen (Cat. No. 70837-3). Origami B strains have mutations in the thioredoxin reductase (trxB) 
and glutathione reductase (gor) genes, these modifications enhance the formation of disulphide 
bonds in the cytoplasm.  Origami bacteria was used for the characteristic of forming disulphide 
bonds to obtain the correct folding of the protein and subunit assembly. Origami B strains are 
compatible with ampicillin and carbenicillin resistance plasmids and are adequate for use with 
pET vectors. Selective antibiotics for Origami strains are kanamycin and tetracycline.  
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4.3.3 BACTERIA TRANSFORMATION 
The vector containing the LBD_rGluA2 (15ADDVVC_pHis-SUMO-rGluA2_SUMO-GG-3C-
TONY_R545) was dissolved with 30 µl of purified sterile water. A volume of 1 µl of vector was 
added into 50 µl of E. coli Origami B (DE3) cells and incubated on ice for 30 minutes. Heat shock 
was performed at 42°C for 40 seconds, and then the vial was transferred on ice for 2 minutes. 
To finalize with the addition of 200 µl of super optimal broth with catabolite repression medium 
(SOC) (Invitrogen, Cat. No. 1544-034) and further incubation at 37°C for 1 hour in the shaking 
incubator. The cell suspension was plated into LB-agar plates (Cat. No. L2897, Sigma-Aldrich) 
containing 15 µg/ml kanamycin and 50 µg/ml carbenicillin. The use of carbenicillin instead of 
ampicillin is due to higher stability and selectivity in bacteria containing the selective plasmid. 
The plates were incubated for 24 hours at 37°C, 5% CO2.   
Antibiotics used: Kanamycin sulphate from Streptomyces Kanamyceticus Cat. No. K4000-25G 
(Sigma-Aldrich) and Carbenicillin disodium salt Cat. No. C1389-5G (Sigma-Aldrich). 
 
4.3.4 PROTEIN EXPRESSION  
The colonies which grew in the presence of antibiotic were the ones carrying the plasmid in the 
competent cells. One single colony was scraped and added into 60 ml of turbo broth (Cat. No. 
MD12-104-1, Molecular Dimensions) containing 15µg/ml kanamycin and 50µg/ml carbenicillin 
in a 200 ml flask. Cells were incubated in the shaker incubator at 37°C until the OD600 reached 
~1.2 and then stored overnight at 4°C. On the next day 10 ml of the 60 ml cell suspension were 
added into each 1L x 6 flasks of turbo broth containing 15µg/ml kanamycin and 50µg/ml 
carbenicillin in a 2L glass flask. Cells were grown in a shaker incubator at 30°C at 200 rpm until 
the OD600 was ~1.2, at which point the temperature was reduced to 18°C until the OD600 reached 
~1.5. Then IPTG (Cat. No. 15529019, Thermo Fisher Scientific) was added to a final concentration 
of 50µM to each flask and cells were grown over night at 18°C on a shaker incubator. The next 
day the cells were centrifuged at 6,000 rpm (Rotor JLA 9.1000, Beckman Coulter, Avanti J-26S 
XP centrifuge) for 20 minutes and pellets were frozen for subsequent purification experiments. 
For protein expression tests, a sample of cells were taken before and after IPTG induction and 
then protein expression was analysed using SDS-PAGE gel electrophoresis at 160 V for one hour 
(SERVAGel™ TG PRIME 4-20%, Cat. No. 43276.01, SERVA).  
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4.3.5 PROTEIN PURIFICATION  
4.3.5.1 IMMOBILIZED METAL AFFINITY CHROMATOGRAPHY (IMAC)  
The purpose of IMAC is to purify a large amount of protein with high selectivity using the method 
of a chelating agent in a beaded agarose to immobilize the specific desired metal ion followed 
by binding and purification of the protein of interest. Talon resin has a nitrilotriacetic acid (NTA) 
group loaded with cobalt divalent metal which produce high selectivity for his-tagged proteins. 
Protein with a poly-his tag binds in a specific manner to IMAC resins in neutral buffer conditions. 
Imidazole is also used in the buffer conditions in low concentration (10 mM) as a wash step to 
remove any nonspecific binding of endogenous proteins that might contain histidine groups. 
However, a high concentration of imidazole (≥300 mM) is used in elution steps for removing the 
binding of the protein in NTA-Co2+ resin owing to the similarity of the side chain to histidine 
groups (Fig.4.5). 
 
Figure 4.5. Talon resin loaded with NTA-Co2+ for protein purification. The bead agarose contains 
covalently linked NTA which binds to a divalent cobalt.  The Co2+ then selectively binds to his-
tagged protein. Imidazole is used for the elution of the protein of interest because of the similar 
structure of the histidine side-chain. (Adapted from Takara Clontech supplier website 
http://www.clontech.com/US/Support/Applications/Tagged_Protein_Purification/Ni-
NTA_Resin_vs._Talon) 
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Experimental procedure 
Buffers for protein purification experiment; each buffer was filtered at 0.45 µm (Cellulose nitrate 
membrane filters, Whatman™ Cat. No. 514-8073, VWR).  
Lysis Buffer  Elution Buffer  Cat. No.  
20 mM HEPES pH 7.5 20 mM HEPES pH 7.5 BP310-1, Fisher BioReagents  
500 mM NaCl 500 mM NaCl S/3120/63, Fisher Chemical 
10 mM Imidazole 300 mM Imidazole 122025000, Acros Organics  
0.5 mM TCEP 0.5 mM TCEP 646547-10x1ml, Sigma-Aldrich 
Distilled H2O up to 500 ml  Distilled H2O up to 250 ml N/A 
 
Pellets of cells were defrosted and resuspended in 50 ml of Lysis buffer with one tablet of 
protease inhibitor cocktail (11055700, Roche) and 250µM of glutamic acid in 20 mM HEPES-
NaOH pH 7.5(L-glutamic acid monosodium salt hydrate Cat. No. G1626, Sigma-Aldrich). Cells 
were lysed by sonication with a large sonicator probe, 5 sec on, 5 sec off, 40% amplitude for 5 
minutes. Cell debris and insoluble fractions were removed by centrifugation at 40,000g for 30 
minutes at 4°C. Supernatant (soluble fraction) was filtered through a 0.45 µm syringe filter 
(Sterile PES syringe filter Cat. No. 15216869, Fisher Scientific).  The filtered supernatant was 
applied to a gravity column containing 7.5 ml of talon metal affinity resin (Clontech Takara Cat. 
No. 635503) and incubated for 1 hour at 4°C. The column was washed with several applications 
of lysis buffer (approximately 200 ml). The retained protein was eluted with several applications 
of elution buffer (~7.5 ml each). Eluted fractions were finally incubated with PreScission 
protease (27-0843-01, GE Healthcare Life Sciences) at 1 unit per ml at 4°C overnight for the 
removal of the 6xHis-SUMO tag.  
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4.3.5.2 SIZE EXCLUSION CHROMATOGRAPHY (SEC)  
SEC is a method used for purifying proteins of interest by separating molecules based on the 
differences in size (Fig. 4.6) and uses a column packed with a resin medium and connected to a 
FPLC system. In these experiments the HiLoad Superdex 75pg column was used, which is 
prepacked with a prep grade media Superdex. Superdex is a high resolution resin composed of 
cross-linked agarose and dextran beads with a molecular weight range of 3,000 to 70,000 Da.  
 
Figure 4.6. SEC principle. A) Electron microscopy image of a Superdex bead illustrating the 
different pore sizes. B) Sample representation of the column beads passing through and entering 
the various pores. C) Schematic representation of the separation, i) the top line represents the 
sample injected into the column, ii) samples passing through the column in which the smallest 
molecules in yellow diffuse into the pores delaying the flow through, iii) while large molecules 
pass through the column first. D) Typical chromatogram representing the elution of molecules 
by size. (Image taken from Size Exclusion Chromatography handbook from GE Healthcare Life 
Sciences, 
https://www.gelifesciences.com/gehcls_images/GELS/Related%20Content/Files/14661588415
39/litdoc18102218_20161012165335.pdf)  
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Experimental procedure 
The protein solution from IMAC fractions totalling ~45 to 60 ml was concentrated to 10 ml using 
a centrifugal filter unit (Vivaspin 20 Molecular weight cut-off (MWCO) 10,000 Cat. No. 28932360, 
GE Healthcare Life Sciences) at 4,000g for approximately 30 minutes. The ÄKTA purifier system 
(GE Healthcare Life Sciences) was used for SEC purification with the HiLoad 26/600 Superdex 75 
pg column (Cat. No. 28-9893-34, GE Healthcare Life Sciences).  
The FPLC buffer used for purification was 20mM HEPES pH 7.5, 500 mM NaCl and 0.5 mM TCEP 
pH 7.0, filtered and degassed first and the column was equilibrated with FPLC buffer overnight. 
The next day, 2ml fractions were collected in a 2.4 ml 96-deep block plate (Greiner Master Block 
M1061-50EA, Sigma-Aldrich); samples of which were analysed using SDS-PAGE gel 
electrophoresis at 160 V for one hour (SERVAGel™ TG PRIME 4-20%, Cat. No. 43276.01, SERVA) 
and Coomasie stain for one hour (Cat. No. GEN-QC-STAIN-1L, Generon). Destain was performed 
by incubating the gel with water for 2 to 3 hours in the shaker. Fractions with most abundant 
protein were collected (~20ml) and concentrated with a centrifugal filter unit to a final volume 
of approximately 1 ml. To remove remains of the 6xHis-SUMO tag that remained after 
Prescission proteolytic digestion and SEC experiments, protein solution was further incubated 
with 1ml of talon metal affinity resin using a 10 ml centrifuge column for 30 minutes (Pierce™ 
Centrifuge column 10ml Cat. No. 89898, Thermo Fisher Scientific). After incubation was 
completed, the eluted solution was concentrated up to 500 µl, the protein concentration was 
quantified with a nanoDrop at absorbance A280 nm and purity of the protein was verified by SDS-
PAGE gel electrophoresis. Several batches of protein were obtained and the final yield of purified 
protein was calculated using the concentration mg/ml adjusted with the final volume obtained. 
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4.3.6 CRYSTALLOGRAPHY  
Crystallography is used to study protein crystallisation, and thereby properties and structures to 
help determine the arrangement of atoms and their function in biological and biochemical 
processes. X-ray crystallography is an important technique for the determination of the 
structure of a protein and plays an important role in structure-based drug discovery. X-ray 
crystallography can be found in detail in chapter 1, section 1.2.2.1.  
The principle of protein crystallisation experiments is based on the solubility properties of a 
protein. Factors such as thermodynamics, pH and physical chemistry will control the process of 
crystallisation of the protein. A solubility curve is a schematic representation of the solubility of 
a protein in relationship with the concentration of precipitant (Fig. 4.7). Crystals will be formed 
in the supersaturated zone, when the protein concentration surpasses the solubility; the 
supersaturated zone comprises the metastable, nucleation and precipitation zones (Asherie 
2004). The diagram illustrates the different levels of supersaturation; precipitation zone, 
nucleation zone and metastable zone. The precipitation zone occurs when the supersaturation 
is extremely high and the protein will form aggregates or precipitates and these conditions will 
not be favourable for crystal formation. The nucleation zone is when supersaturation is large 
enough so the nucleation and formation of crystals can occur and metastable zone is when 
supersaturation is lower and only supports crystal growth (Russo Krauss et al. 2013).  
 
Figure 4.7. Crystallisation phase diagram. The solubility of a protein will depend on the 
concentration of the precipitant. The more supersaturated the protein becomes in solution the 
greater the probability of forming nucleation and crystal formation. The supersaturation phase 
includes the metastable, nucleation and precipitation zones (University of Cambridge, 
Biochemistry department; http://www.xray.bioc.cam.ac.uk/xray_resources/whitepapers/xtal-
in-action/node3.html). 
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Experimental procedure 
Preliminary crystallography screening experiments were performed in 2-drop, 96-MRC 
polystyrene crystallisation plate (MD11-00-100, Molecular Dimensions). Sitting drop 
experiments were set up using different commercial matrix screen solutions. A protein solution 
of 8 mg/ml diluted in FPLC buffer (20mM HEPES pH 7.5, 500 mM NaCl and 0.5 mM TCEP) with 
the addition of 5 mM zinc acetate and sodium cacodylate final concentration. A drop ratio of 1:1 
was prepared using the Art Robbins Crystal Phoenix dispenser (AlphaBiotech). Crystallography 
plates were incubated at 14°C for 3-5 days. Further optimisation was performed of the crystal 
hits from screening experiments. Crystals were flash-cooled in liquid nitrogen for short-term 
storage. The best quality crystals (size and form) were exposed to X-ray beam to obtain 
diffraction data using the i04-1 beamline at Diamond Light Source synchrotron (Didcot, 
Oxfordshire).  
Crystallography salt additives; zinc acetate (Cat. No. 1724703, Sigma-Aldrich) and Sodium 
cacodylate (Cat. No. C0250, Sigma-Aldrigh).  
 
Table 4.1. Commercial crystallisation screens used for primary crystallography experiments.  
Matrix crystallisation 
screen 
Catalogue number and supplier 
Morpheus® HT-96 MD1-47, Molecular Dimensions 
JCSG-plus™ HT-96 MD1-40, Molecular Dimensions 
PACT premier™ HT-96 MD1-36, Molecular Dimensions 
MIDASplus™ HT-96 MD1-107, Molecular Dimensions 
Crystal Screen HT HR2-130, Hampton Reserch 
SaltRx HT™ HR2-136, Hampton Research 
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4.3.7 FRAGMENT SCREENING-XCHEM 
The purpose of this technique is to identify small fragments binding in the LBD of rat AMPA 
protein and thereby identify novel or established binding sites for allosteric modulators. The 
fragment hits will provide the starting points for further chemical optimisation to improve the 
biological activity and physicochemical properties. The Diamond Fragment Screening (XChem) 
was performed at Diamond Light Source facilities. At these facilities, they have implemented a 
highly streamlined process for the screen of compounds in a shorter period of time (less than a 
week). The full methodology includes crystal targeting, crystal soaking, crystal harvesting, 
automatic data collection and data analysis. XChem has several fragment libraries, over 2000 
compounds available at 100-500 mM in DMSO (Fragment Screening - XChem, Diamond Light 
Source website).  A total of 700 fragments were screened from three different libraries; DSPL-
Diamond Poised, Oxxchem and Leeds 3D.  
 
 Crystals preparation  
The best diffracting crystals grew in the well condition B1 of Morpheus® screen, solutions 
present in that condition are listed in Table 4.2.  
Table 4.2. Conditions of well B1 of commercial Morpheus® screen. (Appendix II) 
Well screen condition Solution mix 
0.09 M Halogens Halogens: Sodium fluoride; sodium 
bromide and sodium iodide 
0.1 M Buffer system 1 pH 6.5 Imidazole; MES monohydrate (acid) 
50 % v/v Precipitant Mix 1 PEG 500 MME and PEG 20,000 
MES - 2-(N-morpholino) ethanesulfonic acid; PEG – Polyethylene glycol 
and MME – Mono methyl ether  
 
Solutions were set up in a 96-well SwissCi 3 drop plate (Cat. No. 3W96TPS, SWISSCI Scientific 
Innovation), using the sitting drop method along with 30 µl of the reservoir solution from the 
Morpheus screen (Cat. No. MDSR-47-B1, Molecular Dimensions). Experiments were performed 
using the Oryx8 protein crystallisation robot (Douglas instrument) with 5 mg/ml of protein 
solution with a final drop ratio of 1:1 of protein and reservoir solution (total volume per drop of 
0.30 µl); they were dispensed at least 2 drops in each well of the plate. Plates were stored at 
14°C for 1-2 days until crystals appeared and then stored for fragment screening. 
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 Crystal targeting  
Crystal plates were transported to the Diamond Light Source facilities where they were given a 
barcode number. Plates were then imaged to identify the crystals in each drop and with the 
software TexRank the crystals were targeted for compound injection by selecting an area 
opposite the crystal.  
 
 Crystal Soaking  
Compounds were transferred to the crystals using an ECHO® 550 acoustic liquid handler 
(Labcyte). The dispense coordinates were selected by TexRank software. Plates were inverted 
and ultrasonic pulses were used for dispensing the compound in nanoliter volume. Compounds 
were injected at final concentration of 25 mM (5% DMSO) and 50 mM (10% DMSO). After 
compound injection, the plates were incubated for 1 hour at 14°C.  
 
  
 
 
 
 
 
 
Figure 4.8. ECHO acoustic droplet ejection. Sound waves eject precise drops of compound from 
a microplate and deposit into inverted crystallisation plate (Adapted Acta Crystallographica 
Section, http://journals.iucr.org/d/issues/2017/03/00/ba5268/ba5268fig1.html). Compounds 
were injected to have a final concentration of 25 and 50 mM.  
 
 
 
 
155 
 
 Crystal Harvesting  
Following a one hour incubation with compound at 14°C, crystals were harvested manually using 
the OLT Crystal Shifter (Oxford lab technologies). This equipment is automated to speed up the 
process of crystal harvesting by using a microscope x-y stage, which maintains unsealed plates 
under a thick plastic cover to avoid quick evaporation of drops and allows the harvesting of one 
crystal at a time. Usually around 100 crystals can be harvested per hour.  
 
 X-ray data collection and analysis  
Crystals were exposed to X-rays on beamline i04-1 (Diamond Light Source) with the automated 
robot BART system, a new sample-changing robot with improved sample exchange times. Data 
was collected and analysed using XChemExplorer and pan-dataset density analysis (PanDDA 
software). The process is automated and it gave compound hits as “events” to analyse in the 
Crystallography object-oriented toolkit (COOT) software package, to then perform model 
building and space refinement.  
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4.4 RESULTS 
4.4.1 IMMOBILIZED-METAL AFFINITY CHROMATOGRAPHY (IMAC) 
Protein IMAC purification experiments resulted in six elution fractions of approximately 7.5 ml 
each (E1-6; Fig. 4.9) containing rGluA2 LBD protein. The elution fractions, flow though and wash 
fractions were collected and characterised in a SDS-PAGE gel electrophoresis. In the gel (Fig. 4.9), 
the flow though fraction showed the proteins that were not retained by the talon beads. More 
importantly, the band of 45 kDa present in the elution fractions correspond to the purified 
protein rGluA2 LBD. The rGluA2 was present in high abundance in fraction E2 displaying a strong 
band of 45 kDa. In addition, the gel displayed a concentrated band in the talon beads sample 
(B1) before elution, which means the retention of the protein by the talon beads and comparison 
with the talon beads sample (B2) after elution, indicated that most of the protein bound to the 
talon beads was eluted with 300 mM Imidazole.  
Wash fractions W1 and W2 displayed a number of unspecific proteins of 27 kDa, 70 up to 100 
kDa, these observed bands were almost fully removed with the wash buffer with low 
concentration of imidazole.  The remaining bands not corresponding to rGluA2 from elution 
fractions 1-6 were removed using size exclusion chromatography (SEC).  
In order to observe if the protein eluted correspond to rGluA2, samples of elution fractions were 
collected and incubated with 3C protease enzyme. Samples before and after incubation with 3C 
protease were run on a SDS-PAGE gel to verify the cleavage of rGluA2-6xHis-SUMO protein by 
protease 3C. The gel displayed a band of 45 kDa in the sample without 3C protease (Fig.  4.10). 
Whereas, the sample following 3C protease incubation displayed two bands of 30 kDa and 15 
kDa, corresponding to rGluA2 protein and 6xHis-SUMO tag respectively (Fig. 4.10). These results 
demonstrated the correct purification of rGluA2 protein, to further purify the sample size 
exclusion chromatography was performed.  
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Figure 4.9. SDS-PAGE gel of IMAC purification of the rGluA2 LBD protein. Bands of 45 kDa 
corresponding to the LBD protein rGluA2. Approximately 50 ml of supernatant was added to 7.5 
ml of talon beads, the flow thought was ~50 ml, washes 1 and 2 were ~ 100ml each and samples 
of 25 µl were taken for the SDS-PAGE gel. 10 µg of protein loaded per well, gel stained with Blue 
Coomassie, protein ladder Precission Plus Protein™ All Blue (Cat. No. 1610373, Bio-Rad).  
 
Figure 4.10. SDS-PAGE gel of 3C protease activity. Elution mix samples correspond to the pooled 
E1-6 fractions (shown in Fig. 4.9) before the addition of 3C protease and displayed a 
concentrated band of rGluA2 at 45 kDa.  Elution mix + Protease correspond to elution fractions 
after incubation with 3C protease with the production of two bands of 30 kDa and 15 kDa, 
corresponding to rGluA2 LBD and 6xHis-SUMO tag respectively.  
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4.4.2 SIZE EXCLUSION CHROMATOGRAPHY (SEC) 
Protein SEC purification experiments resulted in a chromatogram displaying the separation of 
components of the protein sample, measured by ultraviolet (UV) light absorption at A280. The 
chromatogram displayed two main peaks, first peak around 60 ml and second peak at 80-85 ml 
(Fig. 4.11A). Fractions from both peaks were collected and run on a SDS-PAGE gel (Fig. 4.11B) 
which showed that the major peak contained a range of proteins varying from 15 to 120 kDa 
corresponding to fraction 1E11 and as a result this major peak was not suitable for further 
purification experiments. More importantly, the second minor peak correspond to the LBD 
rGluA2 protein with bands of 30 kDa in fractions 1G8 to 1H5. A smear band bellow the protein 
band suggest a partial degradation of the protein. A band of 15 kDa was also shown in the gel, 
this band correspond to 6xHis-SUMO tag remain in the sample. Finally, to remove remain 6xHis-
SUMO tag the protein fractions were further purified with IMAC. The final protein solution was 
highly pure (Fig. 4.12), with a concentration of 9.12 mg/ml in ~1.2 ml, with total yield of 10.9 mg 
of protein from starting 8 litres of cell culture. Concentration was measured by nanoDrop using 
the molecular weight of 30.211 kDa and extinction coefficient of 41,370 M-1 cm-1 at 280 nm. 
Finally, the band just below the protein observed previously was not present in the final purified 
protein, suggesting a degraded protein over time (during incubation with further talon beads) 
or some remain tag present in the sample and further removed with talon beads.  
Five batches of purified protein were prepared for crystallography experiments listed in Table 
4.3, different starting cell culture were prepared from 2 to 8 litres. It was observed that the 
larger amount of starting cell culture, the more unspecific proteins were produced.  
Table 4.3. Different batches of purified protein obtained after purification experiments 
Batch 
No. 
Starting cell 
culture (L) 
Concentration 
(mg/m) 
Final volume 
obtained (µl) 
Yield of purified 
protein (mg) 
1 2 8.0 500 4.0 
2 4 12.27 1000 12.3 
3 8 9.12 1200 10.9 
4 6 8.1 800 6.5 
5 2 8.0 500 4.0 
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Figure 4.11. Size exclusion chromatography of the rGluA2 LBD after 3C proteolytic removal of 
the 6xHis-SUMO tag. A) Chromatogram obtained from SEC purification of the LBD rGluA2 protein 
with the second peak marked with an asterisk corresponding to the protein of interest. B) SDS-
PAGE gel of the fractions obtained by SEC, numbering correspond to chromatogram fractions. 
The protein band at 30 kDa correspond to the LBD of rGluA2. 10 µg of protein loaded per well, 
protein ladder use was PageRuler™ prestained ladder (Cat. No. 26616, Thermo Fisher Scientific).  
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Figure 4.12. Final purity of the protein rGluA2. SDS-PAGE gel verification of the pure protein. 
One single band of 30 kDa correspond to the LBD of rGluA2 protein. The gel displayed the protein 
in high purity, with no other bands in the gel. An amount of 2.0, 4.5 and 11.0 µg of protein was 
loaded in the gel.  
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4.4.3 CRYSTALLOGRAPHY  
In crystallisation screen experiments, the only crystal hits with adequate quality were obtained 
with the Morpheus® HT-96 plate (Table 4.4). The best crystal in terms of quality, size and 
diffraction was with the well B1 condition. The rest of the crystals grown were not singular or 
were too small for the X-ray beam.  
Table 4.4. Morpheus® HT-96 crystal hits conditions 
Well Conditions 
A1 
0.06 divalents, 0.1 M buffer system 1 pH 6.5 and 50 % 
v/v precipitant Mix 1 
B1 
0.09 M halogens, 0.1 M buffer system 1 pH 6.5 and 
50 % v/v precipitant Mix 1 
C4 
0.09 M NPS, 0.1 M buffer system 1 pH 6.5 and       
50 % v/v precipitant Mix 4 
C5 
0.09 M NPS, 0.1 M buffer system 2 pH 7.5 and        
50 % v/v precipitant Mix 1 
 
Nitrate Phosphate Sulfate (NPS). Full mixes of additives, buffers 
and precipitants of Morpheus® HT-96 in appendix II. 
 
 
The condition B1 gave consistently long rectangular single type crystals, in orthorhombic space 
group (three unequal axes at right angles). Crystals were prepared with 5.0 mg/ml of protein 
diluted with FPLC buffer, using the hanging drop method with the reservoir solution 
corresponding to the condition B1 from Morpheus commercial screen.  
Crystals grew after 24 -48 hours at 14°C and drops displayed a high amount of precipitation and 
skin formation. In addition, the crystals presented at least one irregular edge (Fig. 4.13) and size 
varied from 0.1 to 0.2 mm. The main advantage of the Morpheus® screen is that the solutions 
already contain cryoprotectant, which makes it suitable for quick storage in liquid nitrogen. The 
Morpheus solution of B1 contains 40 % v/v of polyethylene glycol (PEG) and monomethyl ether 
(MME) 500 which both function as a precipitant and cryoprotectant (appendix II) to protect 
crystals from free radicals from ionising X-rays when collecting diffraction data.  
Crystal diffracted at 1.84 Å resolution in the X-ray beamline i04-1 at Diamond Light Source 
(Didcot). Molecular replacement was carried using a previously described rat GluA2 structure 
(Armstrong & Gouaux 2000), accession code 1FTJ from the protein data bank (PDB). Final models 
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were refined using Collaborative Computational Project No.4 (CCP4) and Python-based 
Hierarchical Environment for Integrated Xtallography (PHENIX) software by Dr. Mark Roe. 
Crystallographic Object-Oriented Tookit (COOT) was used for manual model building. The LBD 
of rGluA2 was in complex with glutamate, from the 250 µM of glutamate added in the lysis buffer 
in purification experiments. The final data collection and refinement statistics are presented in 
Table 4.5.  
 
 
Figure 4.13. Rectangular orthorhombic crystals of the LBD of rGluA2. Crystals were obtained at 
5.0 mg/ml using the hanging drop crystallography method. The formation of skin and 
precipitation was present in all drops. All crystals presented one irregular ending on one side. 
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Table 4.5. Crystallographic statistics for the rGluA2 LBD in complex with glutamate. Crystal shot 
at the i04-1 beamline at Diamond Light Source.  
Data Set 
(Highest shell in 
parentheses) 
rGluA2 
a (Å) 54.47 
b (Å) 113.42 
c (Å) 47.41 
 () 90 
 () 90 
 () 90 
Space Group P 21 21 2 
Wavelength (Å) 0.9281 
Resolution Limit (Å) 113.42 – 1.84  
(1.87-1.84) 
Number of Obs. 26305 
(1297) 
Completeness (%) 100 
(100) 
Multiplicity 6.5 (6.8) 
Rmerge % 0.081 (0.940) 
Rpim(I) % 0.046 (0.515) 
CC1/2 0.999 (0.783) 
I/I 15.2 (2.1) 
Refinement  
Resolution Range 
(Å) 
56.71-1.84 
Rcryst 0.224 
Rfree 0.269 
Number of protein 
atoms 
1,924 
Number of ligand 
atoms 
10 
Number of solvent 
atoms 
81 
Mean B 33.718 
Rmsd bond lengths 
(Å) 
0.019 
Rmsd bond angles 
(°) 
1.980 
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A monomer of the rGluA2 LBD structure was solved in complex with glutamate. The structure 
showed that glutamate binds in the cavity space between the interface of S1 and S2 (Fig. 4.14). 
Zinc ions and acetate are present in the structure, zinc acetate and sodium cacodylate were 
added in the crystallography experiments as additives to facilitate the nucleation and formation 
of crystals. It is noteworthy that crystallography experiments without both additives failed to 
grow crystal suggesting the need of both additives for successful AMPA crystal formation.  
More interestingly, the interactions of glutamate with the LBD of rGluA2 are the same as the 
literature 1FTJ accession code from PDB (Armstrong & Gouaux 2000). The crystal structure 
showed that glutamate α-carboxyl interacts with Ser-142, Arg-96 and Thr-91 of the protein; the 
α-amino group of agonist forms interactions with Tyr-61, Glu-193 and Pro-89 and the δ-carboxyl 
with Thr-143 (Fig. 4.15). The interaction between Arg-96 and the α-carboxyl of glutamate is 
conserved in all glutamate receptors (Kawamoto et al. 1997; Lampinen et al. 1998; Armstrong & 
Gouaux 2000). Arg-96 and Glu-193 residues formed strong salt bridge interactions, suggesting 
their importance for agonist recognition and binding.  
 
Figure 4.14. Monomer of the LBD of rGluA2 in complex with glutamate. The construct consisted 
of S1 and S2 domains, dark blue and light blue respectively. Glutamate in green, Gly-Thr linker 
is displayed in red. 
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Figure 4.15. Glutamate binding interactions with LBD rGluA2. Arg-96 and Glu-193 are important 
for agonist binding. Hydrogen bonds are shown in arrows in fuchsia and salt bridges in blue/red 
line.  Interaction diagram generated from Maestro Schrödinger.  
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4.4.4 FRAGMENT SCREENING-XCHEM 
From the 700 compounds soaked into rGluA2 crystals, a number of events were found by 
PanDDA software, which was further analysed closely to confirm the hits. The hits were analysed 
using COOT to observe the location of the binding sites. Refinement was carried out using the 
internal Diamond software XChemExplorer (XCE)-COOT and exported as a PDB file for further 
refinement performed by Dr. Mark Roe. Crystallography data statistics from crystals with 
fragments are shown in Table 4.7. 
Eight fragments were found to be present in the rGluA2 LBD (Table 4.6). However, these 
fragments were present at low-occupancy in the structure which means a low-electron density 
map of the structure making it difficult to distinguish from different structural conformations 
(amino acid residues). The low-occupancy of the fragment hits could be due to the low 
concentration of the fragment, suggesting that fragments at higher concentration might 
improve the percentage of occupancy in the crystal structure.  
These results suggest the binding sites of allosteric modulators in the dimer interface and in a 
site near the Gly-Thr linker. As previously reported (Ward et al. 2011), a binding site in the dimer 
interface of the LBD was observed. Three different binding sites (at low-occupancy) were 
observed in the LBD of rat GluA2, two binding sites in the dimer interface (1a and 1b) across the 
two-fold symmetry axis of the dimer, one binding site (2) near the Gly-Thr linker located in one 
of the outside loops of the monomer of the structure and one cysteine free site (3) at Cys-58 
(Fig. 4.16). The cysteine free site was not explored further due to lack of functionality of these 
site for drug research.   
 
Figure 4.16. Identified sites in the LBD of rGluA2. For clarity of the binding site only one monomer 
is displayed in this figure.  Site 1a and 1b is located inside the dimer interface of the LBD, site 2 
near the Gly-Thr linker in one of the external loops of the structure chain, and site 3 
corresponding to the free Cys-58, figure generated using Maestro Schrödinger.  
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Table 4.6. Compound hits found in XChem fragment screening library  
Compound Structure Identified sites Residues in identified sites 
Compound 1 
 
Dimer interface 
Site 1a 
Chain A: Lys-104,  Pro-105,  
Phe-106, Met-107 and      
Ser-108 
 
Chain B: Ile-103, Pro116,   
Ser-228, Lys-229 and Gly-230 
Compound 2 
 
Site 2 
Chain B: Lys-217, Gly-129, 
Thr-130, Pro-131,  Lys-196 
and  Gly-197 
Compound 3 
 
Dimer interface 
Site 1a 
Chain A: Lys-104,  Pro-105,  
Phe-106, Met-107 and      
Ser-108 
 
Chain B: Ile-103, Pro116,   
Ser-228, Lys-229 and Gly-230 
Compound 4 
 
Site 2 
Chain B: Lys-217, Gly-129, 
Thr-130, Pro-131,  Lys-196 
and  Gly-197 
Compound 5 
 
Site 2 
Chain B: Lys-217, Gly-129, 
Thr-130, Pro-131,  Lys-196 
and  Gly-197 
Compound 6 
 
Dimer interface 
Site 1b 
Chain A: Ile-92, Pro-105, 
Met-107, Ser-108, Ser-217, 
Lys-218 and Gly-219 
 
Chain B: Lys-115, Pro-116, 
Phe-117, Met-118, Ser-119, 
Leu-250 and Ser-253 
Compound 7 
 
Dimer interface 
Site 1b 
Chain A: Ser-92, Pro-105, 
Ser-108, Ser-217, Lys-218 
and Gly-219 
 
Chain B: Lys-115, Pro-116, 
Phe-117, Met-118, Ser-119 
Compound 8 
 
Dimer interface 
Site 1b 
Chain A: Pro-105, Ser-108, 
Ser-217, Lys-218 and Gly-219 
 
Chain B: Lys-115, Pro-116, 
Phe-117, Met-118, Ser-119, 
Lys-229, Gly-230 and Tyr-231 
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Table 4.7. Crystallographic statistics for the rGluA2 LBD crystals in complex with compound 
fragments. Crystals shot at the i04-1 beamline at Diamond Light Source. 
 
 
 
 
Data Set 
(Highest shell in 
parentheses) 
Compound 1 Compound 2 Compound 3 Compound 4 
a (Å) 54.07 54.34 54.40 54.69 
b (Å) 113.59 133.13 114.73 113.05 
c (Å) 47.17 47.44 47.52 47.53 
 () 90 90 90 90 
 () 90 90 90 90 
 () 90 90 90 90 
Space Group P 21 21 2 P 21 21 2 P 21 21 2 P 21 21 2 
Wavelength (Å) 0.9281 0.9281 0.9281 0.9281 
Resolution Limit 
(Å) 
56.80 – 2.28  
(2.32-2.28) 
56.56 – 1.87   
(1.90-1.87) 
57.36 – 1.88 
(1.91-1.88) 
56.52 – 1.80 
(1.83-1.80) 
Number of Obs. 13219 
(572) 
24891  
(1229) 
24508  
(1196) 
27969 
(1384) 
Completeness (%) 95.2  
 (82.8) 
100  
(98.8) 
98.8  
(98.9) 
99.5  
(98.3) 
Multiplicity 5.9 (5.1)  6.5 (6.8) 6.5 (6.9) 6.3 (6.6) 
Rmerge % 0.069 (0.719) 0.054 (0.787) 0.112 (1.385) 0.093 (0.859) 
Rpim(I) % 0.041 (0.443) 0.031 (0.445) 0.065 (0.790) 0.055 (0.492) 
CC1/2 0.999 (0.709) 0.999 (0.795) 0.997 (0.792) 0.999 (0.757) 
I/I 17.0 (2.1) 18.3 (2.1) 12.1 (2.4) 14.6 (2.3)  
Refinement  
   
Resolution Range 
(Å) 
56.90 – 2.19 56.62 –1.88 57.44 – 1.76 56.60 – 1.74 
Rcryst 0.199 0.216 0.241 0.231 
Rfree 0.261 0.268 0.279 0.271 
Number of 
protein atoms 
1,999 1,999 1,999 1,999 
Number of ligand 
atoms 
22 34 24 34 
Number of 
solvent atoms 
159 147 160 148 
Mean B 47.036 36.944 37.033 29.402 
Rmsd bond 
lengths (Å) 
0.015 0.020 0.019 0.020 
Rmsd bond 
angles (°) 
1.685 2.071 1.962 2.109 
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Data Set 
(Highest shell in 
parentheses) 
Compound 5 Compound 6 Compound 7 Compound 8 
a (Å) 53.87 54.56 54.28 54.59 
b (Å) 113.32 113.60 113.23 114.19 
c (Å) 47.24 47.45 47.30 47.27 
 () 90 90 90 90 
 () 90 90 90 90 
 () 90 90 90 90 
Space Group P 21 21 2 P 21 21 2 P 21 21 2 P 21 21 2 
Wavelength (Å) 0.9281 0.9281 0.9281 0.9281 
Resolution Limit 
(Å) 
113.32 – 2.12 
(2.15-2.12) 
56.80 – 1.81 
(1.84-1.81) 
56.61 – 1.96 
(1.99-1.96) 
114.19 – 1.75 
(1.78-1.75) 
Number of Obs. 17094 
(847) 
27115 
(1328) 
21630 
(1070) 
30250 
(1456) 
Completeness (%) 100 
(99.8) 
99.1  
(98.8) 
100 
(99.5) 
100 
(99.3) 
Multiplicity 6.5 (6.7) 6.6 (6.8) 6.5 (6.3) 6.6 (6.8) 
Rmerge % 0.089 (0.725) 0.055 (0.744) 0.071 (0.786) 0.062 (0.803) 
Rpim(I) % 0.053 (0.405) 0.032 (0.412) 0.041 (0.450) 0.036 (0.440) 
CC1/2 0.999 (0.816) 0.999 (0.772) 0.999 (0.770) 0.999 (0.792) 
I/I 13.4 (2.3) 19.0 (2.3) 15.0 (2.1) 15.6 (2.1) 
Refinement 
    
Resolution Range 
(Å) 
56.70 – 2.16 56.86 – 1.81 56.69 – 1.96 57.17 – 1.79 
Rcryst 0.200 0.219 0.215 0.238 
Rfree 0.268 0.263 0.275 0.277 
Number of 
protein atoms 
1,999 1,999 1,999 1,999 
Number of ligand 
atoms 
28 25 38 28 
Number of 
solvent atoms 
164 162 147 167 
Mean B 42.750 33.131 39.771 34.748 
Rmsd bond 
lengths (Å) 
0.015 0.020 0.017 0.020 
Rmsd bond 
angles (°) 
1.699 2.078 1.951 2.121 
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The crystals obtained resulted in the monomer of the LBD, then the dimers were generated by 
using the symmetry crystal mate function in COOT and Maestro Schrodinger computational 
program. Then structure alignment was performed to verify the correct position of the dimer 
compared to another structure in the PDB (2XX8). Structures and binding sites are listed in Table 
4.6. 
 
Figure 4.17. Summary of LBD of rGluA2 in complex with fragment hits obtained after XChem 
fragment screen. Chain A and B forming the LBD of the protein dimer in light and dark blue 
respectively, glutamate is represented by the red spheres. Positions of the compounds present 
in the structure; compounds 1 and 3 situated in the dimer interface site 1a in purple and green 
respectively. Compounds 6, 7 and 8 also in the dimer interface but in site 1b in black, orange 
and yellow respectively. Compounds 2, 4 and 5 in site 2 of chain B in cyan, mint and pink 
respectively. All compound structures are shown in a stick representation and generated using 
Maestro Schrödinger version 11.1.  
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Figure 4.18. Compounds 1, 2 and 6 in the LBD of rGluA2. Glutamate in red spheres 
representation, chain A and B in light and dark blue respectively. Compound 1 in site 1a in purple 
and compound 6 in site 1b in black within the dimer interface, both located in the site across 
the 2-fold symmetry axis. Compound 2 in site 2 in cyan. Structures of dimer and compound with 
surfaces generated using Maestro Schrödinger version 11.1.  
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Figure 4.19. Compounds 3, 4 and 7 in the LBD of rGluA2. Glutamate in red spheres 
representation, chain A and B in light and dark blue respectively. Compound 3 in site 1a in green 
and compound 7 in site 1b in orange within the dimer interface, both located in the site across 
the 2-fold symmetry axis. Compound 4 in site 2 in mint. Structures of dimer and compound with 
surfaces generated using Maestro Schrödinger version 11.1.  
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Figure 4.20. Compounds 5 and 8 in the LBD of rGluA2. Glutamate in red spheres representation, 
chain A and B in light and dark blue respectively. Compound 8 in site 1b in yellow within the 
dimer interface, located in the site across the 2-fold symmetry axis. Compound 5 in site 2 in pink. 
Structures of dimer and compound with surfaces generated using Maestro Schrödinger version 
11.1.  
 
Compounds found in the binding site 1a are between residues Lys-104, Pro-105, Met-107 and 
Ser-108 of chain A and Ile-103, Pro-116, Ser-228 and Gly-230 of chain B (Fig. 4.21). This binding 
site is situated in the dimer interface between the 2-fold symmetry axis similar to other allosteric 
positive modulators (PAMs) found in the literature to bind close to the “hinge” of clamshell-type 
structure of the LBD (Sun et al. 2002; Jin et al. 2005; Ward et al. 2011). Similarly, compounds 
located in site 1b (Fig.4.22) also in the dimer interface of the LBD with residues Pro-105, Ser-108, 
Ser-217 and Lys-218 from chain A and Pro-116, Met-118 and Ser-119 from chain B. The full list 
of residues found in these sites are summarised in Table 4.6. Binding site 1a and 1b are close to 
each other, both sites have residues Pro-105 and Ser-108 (chain A) and Pro-116 from (chain B) 
near the compounds.  
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More interestingly, the binding sites of 1a and 1b are similar to previously published LBD GluA2 
protein structures  in complex with allosteric modulators such as aniracetam and CX614 (Jin et 
al. 2005). These compounds were shown to bind between two prolines and two serines in a cleft 
type space formed in the dimer interface of the LBD of rGluA2. Sites 1a and 1b also are located 
between proline and serine residues. Furthermore, compounds found in site 1a and 1b fit 
between a cleft formed by prolines and serines (Fig. 4.21 and 4.22); for site 1a these are Pro-105 
and Pro-116 and Ser-108 and Ser-228 from chain A and B. For site 1b these are Pro-105 and Pro-
116 and Ser-217 and Ser-119. In addition, site 1a is shown to be located in a higher position than 
1b, in which the two prolines from chain A and B are situated closer to the base of the cleft, 
compared to site 1b in which the prolines are situated at the top of the cleft and the serines in 
the lower part of the cleft in the dimer interface. To summarize, binding sites identified 1a and 
1b are located in the dimer interface of the LBD of GluA2, this site is a previously found site for 
positive allosteric modulators of AMPA receptors and has potential for the improvement of 
cognitive functions.  
The binding site 2 located near the GT linker which connects S1 with S2 near the transmembrane 
linkers M1 and M3 is located near to a negative allosteric modulator (NAM) site found in 2016 
(Yelshanskaya et al. 2016). This published novel NAM site for GluA2 AMPA receptor located in 
the transduction domain was studied using X-ray crystallography experiments and displayed 
antagonists Perampanel, GYKI53655 and CP 465,022 binding at the interface between the LBD 
and the TMD, more specifically between S1-M1 and M3 (Fig. 3.28 & 4.24). Similarly, XChem 
fragment screening showed compounds 2, 4 and 5 located near the Gly-Thr linker of S1 and S2 
segments of the LBD of rGluA2 (Fig. 4.23). In order to observe the position of site 2 it was 
necessary to superimpose the crystal structure of the LBD of rGluA2 in complex with compound 
2 with the literature full length rGluA2 in complex with antagonist CP 465,022 (accession code 
5L1E). We found that site 2 is located above the transduction domain site, closer to the position 
of the Gly-Thr linker joining residues Lys-697 from S1 and Pro-507 from S2 (residues numbering 
according to full length structure). CP 465,022 a quinazoline-4-one antagonist binds further 
down in the transduction domain between S1-M1 and M3 (Fig. 4.24). In conclusion, site 2 is 
located in a higher position than the previous NAM site found in the literature (Yelshanskaya et 
al. 2016), suggesting a possible novel NAM site for AMPA receptor. Also it could be that the Gly-
Thr linker is causing an interaction with the fragments (artefact binding).  However, these results 
need further studies to confirm and verify the exact binding mode of compounds in this site.  
 
175 
 
  
 
Figure 4.21. Comparison of the possible binding mode of compounds 1 and 3 in the binding site 
1a. Compound 1 and 3 in purple and green respectively situated near residues Lys-104, Pro-105, 
Met-107 and Ser-108 from chain A; and residues of chain B are Ile-103, Pro-116, Ser-228 and 
Gly-230. No binding interactions were observed due to the low-occupancy of data obtained. 
Chain A and B in light and dark blue, compounds in stick-model representation, diagram 
generated using Maestro Schrödinger version 11.1. 
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Figure 4.22. Comparison of the possible binding mode of compounds 6, 7 and 8 in the binding 
site 1b. Compound 6, 7 and 8 in black, orange and yellow respectively, situated near residues 
Ser-119, Met-118, Pro-116 and Lys-115 from chain B and Ser-108, Lys-218, Pro-105 and Ile-92 
from chain A. No binding interactions were observed due to the low-occupancy of data obtained. 
Chain A in dark blue and chain B in light blue, compounds in stick-model representation, diagram 
generated using Maestro Schrödinger version 11.1. 
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Figure 4.23. Comparison of the possible binding mode of compounds binding site 2. Compounds 
2, 4 and 5 in cyan, mint and pink respectively, situated near residues Gly-129, Thr-130, Pro-131 
and Gly-197 of chain B in dark blue. No binding interactions were observed due to the low-
occupancy of data obtained. Compounds in stick-model representation, diagram generated 
using Maestro Schrödinger version 11.1. 
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Figure 4.24.  Transduction domain of rGluA2 in complex with antagonist CP 465,022 and 
Compound 2. The full length structure of rGluA2 accesion code 5L1E (Yelshanskaya et al. 2016)  
was superimpose with the structure with compound 2 to observe the different binding sites near 
the transduciton domain. The NAM antagonist CP 465,022 in green and compound 2 in pink. 
Compounds in stick-model representation, diagram generated using Maestro Schrödinger 
version 11.1. 
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Figure 4.25. Hypothetical ligand “X” formed by two fragment hits. A) Compounds 3 and 7 were 
joined using a carbon linker shown in gray. B) Ligand X interaction diagram displaying the 
residues around the ligand in the dimer interface of rGluA2. Diagrams generated using Maestro 
Schrödinger version 11.1. 
180 
 
 
 
Figure 4.26. Ligand X in the dimer interface of rGluA2. The ligand formed by compounds 3 and 7 
are located in the dimer interface of the structure, with a possible higher binding affinity than 
the fragments alone. Glutamate in red spheres representation, chain A and B in light and dark 
blue respectively. Structures of dimer and ligand X generated using Maestro Schrödinger version 
11.1.  
 
Using computational methods (Maestro Schrödinger) a virtual ligand “X” formed by two 
fragment hits (compound 3 and 7) was generated to observe the possible binding affinity in the 
PAM site of rGluA2 (Fig. 4.25 & 4.26).  
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4.5 DISSCUSSION 
The purification approach was a multi-step methodology, which successfully gave a 
homogenous and highly pure protein with an average yield of 7.54 mg of protein. Immobilized 
metal affinity chromatography (IMAC) and size exclusion chromatography (SEC) were used for 
purification of the LBD of rGluA2 consistent with previous publications (Chen & Gouaux 1997; 
Chen et al. 1998). IMAC purification provided an excellent purification step due to the use of a 
His-SUMO tag on the rGluA2 LBD; the SUMO tag increased the solubility and correct folding of 
the protein and the six histidines provided metal stable binding sites to permit purification using 
talon resin which contains cobalt (Block et al. 2009). A resin charged with cobalt instead of nickel 
was used because cobalt charged resins bind to his-tag recombinant proteins with greater 
specificity to obtain higher purity of proteins (Clontech, Takara). The rGluA2 LBD recombinant 
protein was successfully expressed and purified in a large scale format for further structure-
based drug discovery research. The cleavage of the protein from the 6xHis-SUMO was 
performed with high efficiency by the PreScission protease, also helping to identify the correct 
purification of the recombinant protein.  
Preliminary crystallography experiments gave a reproducible hit condition that resulted in 
crystals with resolution that ranged from 1.87 to 2.5 Å that were further optimised using 
microseeding experiments for fragment screening. The utilisation of additives in crystallography 
experiments are essential for crystal formation and the addition of certain salts such as zinc 
acetate and sodium cacodylate promotes crystallisation as observed in rGluA2 crystals. More 
specifically, the zinc cause the protein to strongly precipitate and facilitate the nucleation event. 
Importantly, it was observed that rGluA2 protein without the addition salts did not form crystals 
or precipitation suggesting an essential role of both salts in controlling the ionic strength 
interactions for crystal formation. This is similar to the previously published structure of the LBD 
GluA2 in which zinc acetate and cacodylate were used for crystallisation experiments 
(Armstrong & Gouaux 2000). Other structures of the GluA2 LBD in complex with the antagonist 
2-Me-Tet-AMPA (Hogner et al. 2002) and  the amino acid L-Aspartate (Krintel et al. 2014) used 
zinc acetate and/or sodium cacodylate in crystallisation experiments (1M5B and 4O3A, PDB 
accession codes). Another reason for the use of zinc acetate in crystallography of AMPA rGluA2 
is the evidence of zinc ions located in the crystal packing interfaces (crystal contacts) important 
for the formation of crystals (Armstrong & Gouaux 2000).  
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 X-ray crystallography data was solved and the final LBD structure in complex with glutamate 
displayed similar amino acid interactions previously described in the literature. Hence, it was 
observed that glutamate α-carboxyl, α-amino and δ-carboxyl groups formed interactions with 
arginine, serine, proline and threonine of the LBD of rGluA2, similar to previously solved 
structures of rat GluA2 in complex with glutamate (1FTJ, accession code from PDB; Armstrong 
& Gouaux 2000).   
The purpose of the XChem fragment screening was to find small molecules that with further 
characterisation can act as PAMs or NAMs for AMPA receptors. The results suggest three 
possible binding sites of AMPA receptors. A total of 8 fragments were found in the LBD crystal 
structure, in which 5 compounds were found in the dimer interface of the LBD and three 
compounds found near the Gly-Thr linker. Sites 1a and 1b found in the dimer interface are 
similar to literature structures binding between two prolines and two serines in the cleft formed 
in the 2-fold symmetry axis of the LBD of rGluA2 (Sun et al. 2002; Jin et al. 2005; Ward et al. 
2011; Nørholm et al. 2013). These possible binding sites found in the dimer interface might allow 
the further identification and development of new PAMs of AMPA receptors with the potential 
to improve cognitive performance in Schizophrenia patients. The compounds found need to be 
confirmed to characterise the binding modes and residues that interact in the binding site, also 
these compound fragments need to be further optimised using medicinal chemistry properties 
to identify and confirm any functional effect in vitro and in vivo.  
Other fragments found near the Gly-Thr linker in the S1-S2 of the LBD suggest a possible novel 
binding site of NAMs of AMPA receptor for epilepsy treatment similar to previously published 
structures in which an antagonist binding site was found in the interface between S1-S2 and 
transmembrane M1 and M3 of GluA2 (Yelshanskaya et al. 2016). However, the binding of 
fragments found in this site has to be confirmed and further characterisation experiments need 
to be done in order to identify the specific binding mode in this site and the possible therapeutic 
use in patients with epilepsy. The main disadvantage of this site is the need of the transduction 
domain in the structure, however the transduction domain has never been identified isolated 
or with the LBD in X-ray crystallography (only in full-length structure) due to the hydrophilic cell 
membrane properties. One alternative considered in this project was to identify the full length 
of rGluA2 AMPA receptors, however the capabilities of our research group are limited, and an 
external collaboration with other research groups can be a potential for the expression of the 
full-length protein.   
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CHAPTER 5 
KAINATE PROJECT 
5.1 ABSTRACT   
The finding of new anti-epileptic drugs (AEDs) is important for avoiding undesirable side effects 
and for the treatment of refractory (intractable) patients. Kainate is established to induce 
seizures by binding on iGluRs kainate receptors. Competitive antagonists have been discovered 
to reduce seizures however the development of these antagonists has been challenging due to 
the focus on targeting the agonist glutamate binding site (orthosteric site) in kainate and AMPA 
receptors. High levels of homology in the orthosteric site between iGluRs leads to non-selective 
drugs that can cause high levels of adverse effects. Novel AEDs targeting new allosteric 
modulator sites might provide an effective treatment for refractory patients and reduce side 
effects. This project was focused on obtaining X-ray structural information for GluK1 and GluK2 
kainate receptors, more specifically in the LBD for the further finding of negative-allosteric 
modulators (NAMs) and positive-allosteric modulators (PAMs). NAMs and PAMs can give 
important structural information for early development of new drugs in the treatment of 
epilepsy. The experiments resulted in a successful protein production, purification and 
crystallography for the LBD of GluK1 and GluK2. Both proteins were soaked with fragments 
synthesised in-house by the SDDC group, however only one compound with 20% occupancy in 
GluK2 was identified, these results are not suitable for medical chemistry optimisation, 
nevertheless both crystal structures can potentially be used for further fragment screening 
experiments. The resulting structural information can help in the identification of new fragments 
that can be further optimised for the development of new kainate allosteric antagonists.  
Additionally, the biological functional assay for human GluK1 and GluK2 receptors expressed in 
HEK-293 cell line was successfully tested with standard agonists and antagonists.   
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5.2 AIMS 
The overall aim of the kainate project was to find novel molecules that bound to the LBD of the 
GluK1 and the GluK2 proteins with the potential to be negative allosteric modulators that could 
be suitable for development into a new, more effective and tolerable drug for treating epilepsy. 
The initial stage of the project was to use kainate antagonist compounds from the literature to 
perform medicinal chemistry and calcium assay experiments to confirm the activity of 
compounds (Fig. 5.1, stage 1). The next stage was to characterise these compounds by structure-
based X-ray crystallography experiments (Fig. 5.1, stage 2). In parallel, it was planned to conduct 
a large fragment screen (XChem) to find novel compounds that bind to the LBD of GluK1 and, 
potentially, GluK2 protein. The work in this chapter of the thesis covers the experiments in stage 
2, which serve not only to characterise the compounds originating from stage 1 (work being 
conducted by Dr. Iain Barret) but also enable a fragment screen to be conducted to identify 
novel chemotypes (stage 3, planned for 2018). The structural component of the GluK1 project is 
the critical identification and characterisation of novel compounds that can be further optimised 
for the development of new kainate allosteric antagonists. In addition, small molecule 
modulators of GluK2 will be useful in identifying the therapeutic potential of this subtype of 
glutamate receptor.  
 
Figure 5.1. Scheme of overall strategy and screening cascade. Stage 1 for the identification and 
characterisation of compounds for Stage 2, the dash arrow represents this process; however, 
this order was not followed. Stage 2 started without the completion of stage 1, with a selection 
of in-house compounds with potential antagonist activity from the literature.  
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5.3 MATERIALS AND METHODS 
5.3.1 CLONING AND PLASMID VECTOR  
The plasmid used for over-expression and purification of the LBD_rGluk1 (ligand binding domain) 
was kindly supplied by Dr. Antony W. Oliver from the Genome damage and stability centre 
(GDSC, University of Sussex). In the GDSC, they used their own pHis-SUMO-3C vector in which 
they cloned a protein of interest for purification purposes, in this case the S1 and S2 domains 
forming the ligand-binding core. S1 and S2 are separated by three membrane spanning regions, 
in order to generate a LBD, S1 and S2 were covalently linked using a Gly-Thr peptide. Similar to 
AMPA experiments this short linker peptide maintains the structural conformation of the ligand 
binding domain without causing domains separation or structural changes. Additionally, a 6xHis-
SUMO tag was used to enhance expression and solubility of the recombinant protein. Fig. 5.2 
shows the protein sequence of fragment S1 and S2 of the LBD, the Gly-Thr linker, the 6xHis-
SUMO tag followed by a HRV3C linker protein sequence based on P. Naur and co-workers 
experiments (Naur et al. 2005). This plasmid was consequently sub cloned into pBR322 plasmid 
using a pET T7 expression system (Invitrogen) following the manufacturer’s commercially 
available instructions.  
 
Figure 5.2. LBD rGluK1 sequence design for protein expression and purification. The expressed 
protein contains an N-terminal 6xHis-SUMO tag, a recognition SUMO cleavage site and the LBD 
rGluK1 sequence consisting of [430-ANRTLI....SILYRK-544], [667-PIDSAD…WRGNGCP-805] 
separated by a Gly-Thr linker. Sequence based on rGluk1 isoform 2 (Glur5-2, P22756-2 UniProt). 
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The pBR322 plasmid with a pET T7 expression system (Fig. 5.3) frequently used for the cloning 
and expression of recombinant proteins in an E. coli strain has the advantage of controlling the 
level of expression by using a T7 RNA polymerase promoter site controlled by isopropyl β-D-1-
thiogalactopyranoside (IPTG) induction. The gene cloning and plasmid DNA purification was 
performed commercially by Invitrogen. The gene of the LBD was from rat GluK1, previously 
published experiments in GluA2 LBD used rat protein due to the  facilitation of crystallisation 
(Ward et al. 2011). In addition, experiments performed with the plasmid of human GluK1 protein 
showed that the human protein is difficult to solubilise and express in purification experiments 
(section 5.4.1).  
 
 
  
Figure 5.3. Plasmid map of the inserted synthetic rat gene GluK1 LBD, of which 5µg of lyophilised 
plasmid was obtained by Invitrogen. The T7_promoter site controls the levels of protein 
expression by IPTG induction.  
 
The plasmid was designed to have an N-terminal 6xHis-SUMO tag to improve solubility and 
purification of the protein, an ampicillin resistance gene to selectively control the recombinant 
bacteria grown, as well as the inducible expression of T7 promoter by isopropyl β-D-1-
thiogalactopyranoside (IPTG).  
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5.3.2 COMPETENT CELLS 
The competent cells used for transformation of the plasmid vector to induce the overexpression 
of LBD_rGluk1 were E. coli Origami™ B (DE3) by Novagen (Cat. No. 70837-3). Origami bacteria 
was used for the characteristic of forming disulphide bonds to obtain the proper folding of the 
protein. Since they have mutations in the thioredoxin reductase (trxB) and glutathione reductase 
(gor) genes and these modifications enhance the formation of disulphide bonds in the cytoplasm.  
Bacteria strains with the designation DE3 are lysogenic for a λ prophage that carry an IPTG 
inducible T7 RNA polymerase. Origami B strains are compatible with ampicillin and carbenicillin 
resistance plasmids and are suitable for use with pET vectors. Selective antibiotics for Origami 
strains are kanamycin and tetracycline.  
 
5.3.3 BACTERIA TRANSFORMATION 
The vector containing the LBD_rGluk1 (15ACWOAP_Gluk1_revised_His6-SUMO-GC-3C_P947) 
was prepared by reconstituted lyophilised DNA with 30µl of sterile purified water. 1µl of the 
vector was added into 50 µL of E. coli Origami B (DE3) competent cells and incubated on ice for 
30 minutes. Heat shock was performed at 42°C for 40s in a heat block, then on ice for 2 minutes 
and finally at 37°C in the shaking incubator for 1 hour with the addition of 200µl of super optimal 
broth with catabolite repression (SOC) medium (Invitrogen, Cat. No. 1544-034). The cell 
suspension was plated into LB-agar (Cat. No. L2897, Sigma-Aldrich) containing 15µg/ml 
kanamycin and 50µg/ml carbenicillin. The use of carbenicillin instead of ampicillin is due to 
higher stability and selectivity in bacteria containing the selective plasmid. The plates were 
incubated for 24 hours at 37°C, 5% CO2.   
Antibiotics: Kanamycin sulphate from Streptomyces Kanamyceticus Cat. No. K4000-25G (Sigma-
Aldrich), Carbenicillin disodium salt Cat. No. C1389-5G (Sigma-Aldrich). 
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5.3.4 PROTEIN EXPRESSION  
The colonies which grew were ones carrying the plasmid in the competent cells. One single 
colony was scraped and added into 60 ml of turbo broth (Cat. No. MD12-104-1, Molecular 
Dimensions) containing 15µg/ml kanamycin and 50µg/ml carbenicillin in a 200 ml flask. Cells 
were incubated in the shaker incubator at 37°C until the OD600 reached approximately 1.2. After 
it reached the desired optical density it was inoculated with 10 ml of cells suspension into 1L x 
6 flasks of turbo broth (15µg/ml kanamycin and 50µg/ml carbenicillin) in a 2L glass flask. Cells 
were grown in a shaker incubator at 30°C at 200 rpm until the OD600 was approximately 1.2, 
temperature was reduced to 18°C until the OD600 reached ~1.5. Then IPTG (Cat. No. 15529019, 
Thermo Fisher Scientific) was added to a final concentration of 50µM to each flask, cells were 
grown over night at 18°C. The next day the cells were centrifuged at 6,000 rpm for 20 minutes 
and pellets were frozen for subsequent purification.  
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5.3.5 PROTEIN PURIFICATION  
5.3.5.1 IMMOBILIZED METAL AFFINITY CHROMATOGRAPHY (IMAC)  
Buffers for protein purification experiment, each buffer was filtered at 0.45 µm (Cellulose nitrate 
membrane filters, Whatman™ Cat. No. 514-8073, VWR).  
Lysis Buffer  Elution Buffer  Cat. No.  
50 mM HEPES pH 7.5 50 mM HEPES pH 7.5 BP310-1, Fisher BioReagents  
500 mM NaCl 500 mM NaCl S/3120/63, Fisher Chemical 
10 mM Imidazole 300 mM Imidazole 122025000, Acros Organics  
1 mM TCEP 1 mM TCEP 646547-10x1ml, Sigma-Aldrich 
Distilled H2O up to 500 ml  Distilled H2O up to 250 ml N/A 
 
Pellets of cells were defrosted and resuspended in 50 ml of Lysis buffer with one tablet of 
protease inhibitor cocktail (11055700, Roche) and 250µM of glutamic acid in 20 mM HEPES-
NaOH pH 7.5(L-glutamic acid monosodium salt hydrate Cat. No. G1626, Sigma-Aldrich). Cells 
were lysate with a large probe sonicator, 5 sec on, 5 sec off, 40% amplitude for 5 minutes. Cell 
debris and insoluble fractions were removed by centrifugation at 40,000g for 30 minutes at 4°C. 
Supernatant (soluble fraction) was filtered through a 0.45 µm syringe filter (Sterile PES syringe 
filter Cat. No. 15216869, Fisher Scientific). The filtered supernatant was applied to a gravity 
column containing 7.5 ml of talon metal affinity resin (Clontech Takara Cat. No. 635503) and 
incubated for 1 hour at 4°C. The column was washed with several applications of lysis buffer 
(approximately 200 ml). The retained protein was eluted with several applications of elution 
buffer (~7.5 ml). Eluted fractions were incubated with PreScission protease (27-0843-01, GE 
Healthcare Life Sciences) at 1 unit per ml at 4°C overnight for the removal of the 6xHis-SUMO 
tag.  
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5.3.5.2 SIZE EXCLUSION CHROMATOGRAPHY (SEC)  
The protein solution (~45 to 60 ml) was concentrated to 10 ml using a centrifugal filter unit 
(Vivaspin 20 Molecular weight cut-off (MWCO) 10,000 Cat. No. 28932360, GE Healthcare Life 
Sciences) at 4,000g for approximately 30 minutes. The ÄKTA purifier system (GE Healthcare Life 
Sciences) was used for SEC purification with the HiLoad 26/600 Superdex 75 pg column (Cat. No. 
28-9893-34, GE Healthcare Life Sciences).  
The FPLC buffer used for purification was 20mM HEPES pH 7.5, 500 mM NaCl and 1 mM TCEP 
pH 7.0, filtered and degassed first.  The column was equilibrated with the FPLC buffer overnight. 
The next day, 2 ml fractions were collected in a 2.4 ml 96-deep block plate (Greiner Master Block 
M1061-50EA, Sigma-Aldrich). Fractions collected were verified for separation by SDS-PAGE gel 
electrophoresis 160 V for one hour (SERVAGel™ TG PRIME 4-20%, Cat. No. 43276.01, SERVA) 
and Coomasie stain (Cat. No. GEN-QC-STAIN-1L, Generon), destain was for 2 hours with distilled 
water. Fractions with most abundant protein were collected (~20ml) and concentrated with a 
centrifugal filter unit until a final volume of 1 ml. To ensure the removal of 6xHis-SUMO tag the 
purified protein solution was further incubated with 1 ml of talon metal affinity resin using a     
10 ml centrifuge column for 30 minutes (Pierce™ Centrifuge column 10 ml Cat. No. 89898, 
Thermo Fisher Scientific). After incubation completed, the eluted solution was concentrated up 
to 500 µl, the protein concentration was quantified with a nanoDrop at absorbance A280 nm and 
purity of the protein was verified by SDS-PAGE gel electrophoresis. Several batches of protein 
were obtained and the final yield of purified protein was calculated using the concentration 
mg/ml adjusted with the final volume obtained.  
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5.3.6 CRYSTALLOGRAPHY  
Preliminary crystal experiments were performed using commercial crystallisation screens, 
protein solution was tested in different concentrations ranging from 5-10 mg/ml and at two 
different temperatures 4°C and 14°C. However, none of these conditions were favourable for 
suitable crystals. A list of commercial screens tested in Table 5.1.  
Table 5.1. Commercial crystallisation screens used for preliminary experiments  
Crystallisation 
screen 
Supplier Cat. No 
Proplex™ Molecular dimensions MD1-42 
Morpheus® Molecular dimensions MD1-47 
MIDASplus™ Molecular dimensions MD1-107 
JCSG-plus™ Molecular dimensions MD1-40 
Additive screen™ Molecular dimensions MD1-11 
PACT premier™ Molecular dimensions MD1-36 
Index HT Hampton Research  HR2-134 
PEG/Ion HT Hampton Research HR2-139 
SaltRx HT Hampton Research HR2-136 
Natrix HT Hampton Research HR2-131 
Crystal screen HT Hampton Research HR2-130 
 
Crystallography was performed as previously described (Venskutonyte et al. 2012). In brief, 
concentrated rGluk1 LBD protein was used for crystallography experiments, normally a 
concentration of ≥ 10 mg/ml was obtained. Protein solution was buffer replaced up to 5.7 mg/ml 
in crystallography buffer (14.3mM kainate, 20mM NaCl, 1mM EDTA and 10mM HEPES pH 7.0) 
using a 500µL centrifugal concentrator with a membrane of 5,000 MWCO (Cat. No. VS0111, 
Sartorius). Crystallography experiments were performed using the hanging drop vapour 
diffusion method at 6°C using a drop ratio of 1:1 (1µl of protein solution and 1µl of reservoir 
solution). Reservoir solution containing 21% PEG 4000, 0.45M of lithium sulphate and 0.1 M of 
cacodylate pH 6.5. Crystals were formed in 4 days incubated at 6°C and crystals were stored with 
cryoprotectants 30% PEG 400 or 30% ethylene glycol before being flash-cooled in liquid nitrogen. 
X-ray data was collected to 1.64 Å resolution at the beamline i03 (Diamond Light Source 
synchrotron, Oxfordshire).  
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5.3.7 FRAGMENT SCREENING (SOAKING) 
Ten fragments synthesised by the SDDC (Chemistry group) were used for soaking experiments 
(Table 5.2). These fragments were selected for antagonist activity from the literature for kainate 
receptors or for having binding properties in the dimer interface of AMPA LBD protein (Table 
5.3). Some compounds were also tested using the validated calcium assay and by 
electrophysiology experiments by Dr. Iain Barret. rGluK1 crystals were soaked with fragments at 
different concentrations 1 mM, 5 mM and 10 mM. A 10 µl drop was used containing 9 μl of 
reservoir solution (from previous crystallography experiments) and 1 μl of 10 mM, 50 mM or 
100 mM stock solution in 100% DMSO, crystals in drops were incubated for 1 hour at 4°C.  
 
Table 5.2. Fragments structures used for soaking experiments, compounds synthesize in-house. 
Compound Structure 
Molecular 
weight 
(g/mol) 
Compound Structure 
Molecular 
weight 
(g/mol) 
UOS-15592 
 
268.24 UOS-31059 
 
370.32 
UOS-14986 
 
190.17 UOS-30693 
 
393.63 
UOS-15326 
 
296.29 UOS-30696 
 
369.6 
UOS-12344 
 
379.42 UOS-21170 
 
495.88 
UOS-12230 
 
282.26 UOS-30695 
 
405.65 
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Table 5.3. Compound selection criteria for soaking experiments with protein crystals 
Compound Selection criteria 
UOS-15592 Compound from previous AMPA research performed by 
Dr. Simon Ward (Ward et al. 2011) 
UOS-14986 Binding in the dimer interface of AMPA, in-house 
rGluA2 LBD crystal structure 
UOS-15326 Binding in the dimer interface of AMPA, in-house 
rGluA2 LBD crystal structure 
UOS-12344 Binding in the dimer interface of AMPA, in-house 
rGluA2 LBD crystal structure 
UOS-12230 Binding in the dimer interface of AMPA, in-house 
rGluA2 LBD crystal structure 
UOS-31059 
Preliminary in-house electrophysiology assay 
experiments reported kainate activity (% of inhibition at 
30 µM, GluK1: 28.3 ± 1.14; GluK2: 10.78 ± 1.98 )  
UOS-30693 Synthesised in-house from literature compound 
(Valgeirsson et al. 2004) 
UOS-30696 Synthesised in-house from literature compound 
(Valgeirsson et al. 2004) 
UOS-21170 Synthesised in-house with structure  and chemical 
similarities from another in-house AMPA compound   
UOS-30695 Synthesised in-house from literature compound 
(Valgeirsson et al. 2004) 
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5.3.8 KAINATE CALCIUM ASSAY  
The calcium assay commercial kit Fluo-4 NW (no-wash) from Thermo Fisher Scientific (Cat. No. 
F36206) was used. This assay is based on detecting the increase of cytosolic Ca2+ with the use of 
calcium-sensitive dye indicators, such as Fluo-3 and Fluo-4. Fluo-4 is a dye analogue of Fluo-3 
(two chloride substituents replaced by fluorines) that increases fluorescence intensity upon 
binding with intracellular Ca2+, this detection can be measured with a FlexStation microplate 
reader (Gee et al. 2000). The Fluo-4 NW is a nonfluorescent dye that does not require a wash 
step or a quencher dye unlike the Fluo-4 and Fluo-3 assay kits. Hence, the opening and closure 
of the kainate receptors induced by agonists or antagonists can be measured using this calcium-
signalling assay.  
The validation of the assay was carried out by Dr. Iain Barret from the Sussex Drug Discovery 
Centre and the validated conditions of the assay were followed to confirm the effect of the 
reference agonists kainate and domoate, and antagonist CNQX with the Gluk1 and GluK2 cellular 
assay.   
Materials and Reagents  
Description Use for Supplier and Catalogue 
DMEM high glucose Cell culture media  D0819, Sigma-Aldrich 
Fetal bovine serum (FBS)  Media supplement  F7524, Sigma-Aldrich  
Penicillin-Streptomycin (PS) Media supplement (antibiotic) P4333, Sigma-Aldrich 
Trypsin-EDTA, phenol red Cell detachment  
25200056, Thermo Fisher 
Scientific 
PBS Assay buffer  79382, Sigma-Aldrich 
DMSO Assay buffer 10080110, Fisher chemical 
Fluo-4 NW Calcium assay 
kit 
Component A: dye mix 
Component B: assay buffer 
Assay kit  
F36206, Thermo Fisher 
Scientific 
Corning®96 well flat clear 
bottom black, sterile 
microplate 
Assay microplate  3904, Corning  
96-V well microplate 
translucent polypropylene 
Source dilution plate  
MIC9050, Scientific 
Laboratory Supplies 
Concanavalin A  
Buffer additive, inhibition of 
receptor desensitization  
J61221, Alfa Aesar  
Domoic acid (domoate) Agonist agent  0269, Tocris Bioscience  
Kainic acid (kainate)   Agonist agent  HB0355, Hellobio  
CNQX disodium salt 
hydrate 
Antagonist agent  C239, Sigma-Aldrich  
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Cell Culture 
The cell line used for these experiments was HEK-293 stably expressing human GluK1 receptors 
purchased from Sophion, Biolin Scientific. The GluK1 expression of the cell line was constitutive, 
meaning that the protein was produced continually at all times. Cells were grown in a T75 flask 
until they became ≥70 % confluent. Cell culture passaging was every 3-4 days.  
 
Calcium Assay procedure   
The commercial Fluo-4 NW Calcium assay kit was used for the calcium assay experiments. HEK-
293-hGluK1 cells were seeded in a Corning® 96-well black microplate, 40,000 cells per well and 
incubated at 37°C, 5 % CO2. Twenty four hours after incubation, media was removed and 50 µl 
of Fluo-4 NW dye solution was added per well (dye previously prepared by diluting 10 ml of 
assay buffer into lyophilised dye vial) and incubated for two and a half hours in the dark at room 
temperature.  
On completion of incubation time the dye had entered the cells and the excess was removed 
and washed with assay buffer 1x. The assay buffer was supplemented with 1 mg/ml of 
concanavalin A, added to cells and incubated for 30 minutes in the dark at room temperature. 
Kainate receptor agonists (kainate and domoate) and antagonist 6-cyano-7-nitroquinoxaline-2, 
3-dione (CNQX) were prepared in serial dilutions in a source plate in assay buffer. The source 
plate was prepared with a final maximal concentration of kainate 50 µM  prepared from a 25 
mM stock solution, domoate 5µM prepared from a 10mM stock solution and CNQX 300µM 
prepared from a 30 mM stock solution. 
Addition of source plate was performed using a FlexStation 3 Multi-mode microplate reader. 
Fluorescence was read at 495 nm excitation and 516 nm emission using the FlexStation. For the 
antagonist plate a dual addition protocol was used, in which the first step was the addition of 
CNQX and the second addition was kainate. Data was analysed using the max-min values with 
Softmax pro software and graphs were generated using GraphPad Prism 7 (SOP 
Glutamate/Kainate Ca2+ assay by Dr. Iain Barret).  
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5.4 RESULTS  
5.4.1 PROTEIN EXPRESSION AND PURIFICATION OF HUMAN GLUK1 LBD 
The construct of the hGluK1 LBD protein was provided by the GDSC. Expression test and small 
scale purification were performed. The expression test was performed with 500 ml of cultured 
cells, induction with IPTG (10 µM) was added when the OD600 reached ~1.2. The SDS-PAGE gel 
displayed that after IPTG induction there was no evident protein expression of the human GluK1 
LBD (Fig. 5.4A). A small scale purification was then tested using two litres of cells, the obtained 
protein fractions were incubated with 3C-protease enzyme and samples before and after 
incubation with protease enzyme were observed in a SDS-PAGE gel. The gel did not display a 
difference in bands with 3C-protease enzyme (Fig. 5.4B) suggesting that the faint band at 50 kDa 
does not correspond to the hGluK1 LBD protein. The protein could also be folded in a way so 
that the 6xHis-SUMO tag is placed inside the structure, making it challenging to purify using 
IMAC experiments. These results indicate that using the rat Gluk1 construct will increase the 
solubility and purification of the protein. The purification was then focused on the rGluK1 LBD 
construct. 
 
Figure 5.4 Expression test and purification of the hGluK1 LBD. A. Expression test of hGluK1 LBD 
protein, experiments performed using 250 ml of cultured cells, no evident band of the protein 
was observed. B. Small scale purification (2L) was performed and the resulted fractions were 
incubated with 3C-protease enzyme, the gel displayed no difference between bands with or 
without enzyme incubation. 10 µg of protein loaded per well, protein ladder used Precission Plus 
Protein™ All Blue (Cat. No. 1610373, Bio-Rad).  
198 
 
5.4.2 IMMOBILIZED-METAL AFFINITY CHROMATOGRAPHY (IMAC) PURIFICATION  
IMAC purification successfully purified the LBD of rGluK1 in 6 elution fractions (Fig. 5.5). The 
rGluk1 bands are approximately 45 kDa (protein 29.7 kDa + 6xHis-SUMO tag 15 kDa), the gel 
showed a highly concentrated band in the talon beads before elution which means the retention 
of the protein. Each elution fraction of 7.5 ml of buffer gives a protein band with higher 
concentration in elution two and three. The flow through fraction represents all the proteins 
that do not bind to the talon beads. A sample of beads before and after elution, B1 and B2 
respectively (Fig. 5.5), show that most of the protein was eluted providing a large amount of 
purified protein, although some small fraction of protein was still retained in B2. There were 
some nonspecific bands around 60-70 kDa and 25 kDa that were further removed by size 
exclusion chromatography (SEC) experiments as a further purification step.  
In order to verify if the concentrated bands are the protein of interest a SDS-PAGE gel of the 
eluted fractions was run before and after incubation with 3C protease. In Fig. 5.6 it can be 
observed that elution fractions before 3C protease exhibit a strong band around 45 kDa and 
after incubation with 3C protease the band of 45 kDa is not present any more. However, two 
bands are present at 29 kDa and 15 kDa demonstrating the removal of the 6xHis-SUMO tag in 
rGluk1 protein, this also indicates that the protein eluted and purified was rGluk1 and no other 
nonspecific protein.  
 
Figure 5.5. SDS-PAGE gel of IMAC purification. Gel stained with Blue Coomassie, strong bands of 
45 kDa corresponding to the LBD of rGluk1 protein. Approximately 50 ml of supernatant was 
added into 7.5 ml of talon beads, the flow through was ~50 ml, wash 1 and 2 was ~ 100ml each 
and a sample of 25 µl of talon beads was used for running the SDS-PAGE gel.  10 µg of protein 
loaded per well. Protein ladder PageRuler™ Cat. No. 11892124, Thermo Scientific. 
199 
 
 
Figure 5.6. SDS-PAGE gel of 3C protease activity.  Protein before 3C protease incubation exhibits 
a band of 45 kDa and after 3C protease incubation exhibits two bands of 29 kDa corresponding 
to rGluK1 and 15 kDa corresponding to the 6xHis-SUMO tag. Lane one and two loaded with 4 µg 
of protein and lane three and four with 7 µg of protein.  
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5.4.3 SIZE EXCLUSION CHROMATOGRAPHY (SEC) PURIFICATION  
SEC purification results in a graph (chromatogram) that displays the separation of components 
of a mixture after a size exclusion chromatograpy column. Ultraviolet (UV) light absorption at 
A280 was used to measure the fractions separation.  A chromatogram was obtained (Fig. 5.7A) 
with two main peaks, a larger first peak around 120 ml with higher molecular weight molecules 
that indicates a possible aggregation formation (fractions 1E6-1F2). Additionally, the presence 
of a 60 kDa band suggests a dimer formation, as this is double the size of the protein of interest. 
However, these nonspecific bands can be the product of bacteria metabolism products. This 
larger peak and its respective fractions were not adequate for further purification experiments.  
The second peak at 160-180 ml is consistent with the protein rGluk1 with less UV absorption 
(Fig. 5.7A). Selected fractions collected from FPLC SEC experiments were run in a SDS-PAGE gel 
electrophoresis (Fig. 5.7B). Fractions between 1G9 and 1H6 display the protein of interest in a 
higher purity. A degradation band just under 29 kDa was observed and a small amount of 6xHis-
SUMO tag around 15 kDa was also observed.  
To remove the 6xHis-SUMO tag which remained, the sample was further purified with IMAC, 
resulting in a flow through with protein rGluk1 with higher purity. This was confirmed by SDS-
PAGE gel analysis (Fig. 5.8). The degradation band was not observable in the final purified 
protein, suggesting a degraded protein over time or the presence of a protein with some tag 
remain. Final protein concentration was verified by nanoDrop using the molecular weight 29.740 
kDa and extinction coefficient of 42,860 M-1 cm-1 at 280 nm, obtaining a final protein yield of 3.0 
mg of protein from 6 litres of culture (8.7 mg/ml in ~350µl). Fifteen batches of purified protein 
were prepared for crystallography experiments listed in Table 5.4, different starting cell cultures 
were prepared from 2 to 8 litres.  
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Figure 5.7. Size exclusion chromatography for rGluk1. A) Chromatogram obtained with SEC 
purification of the rGluk1 protein with 200ml of FPLC buffer through the column. B) SDS-PAGE 
gel of the fractions obtained by SEC, bands of 29 kDa indicate the rGluk1 protein and a lower 
band just under 29 kDa suggests proteolytic degradation during the experiment. 10 µg of protein 
loaded per well, protein ladder used Precission Plus Protein™ All Blue (Cat. No. 1610373, Bio-
Rad).  
A) 
B) 
* 
202 
 
 
Figure 5.8. SDS-PAGE gel verification of pure rGluk1 protein. 0.5, 1.0, 1.5 and 2.0 µg of protein 
loaded to verify the purity of the protein, one single band of 29 kDa corresponding to rGluK1, 
no other proteins were detected in the gel.  
 
Table 5.4. Different batches of purified protein obtained after purification experiments 
Batch 
No.  
Starting cell 
culture (L) 
Concentration 
(mg/m) 
Final volume 
obtained (µl) 
Yield of purified 
protein (mg) 
1 2 12.75 60 0.8 
2 4 7.21 250 1.8 
3 4 7.8 300 2.3 
4 4 10 200 2.0 
5 6 8.7 350 3.0 
6 6 8.0 400 3.2 
7 6 9.5 250 2.4 
8 6 10.75 300 3.2 
9 6 8.81 350 3.1 
10 6 12.7 200 2.5 
11 6 10.75 300 3.2 
12 6 14.5 200 2.9 
13 8 8.0 350 2.8 
14 8 8.14 200 1.6 
15 8 12.6 200 2.5 
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5.4.4 CRYSTALLOGRAPHY 
A wide range of commercial crystallisation screens were tested including: Proplex™, Morpheus®, 
MIDASplus™, JCSG-plus™, additive screen, PACT premier™, Index, PEG/Ion, SaltRx, Crystal 
screen and Natrix. None of these gave any suitable crystals for X-ray crystallography.  
Crystals were prepared with 5.7 mg/ml protein diluted with crystallography buffer (14.3 mM 
kainate, 20 mM NaCl, 1 mM EDTA and 10 mM HEPES PH 7.0). Crystals appeared after 4 days of 
incubation using the hanging drop method at 6°C with a reservoir solution of 21% PEG 4000, 
0.45M lithium sulphate and 0.1 M cacodylate pH 6.5.  
Crystals had a tetragonal (based on a rectangular inner structure) crystal configuration ranging 
from 0.2 mm to 0.5 mm length size (Fig. 5.9). It was necessary to separate the cluster of crystals 
with a needle to obtain single individual crystals. Crystals grew in similar conditions to those 
described in the literature (PDB 4E0X; Venskutonyte et al. 2012). 
 The use of cryoprotectant before collecting X-ray diffraction data helps protect the crystal 
structure from free radicals originating in ionising x-rays that can frequently cause crystal 
damage. In the literature PEG 400 was used as a cryoprotectant in rGluK1 LBD crystals before 
collecting X-ray diffraction data (Venskutonyte et al. 2012). PEG 400 and ethylene glycol were 
compared as a cryoprotectant in rGluk1 crystals before being quick-frozen in liquid nitrogen.  
The rGluk1 structures were solved by molecular replacement using a well-known structure PDB 
4E0X, models were refined using Collaborative Computational Project No. 4 (CCP4) and Python-
based Hierarchical Environment for Integrated Xtallography (PHENIX) software. Crystallographic 
Object-Oriented Toolkit (COOT) was used for manual model building by Dr. Mark Roe. Diffraction 
data was collected for both crystals with a final resolution of 1.64 Å for 30% PEG 400 and 1.89 Å 
for 30% ethylene glycol.  
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Figure 5.9. rGluk1 tetragonal crystals. Crystals obtained at 5.7 mg/ml protein with a reservoir 
solution of 21% PEG 4000, 0.45M lithium sulphate and 0.1 M cacodylate pH 6.5. Crystals with a 
size ranging from 0.2 to 0.5 mm.  
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Table 5.5. Crystallographic Statistics of rGluK1 LBD. Crystals shot at the i03 beamline at Diamond 
Light Source. 
 
Data Set 
(Highest shell in 
parentheses) 
rGluk1 PEG  rGluk1 EG  
a (Å) 70.13 70.88 
b (Å) 70.13 70.88 
c (Å) 232.98 235.9 
 () 90 90 
 () 90 90 
 () 90 90 
Space Group P 41 21 2 P 41 21 2 
Wavelength (Å) 0.9762 0.9762 
Resolution Limit (Å) 48.50-1.64 
(1.67-1.64) 
50.1-1.89  
(1.92-1.89) 
Number of Unique  
Obs. 
70471 
(3435) 
49218  
(2376) 
Completeness (%) 97.2 
(95.8) 
99.8 
(97.9) 
Multiplicity 7.3 (7.7) 8.4 (7.2) 
Rmerge % 0.111 (1.545) 0.085 (1.532) 
Rpim(I) % 0.044 (0.590) 0.032 (0.608) 
CC1/2 0.997 (0.505) 0.997 (0.761) 
I/I 9.4 (1.3) 12.3 (1.1 
Refinement 0.9762 0.9762 
Resolution Range (Å) 232.98 – 1.64 235.97 – 1.89 
Rcryst 0.187 0.19555   
Rfree 0.225 0.246 
Number of protein 
atoms 
3,979 4,013 
Number of ligand 
atoms 
31 31 
Number of solvent 
atoms 
234 102 
Mean B 25.593 44.083 
Rmsd bond lengths 
(Å) 
0.020 0.020 
Rmsd bond angles (°) 2.037 1.968 
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Figure 5.10. LBD rGluK1 structures obtained with X-ray crystallography. Chain A and B, orange 
and blue respectively. Kainic acid (kainate) shown in fuchsia, SO4 in yellow and solvent ethylene 
glycol in green. The dimer interface of ethylene glycol (EG) structure displays solvent molecules 
but the dimer interface of PEG 400 does not.  
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Figure 5.11. Ligand binding domain of rGluk1 in complex with kainic acid. Kainic acid is shown in 
fuchsia stick representation. The construct consisted of S1 and S2, dark orange and light orange 
respectively, GT linker in dark blue and SO4 molecules in cyan. Structure generated using PyMOL 
2.0 
 
The solved structures show kainic acid binding in the cavity formed between the interface 
segment S1 and S2 (Fig. 5.10 & 5.11). Chain A and Chain B of the structure forms a dimer in the 
LBD of the protein (Fig. 5.10). Crystals with different cryoprotectant (PEG 400 and ethylene 
glycol) presented similar diffraction data (Table 5.5), however crystals with PEG 400 are better 
suited for fragment/inhibitor binding studies because there are not solvent molecules present 
in the dimer interface compared to the structure with ethylene glycol (Fig. 5.10).   
Sulphate (SO4) molecules were present in the structure because of the addition of lithium 
sulphate in crystals grown; this salt is used as an electrostatic stabilisation agent to stabilize the 
protein conformation. The monomers of LBD rGluk1 and GluA2 (both produced in-house) were 
compared and both shared similar conformation and structure. In order to determine 
ligand/inhibitor binding similarity with GluA2 LBD, the dimer of rGluK1 LBD with kainate 
obtained was aligned with an in-house LBD structure of GluA2 (Fig. 5.12).  Both proteins shared 
the same dimer conformation suggesting similar ligand binding sites for compounds in the LBD.  
208 
 
 
 
 
Figure 5.12. Structure alignment between rGluk1 LBD and GluA2 LBD. Left, alignment between 
rGluK1 LBD monomer with kainate (green) and GluA2 monomer (yellow, in-house structure). 
Right, LBD dimer alignment between rGluK1 (yellow and green) and GluA2 (yellow). Alignment 
processed with COOT and PyMOL software. 
 
5.13. Sequence alignment of the LBD of rGluA2 and rGluK1. The LBD sequence alignment was 
performed using Clustal Omega (European Molecular Biology Laboratory-European 
Bioinformatics Institute, EMBL-EBI). The level of identity between both proteins in the LBD is 53% 
(259 amino acids analysed) and 73% positives (positives refer to the amino acids which are 
similar in their physicochemical properties). The amino acid residues involved in the PAMS 
binding sites in AMPA are highlighted in yellow with their equivalent for rGluK1 (~80% identity 
between both proteins in the dimer interface pocket).  
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Kainate binding in the cavity of the LBD was found to form hydrogen bonds with residues of the 
protein. These interactions observed are: the α-carboxyl group of kainate formed interactions 
with Thr-90 and Arg-95 and the α-amino group of kainate formed interactions with Glu-190 (Fig. 
5.14), similar to a previously published LBD rGluK1 structure 4E0X (PDB, accession code; 
Venskutonyte et al. 2012).  In addition, the residues arginine and glutamic acid showed to be 
conserved in rGluA2, rGluK1 and rGluK2, forming interactions with the α-carboxyl group and the 
α-amino group of agonists glutamate and kainate respectively (Fig. 4.15, 5.14 and 5.30).   
 
Figure 5.14. Kainate binding interaction diagram for rGluK1 LBD. Kainate agonist forms hydrogen 
bonds with Residues Thr-90, Arg-95 and Glu-190. Hydrogen bonds are represented in fuchsia 
arrows. Ligand interaction diagram generated using Maestro Schrödinger version 11.1. 
  
5.4.5 FRAGMENT SCREENING (SOAKING)  
A.H Ahmed and co-worker found a new binding site in the LBD of GluA2 for a nootropic drug 
(Piracetam), binding in multiple positions along the dimer interface (Ahmed & Oswald 2010). 
This suggests a similar binding pocket for rGluK1 LBD. For that reason, rGluK1 crystals were 
soaked with ten different fragments synthesised in-house. Fragments were selected according 
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to the possibility of binding into the LBD (dimer interface or other novel biding site) or their 
antagonist activity from the literature.  
Unfortunately, none of the fragments displayed a binding interaction with rGluK1 protein. At 
high concentration of compounds, DMSO caused difficulties in handling the crystals and resulted 
in low-resolution diffractions from 3.5 Å to 6.5 Å resolution.   
 
5.4.6 KAINATE CALCIUM ASSAY  
In case compounds were found to bind in the LBD of the protein (after soaking experiments) it 
was planned to verify the hits using a previously optimised calcium assay, however no 
compounds were identified as binding in the LBD of rGluK1. In addition, the purpose of these 
results was to verify the biological calcium assay in determining IC50 values and dose-response 
curve. The assay development was performed by Dr. Iain Barret and summarised in Table 5.6.   
Table 5.6. Parameters tested for 96-well plate for human GluK1/GluK2 Ca2+ assay development.  
Parameters Conditions tested Best parameters 
Cell seeding 
densities  
Various densities varying from  
10,000 to 30,000 cells per well 
Cell density higher than 30,00 cells per 
well had better resistance to washing 
off steps and improved assay signal  
Poly-D-lysine 
(PDL) coating  
PDL used at 1mg/ml  
Increased signal without PDL, final 
assay without PDL for simplicity.  
Dye solution   Dilutions tested from 0.5 to 2x 1x dye improved results  
Dye incubation  
37°C for 2 hours  
37°C for 1 hour then at RT for 
1 hour 
Room temperature for 1-3 
hours  
 
Best incubation time was at room 
temperature for 2.5 hours, followed 
by at least 30 min in wash buffer (up 
to 2 hours)  
Concanavalin A 
(ConA) 
1.5 to 2.0 mg/ml in assay 
buffer 
0 to 60 minutes incubation 
time at RT  
Improved results with ConA 1mg/ml in 
assay buffer for 30 minutes at RT 
 
In order to measure the activity of standard agonists and antagonists for GluK1 and GluK2 
kainate receptors the commercial Fluo-4 NW calcium assay kit was used. Fluo-4 is a green 
fluorescent indicator used for the detection of intracellular calcium (Ca+2) in which high 
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fluorescence measurements are directly correlated with Ca2+ binding in AMPA and kainate 
calcium permeable receptors. Fluo-4 NW dye is widely used for identification of 
agonist/antagonist calcium signalling, having higher sensitivity compared to Fluo-3 and Fluo-4 
AM in an assay type format. HEK-293 expressing human protein GluK1 were used to measure 
the activity of kainate/domoate agonist and CNQX antagonist (Fig. 5.15). The kainate dose-
response curve gave an EC50 of 3.03 µM, 4-fold less than the literature value of 12 µM (Solly et 
al. 2015) and Domoate dose response curve gave an EC50 of 0.077 µM 20-fold less than literature 
value of 1.6µM (J. K. Christensen et al. 2004). It was observed that domoate had a lower EC50 
(higher Emax) compared with kainate agonist (Fig. 5.16). Similar EC50 values obtained from 
literature demonstrated that calcium assay using Fluo4 dye is suitable for compound screening 
characterisation. The signal-to-background ratio (S/B) was calculated for kainate, domoate and 
CNQX and resulted in 15.01, 37.97 and 30.64 respectively. The calculations were based on the 
mean of the maximal response divided by the mean of the background. For CNQX the calculation 
of S/B ratio used the maximal response obtained after addition of kainate. The S/B ratio was 
higher with domoate suggesting a higher response signal ratio compared to the background.  
 
 
Figure 5.15. Chemical structures of kainate, domoate and CNQX. 
 
CNQX antagonist dose response curve gave IC50 of 17.5µM when kainate was added to final 
concentration of 50 µM, CNQX was added to cells at 300 µM final top concentration in a double 
addition format experiment, in which the second addition was kainate at single final 
concentration of 50 µM (Fig. 5.17). The addition of kainate increases fluorescence in the lower 
concentrations of CNQX. The IC50 literature value is 1.5 µM for kainate receptors (value from 
Cayman chemical supplier).  
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Agonist EC50 
Kainate 3.03 µM 
Domoate 0.077 µM 
 
Figure 5.16. Gluk1 kainate/domoate agonist dose response curves. HEK-293 cells stably 
expressing GluK1, cells were incubated with 50µM kainate and 5µM domoate top concentration.  
RFU, relative fluorescence units in y-axis. Error bars (SD) are indicated representing n=3 
individual experiments.  
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Figure 5.17. Gluk1-CNQX antagonist dose response curve. HEK-293 cells expressing human 
GluK1 receptors were incubated with CNQX (first addition step) then kainate added at 50µM 
final concentration (second addition step), labelled as CNQX post addition. Error bars (SD) are 
indicated representing n=3 individual experiments.  
 
 
 
 
 
 
 
 
 
 
Antagonist IC50 
CNQX 17.5 µM 
214 
 
5.5 DISCUSSION  
The main objective of these experiments was to express and purify the LBD of the rat GluK1 
protein in a large-scale quantity to further continue with crystallography experiments with the 
aim of obtaining X-ray structure data for further drug discovery design.  
Full-length Gluk1 protein has not been purified or crystallised due to being an integral 
membrane protein. The transmembrane domain is embedded in the phospholipid bilayer and 
interacts strongly with hydrophobic groups (fatty acyl groups) in the membrane (Uzman et al. 
2000; Smith 2011).  This property makes the purification and crystallisation extremely difficult, 
in membrane proteins strong non-polar solvents are usually used to help solubilise the protein. 
For example, the purification of the full-length rat rGluA2 receptor was achieved using a large 
amount of detergents such as, n-Dodecyl-β-D-Maltoside and n-undecyl-b-D-thiomaltoside to 
improve protein solubilisation and purification. For NMDA rat GluN1-GluN2B protein an 
amphiphilic detergent, lauryl maltose neopentyl glycol (MNG-3), was used to improve the 
stabilisation and solubilisation of the membrane protein. In addition, in both proteins a 
baculovirus-insect cell system was used to maximise protein production of membrane proteins 
(Sobolevsky et al. 2009a; E. Karakas & Furukawa 2014). Furthermore, the recent use of cryo-
electron microscopy (EM) gives an advantage for determining structures without the crystal 
form of the protein, however the structures obtained are at low resolution ranging from 5 Å to 
10 Å (Zanotti 2016).  For this reason, not all iGluRs subtypes have been identified in a full-length 
structure because it is a long multi-step procedure with the use of different detergents and 
expression systems to take into consideration.  
For structure based drug design purposes, attention was focused in the ligand binding domain 
of rat GluK1 as an important drug target structure for the study in epilepsy treatment. Ahmed 
and Oswald successfully characterised the structure of the LBD of AMPA GluA2 and GluA3 
receptors with piracetam and aniracetam (Ahmed & Oswald 2010). Currently these nootropic 
drugs are marketed as a supplement for improving cognitive function and also used in dementia, 
however both drugs have not been approved by the FDA (Gouliaev & Senning 1994; Malykh & 
Sadaie 2010). In Ahmed’s review, they found a potential new binding site in the LBD of AMPA 
receptors, they demonstrated the binding of aniracetam at the centre of the dimer interface 
and piracetam binding to multiple sites along the dimer interface for GluA2 and GluA3. 
 Gluk1 protein has over 90% sequence identity in the LBD, it was assumed that Gluk1 may have 
the same binding site in the dimer interface of the LBD and for that reason it was decided to 
focus on expressing and purifying the LBD of the rat Gluk1 protein. The rat protein was used due 
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to the difficulty of expressing human rGluK1 protein and to have uniformity to the AMPA rat 
GluA2 expression and purification system.  
The expression construct was kindly provided by Dr. Antony W. Oliver (GDSC, University of 
Sussex). The plasmid construct was designed to express the S1 and S2 segments of the LBD 
following previous purification strategy from M. Mayer for AMPA receptors (Mayer 2005). This 
construct contains a 6xHis-SUMO tag to improve solubilisation and purification of the protein. 
The rGluk1 LBD protein was successfully purified on a large scale following a standard 
purification method used previously for AMPA LBD purification. Several batches of purified 
protein were produced, from different starting material (cell culture) a sufficient amount of 
purified protein was observed with six litres of cell culture ranging from 2.4 mg up to 3.2 mg 
final yield.  With eight litres of cell culture it was observed to yield a reduced amount of protein, 
with a larger amount of unspecific proteins, suggesting a larger amount of aggregate formation 
from bacteria metabolism. It was also observed that with higher amounts of protein to produce 
(from higher amounts of cells in the starting culture) it was more difficult to handle the 
purification experiments, such as sonication, volume of buffers, amount of talon beads, elution 
fractions and incubation time with beads.  
Preliminary crystallisation trials using commercial screening kits resulted in non-single crystals 
that gave low-resolution diffraction. Previously published crystallography for LBD rGluk1 (PDB 
4E0X) was reproducible and single crystals with resolution of 1.64 Å, higher resolution than 
published crystal structure (2.0 Å) was obtained (Venskutonyte et al. 2012) . Crystals obtained 
of rat Gluk1 were high resolution diffracting crystals, however these crystals could be improved 
in order to facilitate larger fragment screens. rGluK1 protein was crystallised in complex with 
kainate, because all the crystallography experiments with only glutamate in the purification and 
without kainate (crystallography buffer) resulted in poor quality crystals. The high affinity of 
kainate in kainate receptors might give the stability of the structure to crystallize, however this 
is just a theory due to the difficulty of obtaining crystals with glutamate in the orthosteric site in 
this recombinant protein.  
Finally, Dr. Iain Barret’s previously optimised calcium assay was reproduced using standard 
agonists (kainate and domoate) and antagonist (CNQX). An EC50 dose response curve was 
obtained with values of 3.03 µM for kainate, 0.077 µM for domoate and 17.5 µM for CNQX. The 
assay had a signal-to-background ratio (S/B) of 15.01, 37.97 and 30.64 respectively suggesting 
an adequate assay limit of detection. For future work, other fragments can be screened using 
this calcium assay optimized methodology.  
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The overall strategy was to obtain pure rat GluK1 LBD protein for X-ray crystallography 
experiments. Then using fragment soaking to observe the binding mode of these compounds 
into the structure to further confirm in a calcium assay format, as well as the possibility to 
perform in future a larger screen to optimise compounds binding in the structure. However, 
none of the ten fragments tested at different concentrations (1, 5 and 10 mM) displayed binding 
properties with the LBD structure of rat GluK1. At higher concentration of compounds more 
difficulties arose due to the higher % of DMSO affecting the quality and stability of the crystals 
resulting in poor diffraction values. Structural information obtained from X-ray crystallography 
and crystals obtained could be used for future work such as larger fragment screening and lead 
compound optimisation.  
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5.6 MATERIALS AND METHODS 
5.6.1 CLONING AND PLASMID VECTOR  
The plasmid of the rat ligand binding domain (LBD) of GluK2 was kindly supplied by Dr. Antony 
W. Oliver from the Genome Damage and Stability Centre (GDSC, University of Sussex). The GDSC 
frequently used its own pHis-SUMO-3C vector to facilitate protein production and purification. 
The construct of rat GluK2 containing the LBD is formed by S1 and S2 segments linked by a Gly-
Thr dipeptide to maintain the structure of the LBD and to form a stable structure without the 
amino terminal domain (ATD), transduction domain (TD) and transmembrane domain (TMD). 
This construct was designed according to previously published experiments (Mayer 2005) based 
on the design of AMPA receptor rGluA2 S1S2 construct  (Armstrong & Gouaux, 2000). Similar to 
rGluK1, a 6xHis-SUMO tag was used to increase expression and solubility of the recombinant 
protein. The protein sequence based on rGluK2 P42260-1 from UniProt is shown in Fig. 5.18.  
 
 
Figure 5.18. LBD rGluK2 sequence design for protein expression and purification. The sequence 
protein contains a N-terminal 6xHis-SUMO tag, a recognition SUMO cleavage site and the 
sequence of the LBD of the rGluK2 protein consisting of [429-SNRS…LYRK-544] and [667-
PIDS...GCPE-806] linked using a dipeptide Gly-Thr, sequence based on P42260-1 (GRIK6, UniProt).  
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The pHis-SUMO-3C plasmid containing the rGluK2 LBD protein was sub cloned externally by 
Invitrogen. The protein construct was subcloned into a pBR322 plasmid with a pET T7 expression 
system controlled by isopropyl β-D-1-thiogalactopyranoside (IPTG) using a T7 promoter site. The 
final plasmid contained an ampicillin resistance gene site to selectively control the bacteria 
grown carrying the recombinant protein and specific restriction enzymes such as NdeI, EcoRI, 
Notl, Xhol and Scal (Fig. 5.19). In addition, the plasmid was designed to have an N-terminal 6xHis-
SUMO tag to improve the solubility and purification of the protein. The gene cloning and plasmid 
DNA purification was performed commercially by Invitrogen. Consistent with rGluA2 and rGluK1 
experiments, the GluK2 protein was designed on rat protein gene sequence, to facilitate 
solubility, purification and crystallography experiments.  
 
 
 
Figure 5.19. Plasmid map of the inserted recombinant rat gene GluK2 LBD. Invitrogen provided 
5µg of lyophilised plasmid ready to reconstitute with 30µl of sterile water and use for 
transformation experiments.  
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5.6.2 COMPETENT CELLS 
The competent cells used for bacteria transformation were the E. coli Origami™ B (DE3) by 
Novagen (Cat. No. 70837-3). The origami bacteria strain was used due to its ability to form 
disulphide bonds required for the correct folding of the protein. This bacteria strain is 
compatible with ampicillin and carbenicillin resistance plasmids. Selective antibiotics for Origami 
strains are kanamycin and tetracycline.  
 
5.6.3 BACTERIA TRANSFORMATION 
The vector containing 5µg of lyophilised DNA was reconstituted with 30µl of sterile purified 
water. The methodology followed was the same as rGluk1 bacteria transformation section 5.3.3, 
with the difference of adding 1 µl of the vector 15ADDVNC_pHIS-SUMO-rGluK2_SUMO-GG-3C-
TONY_R545 corresponding to the rGluK2 LBD protein. The rest of the plasmid solution was 
stored at -20ᵒC.  
 
5.6.4 PROTEIN EXPRESSION  
Protein expression experiment was the same as rGluK1 experiments, see section 5.3.4. Cells 
pellets from 6 L of culture broth were frozen at -20ᵒC for further IMAC and SEC purification 
experiments.  
 
5.6.5 PROTEIN PURIFICATION  
5.6.5.1 IMMOBILIZED METAL AFFINITY CHROMATOGRAPHY (IMAC) 
Buffers for protein purification experiments below, each buffer was filtered at 0.45 µm 
(Cellulose nitrate membrane filters, Whatman™ Cat. No. 514-8073, VWR).  
Lysis Buffer  Elution Buffer  Cat. No.  
20 mM HEPES pH 7.5 20 mM HEPES pH 7.5 BP310-1, Fisher BioReagents  
500 mM NaCl 500 mM NaCl S/3120/63, Fisher Chemical 
10 mM Imidazole 300 mM Imidazole 122025000, Acros Organics  
0.5 mM TCEP 0.5 mM TCEP 646547-10x1ml, Sigma-Aldrich 
Distilled H2O up to 500 ml  Distilled H2O up to 250 ml N/A 
 
The IMAC purification was the same as followed by rGluK1 experiments, section 5.3.5.1. 
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5.6.5.2 SIZE EXCLUSION CHROMATOGRAPHY (SEC) 
The SEC purification was the same as followed by rGluK1 experiments, section 5.3.5.2 
 
5.6.6 CRYSTALLOGRAPHY  
Preliminary crystal experiments were performed using commercial crystallisation screens (Table 
5.7). The pure rGluk2 protein was diluted with crystallography buffer (10mM HEPES pH 7.0, 30 
mM NaCl, 1 mM EDTA and 20 mM glutamate) to a final concentration of 5 mg/ml. For 
crystallography screening, the crystal Phoenix liquid handling system (Alpha Biotech) was used. 
Using the MRC 2-well 1 protein protocol a drop ratio of 1:1 of protein and reservoir solution was 
dispensed into a 96 MRC crystallography plate. Experiments were performed using the hanging 
drop vapour diffusion method at 14oC. From crystallography screening, the best crystals grown 
were under the following conditions:  0.06M Citric acid, 0.04M BIS-TRIS propane pH 4.1 and 16% 
w/v PEG 3350 corresponding to PEG/Ion HT screen condition H1.  
 
Table 5.7. Commercial crystallisation screens used for preliminary crystallography experiments. 
Crystallisation 
screen 
Supplier Cat. No 
JCSG-plus™ Molecular dimensions MD1-40 
Proplex™ Molecular dimensions MD1-42 
Morpheus® Molecular dimensions MD1-47 
Index HT Hampton Research  HR2-134 
PEG/Ion HT Hampton Research HR2-139 
SaltRx HT Hampton Research HR2-136 
Crystal screen HT Hampton Research HR2-130 
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Microseeding  
In order to optimise the size and quality of single crystals, a seed stock was prepared from 
previous crystal hits. Crystals were crushed with a probe and transferred into a seed bead tube 
(HR2-320, Hampton Research) with 50 µl of reservoir solution (0.06M Citric acid, 0.04M BIS-TRIS 
propane pH 4.1 and 16% w/v PEG 3350). The seed bead tube was vortexed for 2 minutes and 
this solution became the 100% seed stock. 1%, 5% and 10% seed stock dilutions were prepared 
using the reservoir solution.  
The 1%, 5% and 10% seed stocks were seeded (Fig. 5.20) in a 48-well MRC maxi plate (MD11-
004-10, Molecular Dimensions). The volumes added per drop were 0.6µl protein + 0.4µl 
reservoir solution + 0.2µl seed stock using the Oryx8 protein crystallisation robot from Douglas 
Instruments.  Plates were incubated for 5 days at 14ᵒC and crystals which grew after 24 hours 
were stored with cryoprotectant (30% ethylene glycol) before being flash-cooled in liquid 
nitrogen. X-ray data was collected to 1.95 Å resolution at the beamline i04 (Diamond Light 
Source synchrotron, Oxfordshire).  
 
Figure 5.20. Layout plate of the microseeding experiments performed for crystal optimisation. 
48-well MRC maxi optimisation plate used for microseeding experiments. This plate type has the 
characteristic of having wider wells for depositing larger drops to obtain larger crystals by using 
less reservoir solution.  
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5.6.7 FRAGMENT SCREENING (SOAKING)  
In the same way as rGluK1, ten internally-synthesised fragments (SDDC, Chemistry group) were 
used for soaked experiments (Table 5.2). Crystals of rGluK2 were soaked with different 
concentrations of fragments (1, 5 and 10 mM) and incubated for 1 hour at 4ᵒC.  Additional detail 
of the experimental procedure is provided in section 5.3.7.  
 
Table 5.2. Fragments structures used for soaking experiments, compounds synthesize in-house. 
Compound Structure 
Molecular 
weight 
(g/mol) 
Compound Structure 
Molecular 
weight 
(g/mol) 
UOS-15592 
 
268.24 UOS-31059 
 
370.32 
UOS-14986 
 
190.17 UOS-30693 
 
393.63 
UOS-15326 
 
296.29 UOS-30696 
 
369.6 
UOS-12344 
 
379.42 UOS-21170 
 
495.88 
UOS-12230 
 
282.26 UOS-30695 
 
405.65 
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5.6.8 KAINATE CALCIUM ASSAY 
The calcium assay commercial kit Fluo-4 NW (no-wash) from Thermo Fisher Scientific (Cat. No. 
F36206) was used for detecting the increase of cytosolic Ca2+ resulting from activation and 
pharmacological modulation of the rGluK2 receptor. For more information about the assay 
principle, see section 5.3.8. 
The validation of the assay was carried out by Dr. Iain Barret from the Sussex Drug Discovery 
Centre and the validated conditions of the assay were followed to confirm the effect of the 
reference agonist kainate and domoate, and internal antagonist UOS-30693 with the GluK2 
cellular assay.   
Description Use for Supplier and Catalogue 
DMEM/F-12 GlutaMAX Cell culture media  
10565018, Thermo Fisher 
Scientific 
Blasticidin S HCl  Media supplement (antibiotic) R21001, Invitrogen 
Hygromycin B  Media supplement (antibiotic) 10687010, Invitrogen  
Tetracycline hydrochloride 
Induction of receptor 
expression 
233105000, Acros Organics 
Fetal bovine serum (FBS)  Media supplement  F7524, Sigma-Aldrich  
Penicillin-Streptomycin (PS) Media supplement (antibiotic) P4333, Sigma-Aldrich 
Trypsin-EDTA, phenol red Cell detachment  
25200056, Thermo Fisher 
Scientific 
PBS Assay buffer  79382, Sigma-Aldrich 
DMSO Assay buffer 10080110, Fisher chemical 
Fluo-4 NW Calcium assay 
kit 
Component A: dye mix 
Component B: assay buffer 
Assay kit  
F36206, Thermo Fisher 
Scientific 
Corning®96 well flat clear 
bottom black, sterile 
microplate 
Assay microplate  3904, Corning  
96-V well microplate 
translucent polypropylene 
Source dilution plate  
MIC9050, Scientific 
Laboratory Supplies 
Concanavalin A  Buffer additive, clamping agent J61221, Alfa Aesar  
Domoic acid (domoate) Agonist agent  0269, Tocris Bioscience  
Kainic acid (kainate)   Agonist agent  HB0355, Hellobio  
UOS-30693 Antagonist agent In-house  
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Cell culture and assay methodology  
Methodology was followed as GluK1 experiments (section 5.3.8) with the following differences: 
I. HEK-293_hGluK2 cells stably expressing human GluK2 receptors purchased from 
Sophion, Biolin Scientific. The expression of GluK2 receptor was under a tetracycline-
inducible promoter. 
II. Cells were grown in DMEM/F12 GlutaMAX supplemented with 10% FBS, 1% PS,           
100 µg/ml hygromycin B and 15 µg/ml blasticidin.  
III. 24 hours before calcium assay, cells were incubated with tetracycline at 2.5µg/ml final 
concentration to induce the expression of the GluK2 receptor.  
IV. The source plate was prepared with a final maximal concentration of kainate of 8.3 µM 
prepared from a 25 mM stock solution and a final maximal concentration of domoate 
of 0.83 µM prepared from a 10 mM stock solution. The addition plate was prepared 
with both agonists at 1:6 serial dilutions format.  The antagonist was the compound 
UOS-30693 with a final maximal concentration of 300µM prepared from a 10 mM stock 
solution in a 1:3 serial dilutions format, with an extra addition of kainate at 50 µM (two 
addition format). CNQX antagonist was tested at 300 and 500 µM with GluK2 cells 
however, no antagonist activity was observed. The internal compound UOS-30693 was 
used for antagonist experiments due to being previously identified in the literature as 
a potent antagonist for GluK2 receptors (Valgeirsson et al. 2004).  
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5.7 RESULTS 
5.7.1 IMMOBILIZED-METAL AFFINITY CHROMATOGRAPHY (IMAC)  
The rat GluK2 LBD protein was purified using IMAC and talon affinity chromatography as a first 
step in a purification methodology. The purified protein was obtained in six high-imidazole 
concentrate elution fractions of approximately 7.5 ml each (Fig. 5.21) with a protein band of 44 
kDa (29 kDa of protein + 15 kDa of 6xHis-SUMO tag). The flow-through fraction shown in the gel 
displays all the proteins that do not bind to the talon beads (nonspecific bands). The wash 
fractions 1 and 2 represent all unspecific proteins left in the column or proteins that bind weakly 
to the talon beads. A strong band of protein in the beads sample before elution (B1) 
demonstrates the protein retained by the talon bead and the sample of beads after elution (B2) 
shows a small fraction of protein still bound to the beads. This demonstrates the effective 
retention of the protein of interest for the talon metal affinity resin and the successful first step 
purification procedure. Elution fractions 1-3 gave a strong band of protein of 44 kDa. Other 
nonspecific bands of ~15, 25-30 and 60-100 kDa were observed in the SDS-PAGE gel and were 
further removed by SEC purification experiments.  
 
Figure 5.21. SDS-PAGE gel of IMAC purification. Strong bands of 44 kDa corresponding to the 
LBD of the rat GluK2 protein. Gel stained with Blue Coomassie for 1 hour and destained for 2 
hours. Approximately 50 ml of supernatant was added into 7.5 ml of talon beads, the flow 
through was ~50 ml, washes 1 and 2 ~ 100ml each and a sample of 25 µl of talon beads was used 
for running the SDS-PAGE gel. 10 µg of protein loaded per well, protein ladder used Precision 
Plus Protein™ All Blue (Cat. No. 1610373, Bio-Rad). Wash buffer contains 10 mM Imidazole and 
elution buffer 300 mM Imidazole. 
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To examine if the eluted protein was rGluK2, samples of the elution fractions 1 to 6 (~7.5ml each) 
were collected and incubated with 3C protease enzyme which specifically cleaves the 6xHis-
SUMO recognition site sequence of the protein. One sample of 100µl was taken before adding 
the enzyme and then another sample of 100 µl was taken after incubation with the protease 
enzyme. Samples of elution mix with and without 3C protease incubation were run in a SDS-
PAGE gel and it was observed that elution fractions without 3C protease incubation exhibit a 
strong band of 45 kDa (Fig. 5.22). In contrast, samples of elution mix with 3C protease incubation 
showed two new bands of 29 kDa and 15 kDa corresponding to the protein and the 6xHis-SUMO 
tag respectively. These results demonstrate that the protein eluted in the previous IMAC 
experiments correspond to rGluK2 LBD protein containing 6xHis-SUMO tag. The enzyme 
displayed high protease activity in recognising and cleaving the human rhinovirus (HRV) 3C 
protease cleavage site of the 6xHis-SUMO tag protein. In the gel a faint band of 45 kDa was still 
present in the sample with 3C protease however this was a relatively small amount of protein.  
 
Figure 5.22. SDS-PAGE gel of 3C protease activity. Protein elution fractions before 3C protease 
incubation exhibit a band of 45 kDa corresponding to rGluk2 with 6xHis-SUMO tag. Protein 
elution fractions after 3C protease incubation exhibit two bands of 29 kDa and 15 kDa 
corresponding to the protein rGluK2 and 6xHis-SUMO tag respectively. 15 µg of protein loaded 
per well, protein ladder used Precision Plus Protein™ All Blue (Cat. No. 1610373, Bio-Rad). 
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5.7.2 SIZE EXCLUSION CHROMATOGRAPHY (SEC) PURIFICATION  
Ultraviolet (UV) light absorption at A280 was used to monitor the fractions separated during SEC. 
The elution profile showed two main peaks (Fig. 5.23A), an initial first peak around 120 ml             
(~200 mAU) and a second peak at 160-180 ml (~180 mAU). Fractions of both peaks were 
collected and run in a SDS-PAGE gel electrophoresis to observe the proteins corresponding to 
each UV absorbance peak. Fractions 1E11 and 1F1 of the first peak displayed two bands, 29 kDa 
corresponding to the pure rGluK2 protein and 45 kDa corresponding to the protein with 
remaining 6xHis-SUMO tag (Fig. 5.23B). Fractions 1G9 to 1H4, corresponding to the second peak, 
exhibit the protein rGluK2 with higher purity, fractions 1H5 and 1H6 displayed a 15 kDa band 
suggesting a small amount of cleaved 6xHis-SUMO tag remaining in the sample.  
Fractions with high purity (1G9-1H4) were collected (~16 ml), concentrated and further purified 
with IMAC. The concentrated sample was incubated with 1ml of talon beads to remove any 
amount of cleaved 6xHis-SUMO tag left in the sample because highly pure protein is more 
effective for crystallography experiments. Final pure protein was confirmed by SDS-PAGE gel 
analysis (Fig. 5.24), the gel displayed a single band of 29 kDa and no other nonspecific bands. 
Final protein concentration was verified by nanoDrop using the molecular weight of 29.86 kDa 
and extinction coefficient of 39,880 M-1 cm-1 at 280 nm. A final protein yield of 6.1 mg (12.2 
mg/ml in ~500 µl) was obtained from 4 litres of starting culture. Six batches of purified protein 
were prepared for crystallography experiments (listed in Table 5.8).   
 
Table 5.8. Different batches of pure protein obtained after purification experiments 
Batch 
No.  
Starting cell 
culture (L) 
Concentration 
(mg/m) 
Final volume 
obtained (µl) 
Yield of purified 
protein (mg) 
1 2 3.6 100 0.4 
2 4 9.5 500 4.8 
3 4 7.5 400 3.0 
4 4 12.62 400 5.0 
5 4 8.1 700 5.7 
6 4 12.28 500 6.1 
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Figure 5.23. Size exclusion chromatography for rGluK2 protein. A) Chromatogram displaying the 
elution profile of the rGluK2 with SEC purification. B) SDS-PAGE gel of the elution fractions 
obtained, fractions 1E11 and 1F1 corresponding to first peak; fractions from 1G9 to 1H6 
corresponding to second peak marked with an asterisk.  Bands of 29 kDa corresponding to 
rGluK2 LBD. 10µg of protein loaded per well and protein ladder used Precision Plus Protein™ All 
Blue (Cat. No. 1610373, Bio-Rad). 
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Figure 5.24. SDS-PAGE gel purity verification of rGluK2 protein. 0.5, 1.5 and 2.0 µg of protein 
loaded, one single band of 29 kDa was observed corresponding to rGluK2 LBD protein.  
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5.7.3 CRYSTALLOGRAPHY 
Preliminary crystallography experiments resulted in the formation of seven crystal hits from 
three different commercial screen kits (PEG/ION, Salt Rx and JCSG-PLUS) described in Table 5.9. 
The best single type crystal was condition H1 from PEG/ION HT screen (Fig. 5.25). It was decided 
not to use any hits containing phosphate salts or buffers to avoid the formation of salt crystals 
(false positives).  
 
Table 5.9. Conditions of the crystal hits obtained after crystallography screening. 
System Well Salt Buffer Precipitant 
PEG/Ion 
HT 
E10 8% v/v Tacsimate pH 4.0 None 20 % w/v PEG 3350 
G7 2% v/v Tacsimate pH 4.0 
0.1 M Sodium acetate 
trihydrate  
pH 4.6 
16% w/v PEG 3350 
H1 None  
0.06 M Citric acid, 0.04 M BIS-
TRIS propane / pH 4.1 
16% w/v PEG 3350 
Salt Rx HT 
E2 
1.8 M Ammonium 
phosphate monobasic 
0.1 M Sodium acetate 
trihydrate    pH 4.6 
None 
E8 
1.8 M Sodium phosphate 
monobasic 
monohydrate, Potassium 
phosphate dibasic / pH 
5.0 
None None 
JCSG-PLUS 
HT-96 
C1 0.2 M Sodium chloride 
0.1 M Phosphate/citrate pH 
4.2 
20 % w/v PEG 8000 
D4 0.2 M Lithium sulphate 0.1 M Sodium acetate pH 4.5 30 % w/v PEG 8000 
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Figure 5.25. Light microscopy images of crystal hits from crystallography commercial screening 
kits. Different crystal hits were observed after preliminary crystal screening experiments; the 
conditions of each well are listed in Table 5.9. Crystals obtained were thin plates, most with plate 
aggregation.  
 
Crystals grew after 24 to 48 hours using the sitting drop method at 14°C with a protein solution 
of 5 mg/ml diluted in crystallography buffer (10mM HEPES pH 7.0, 30 mM NaCl, 1 mM EDTA and 
20 mM glutamate). The drop ratio was 1:1 of protein solution and reservoir solution (0.06 M 
citric acid, 0.04 M BIS-TRIS propane pH 4.1 and 16% w/v PEG 3350). Single and larger crystals 
were obtained after microseeding experiments using 1%, 5% and 10% seed stock. The best 
quality crystals grew with 5% and 10% seed stock, with no significant differences between them. 
The final optimised crystals had a monoclinic space group (three unequal axes at right angles) 
ranging in size from 0.12 to 0.20 mm (Fig. 5.26). Crystals were stored with 30% ethylene glycol 
as a cryoprotectant to protect crystals from free radicals of ionising X-rays during diffraction 
collection. rGluk2 crystals diffracted at 1.95 Å resolution. Molecular replacement was performed 
using an rGluA2 structure obtained in house. Final models were refined using CCP4 and PHENIX 
software; COOT was used for manual model building and refinement. Molecular replacement 
and refinement was performed by Dr. Mark Roe. Crystallography statistics of crystal rGluK2 LBD 
are presented in Table 5.10. 
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Figure 5.26. Light microscopic images of rGluK2 monoclinic crystals. Crystals obtained at 5.0 
mg/ml protein concentration with a reservoir solution of 0.06 M citric acid, 0.04 M BIS-TRIS 
propane pH 4.1 and 16% w/v PEG 3350.  
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Table 5.10. Crystallographic statistics of rGluK2 LBD. Crystal shot at the i04 beamline at Diamond 
Light Source. 
 
Data Set 
(Highest shell in 
parentheses) 
rGluK2 
a (Å) 46.50 
b (Å) 105.21 
c (Å) 58.06 
 () 90 
 () 103.5 
 () 90 
Space Group P 1 21 1 
Wavelength (Å) 0.9795 
Resolution Limit (Å) 49.74-1.95 
(1.98-1.95) 
Number of Unique 
Obs. 
39197 
(1937) 
Completeness (%) 99.1 
(98.8) 
Multiplicity 2.6 (2.5) 
Rmerge % 0.106 (0.936) 
Rpim(I) % 0.078 (0.692) 
CC1/2 0.992 (0.643) 
I/I 5.1 (1.2) 
Refinement  
Resolution Range (Å) 49.743 – 1.950 
Rcryst 0.2390 
Rfree 0.2711 
Number of protein 
atoms 
3,950 
Number of ligand 
atoms 
30 
Number of solvent 
atoms 
515 
Mean B 27.4 
Rmsd bond lengths 
(Å) 
0.003 
Rmsd bond angles (°) 0.609 
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The solved structure of the LBD of rGluK2 displayed glutamic acid (glutamate; the orthosteric 
agonist) binding in the cavity formed between the interface of S1 and S2 domains (Fig. 5.27). 
This is the same as other iGluRs LBD receptors such as rGluA2 and rGluK1.  Dimers of the LBD of 
in-house structure rGluK2 in complex with glutamate and the published structure rGluK2 in 
complex with kainate (PBD accession code 1TT1) were aligned to confirm the same dimer 
conformation found in the literature (Mayer 2005). The alignment of both dimers confirms the 
same conformation and same binding core for agonists glutamate and kainate (Fig. 5.28). 
Interestingly, the dimer structure of rGluK2 has different structural conformation from the 
rGluK1 dimer. COOT software was used to compare the dimer conformations of rGluK2 and 
rGluK1 by fixing one monomer of both structures in green (Fig. 5.29), the results show that 
rGluK1 has a different arrangement of the second monomer in yellow with a wider space at one 
side of the dimer interface (Fig. 5.29). Previous alignment of  the LBD of AMPA rGluA2 and rGluK1 
have shown the same dimer conformation suggesting the same binding sites in the dimer 
interface, however these results now show that rGluK2 might have different residues involved 
in the binding sites of the dimer interface compared to rGluK1.  
 
Figure 5.27. LBD rGluK2 dimer structure obtained with X-ray crystallography. Chain A and B are 
coloured in blue and green respectively. Glutamate shown in pink stick representation. Diagram 
of structure generated using Maestro Schrödinger version 11.1. 
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Figure 5.28. Alignment of rGluK2 dimer structures. LBD dimers structures of the in-house rGluK2 
protein in complex with glutamate and published rGluK2 in complex with kainate (PDB accession 
code 1TT1; Mayer 2005) in green and yellow respectively. Glutamate and kainate are displayed 
in stick representation in pink and blue respectively.  
 
 
Figure 5.29. Dimer comparison between in-house crystal structures of rGluK1 and rGluK2. Green 
monomer of both structures were placed in the same position and white cross set in the middle 
of the dimer 2-symmetry axis to compare dimer conformations. Dimers structures processed 
with COOT software.  
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The bond interactions of the agonist-binding pocket showed that glutamate α-carboxyl group 
formed chemical interactions with residues Ala-102, Arg-107 and Ala-153. The α-amino group 
of glutamate formed salt bridge and hydrogen bonds with residue Glu-202 and the δ-carboxyl 
group formed hydrogen interaction with Thr-154 (Fig. 5.30 & 5.31). All these interactions are the 
same as observed in the published structure of the rat GluK2 LBD in complex with glutamate 
(PDB accession code1S50; Mayer 2005). Similarly, the structure of the in-house LBD of rGluA2 
has the same three conserved interactions as rGluK2, these residues are: arginine, glutamate 
and threonine binding to α-carboxyl, α-amino and δ-carboxyl groups of glutamate (Fig. 4.15 & 
5.30). In addition, the in-house crystal structure of the rGluK1 LBD in complex with kainate 
showed that arginine and glutamic acid residues form hydrogen bond interactions with the α-
carboxyl group and the α-amino group of kainate respectively (Fig. 5.30). From these results, it 
can be confirmed that residues arginine and glutamic acid are conserved and important for 
agonist binding in the cavity of the LBD of rGluA1, rGluK1 and rGluK2.  
 
 
Figure 5.30. Glutamic acid binding interaction diagram for rGluK2 LBD. Bound glutamate 
interacts with Ala-102, Arg-107, Ala-153, Thr-154, and Glu-202. Hydrogen bonds are represented 
in fuchsia arrows and salt bridges in blue/red line. Ligand interaction diagram generated using 
Maestro Schrödinger version 11.1. 
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Figure 5.31. Glutamate binding pocket in LBD of rGluK2. Glutamate in stick representation in 
cyan, salt bridges interactions and Hydrogen bonds are shown in fuchsia and blue dash lines 
respectively. Diagram generated using Maestro Schrödinger version 11.1. 
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5.7.4 FRAGMENT SCREEN (SOAKING)  
Ten compounds synthesised in-house (SDDC) were incubated with rGluK2 crystals at 1 and 5 
mM. In one structure, the electron density observed in the dimer interface does not correspond 
to water molecules suggesting the presence of the compound UOS-15592 (5 mM) in a low 
occupancy (~20% map density) and an overlay of AMPA structure displays the same binding site 
in the dimer interface that corresponds to positive allosteric modulators (PAM) of AMPA (Fig. 
5.32). rGluK2 crystals were then soaked with 10 mM compound, however, the compound 
binding in the structure was not observed. No other compounds displayed binding in the LBD of 
rGluK2 crystal. At high concentration of compounds, the DMSO caused difficulties in handling 
and dissolving the crystals which resulted in diffractions from 2.5 Å to 3.0 Å resolution.   
 
 
Figure 5.32. Compound UOS-15592 at 5 mM appeared to bind in the dimer interface of rGluK2 
structure. A. Compound UOS-15592. B. Example of the electron density corresponding to a 
molecule of H2O. C. Gluk2 in yellow displaying the dimer interface with electron density map, 
white arrows show the low-density corresponding to UOS-15592. D. Same dimer interface 
overlay with AMPA structure (green) with ligand sitting in the PAM site. Figures obtained from 
Crystallography Object-Oriented Toolkit (COOT) software.  
 
240 
 
5.7.5 KAINATE CALCIUM ASSAY  
The main purpose of performing the calcium assay in human GluK2 cells was to confirm 
compound hits from soak experiments, however no compounds were found to bind in the LBD 
of the protein.  Dr. Ian Barret previously optimised this calcium assay using the Fluo-4 NW 
commercial kit for human GluK1 and GluK2 receptors. The parameters of the tested and 
optimised conditions of the assay are listed in Table 5.6, section 5.4.6.  In addition, the purpose 
of these results was to confirm the activity of the calcium assay in determining IC50 values and 
dose-response curve of agonists and antagonist in cells stably expressing human GluK2 receptors.  
The standard agonists kainate and domoate were tested using the calcium assay Fluo-4 NW. The 
kainate dose response curve gave an EC50 of 0.095 µM, 6-fold less than literature value of 0.6 
µM (obtained from supplier, Hellobio). Domoate dose response curve gave an EC50 of 0.021 µM, 
19 fold less than literature value of 0.4 µM (Christensen et al., 2004; Fig. 5.33). This cell line 
displayed higher fluorescence signal compared to GluK1 cells in which the maximal signal 
response was ~200 RFU, it is possible that the induction with tetracycline considerably increased 
the levels of expression of receptors in the membrane. The level of background fluorescence 
(control buffer) was also increased for agonists kainate and domoate (~40 RFU) but remained 
low in the antagonist experiments (~9 RFU) compared to kainate of ~10 RFU. The signal-to-
background ratio (S/B) for kainate and domoate resulted in 8.0 and 10.1 respectively, calculation 
based on the mean of the maximal response divided by the mean of the background.   
CNQX did not display any antagonist activity in this assay, CNQX and CNQX disodium salt hydrate 
(improved solubility in water) were tested and both failed to display any activity. Compound 
UOS-30693 is used in literature as a selective antagonist for HEK-293 expressing GluK1 cells 
(Valgeirsson et al. 2004) and it was synthesised by the SDDC as a selective antagonist for kainate 
receptors (Fig. 5.34). Compound UOS-30693 displayed an antagonist activity up to 33.33 µM, at 
higher concentrations of compound it precipitated out causing high levels of calcium in the cell. 
This suggests a disruption of the membrane cell, causing cell death and releasing intracellular 
calcium, as shown in Fig. 5.35.  Kainate competitive binding added to UOS-30693 gave an IC50 of 
11.39 µM (Fig. 5.35). This compound has an IC50 in the literature of 1.5 and 2.0 µM for cells 
expressing GluK1 receptors, for cells expressing GluK2 receptors IC50 value has not been 
reported in the literature due to poor solubility to enable the accurate determination of the 
value (Valgeirsson et al. 2004). The S/B ratio for antagonist UOS-30693 in the assay was 38.31, 
this value was calculated using the maximal response obtained after the addition of kainate.  
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Agonist EC50 
Kainate 0.095 µM 
Domoate 0.021 µM 
 
Figure 5.33. GluK2 kainate/domoate agonist concentration response curves. HEK-293 cells stably 
expressing human GluK2 receptor. Cells were incubated with 8.3 µM kainate and 0.83 µM 
domoate. RFU, relative fluorescence units in y-axis. Error bars (SD) are indicated representing 
n=3 individual experiments. 
 
Figure 5.34. In-house compound UOS-30693. Compound used as an antagonist for calcium 
assays for GluK2 cells.  
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Figure 5.35. GluK2 antagonist concentration response curve. HEK-293 cells expressing GluK2 
protein were incubated with 33 µM UOS-30693 (first addition step) then kainate added at 50µM 
(second addition step), labelled as post addition. Error bars (SD) are indicated representing n=3 
individual experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Antagonist IC50 
UOS-30693 11.39 µM 
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5.8 DISCUSSION  
The main objective of these experiments was the large-scale expression and purification of the 
rat GluK2 LBD protein to then perform crystallography experiments. Sequence alignment of the 
LBD between rGluK1 and rGluK2 demonstrated high homology identity (86.82%, Identity Matrix 
created by Clustal2.1) and for that reason, the expression and purification experiments were 
similar between both proteins. The expression construct was kindly provided by Dr. Antony W. 
Oliver (GDSC, University of Sussex). The construct contains a 6xHis-SUMO tag to improve 
solubility and purification of the protein. The small ubiquitin related modifier (SUMO) tag 
promotes the correct folding and solubility of the protein by having a similar effect as 
mammalian chaperone proteins; in addition,  SUMO tags have been shown to protect target 
proteins from degradation by promoting the translocation to the nucleus (Peroutka  et al. 2011; 
Costa et al. 2014). Furthermore, the polyhistidine (6xHis) tag was used for improving the 
purification since it binds to immobilized metal ion matrices in affinity chromatography 
(Bornhorst & Falke 2000; Costa et al. 2014).  
The ligand binding domain of the rat rGluK2 receptors was isolated using a Gly-Thr dipeptide to 
join S1 and S2 domains, the dipeptide was short but sufficient to covalently bind both domains 
without changing the rest of the conformation and functionality of the LBD (Reddy et al., 2013). 
Expression and purification of the LBD of the protein was successful in a large-scale format. 
Several batches of protein production and purification were performed, an average yield of 4.9 
mg of protein was obtained from four litres of starting cell culture. The yield of purified protein 
from four litres of cells resulted in sufficient protein for the preliminary crystallography and 
optimisation experiments with some protein left (~10 mg purified protein) stored for long-term 
at -80ᵒC.  
The primary crystallography screen using commercial matrix screen kits resulted in a positive hit 
that was further optimised and resulted in single crystals that were suitable for X-ray 
crystallography. The use of 5% and 10% seed stocks in microseeding experiments was necessary 
for obtaining larger crystals. The quality of rGluK2 protein crystals was reduced after periods of 
incubation at 14ᵒC longer than one month. Crystals stored at 4ᵒC maintained the quality 
properties for longer (approximately 3 months). Soaking experiments with ten compounds 
synthesised in-house resulted in compound UOS-15592 binding with 20% occupancy at 5 mM, 
higher concentration of compound (10 mM) was tested and no binding to the structure was 
observed possibley due to the effect of higher DMSO in the crystal. This compound has the 
potential to be used to generate a medicinal chemistry plan for analogues and test their activity 
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as potential for positive allosteric modulator drugs. Crystallography experiments were 
reproducible and optimised for potential future work with a large compound screening format 
(for example XChem screening) for drug screening studies.  
X-ray crystallography data was solved and resulted in a LBD dimer structure. The rGluK2 LBD 
crystal diffracted at 1.95 Å similar to the literature 1TT1 (1.93 Å). Crystals obtained had an 
monoclinic space group and space group P 1 21 1, the same as the previously published structure 
of the LBD of rat GluK2 (Mayer 2005). The X-ray structure showed that the interactions of the 
glutamate binding pocket of the LBD have similar residues interactions to those previously 
described in the literature (Mayer 2005). Residues arginine and glutamic acid showed to be 
conserved in rGluA2, rGluK1 and rGluK2, forming interactions with the α-carboxyl group and the 
α-amino group of agonists glutamate and kainate respectively. The dimer structural 
conformation was the same as previously published structure 1TT1 (Mayer 2005) although the 
dimer conformation of rGluK2 LBD displayed differences with other LBD receptors suggesting a 
narrowed dimer interface for rGluK2 LBD protein compared with rGluK1 and rGluA2.  
The Fluo-4 NW calcium assay was optimised by Dr. Iain Barret and following the optimised 
conditions of the assay the standard agonists and antagonist were tested to obtain a dose 
response curve and EC50 value. The calcium assay experiments demonstrated the suitability of 
the assay for further screening experiments.  The agonists kainate and domoate dose response 
curves displayed activity similar to literature with EC50 values of 0.095 µM and 0.021 µM 
respectively (Christensen et al. 2004 and Hellobio supplier).  
The antagonist CNQX failed to display antagonist activity, the reason for this might be due to cell 
behaviour, dye solution, buffer interaction, compound solubility, etc. In an electrophysiology, 
experiment published in the literature 100 µM of CNQX treatment with rGluK2 receptors did not 
show any change in the effect response of the receptor with the antagonist (Fisher & Housley 
2013). Compound UOS-30693  (named as 5d compound in the literature) was synthesised in-
house and selected from previous literature experiments as a potential antagonist for kainate 
receptors (Valgeirsson et al. 2004). This compound has been shown to be a potent non-
competitive antagonist for GluK1 cells, suggesting it could have similar antagonist activity for 
GluK2 cells. The compound UOS-30693 in GluK2 cells gave an antagonist response IC50 of 11.39 
µM tested with a maximal concentration of 33 µM because higher concentrations caused 
precipitation and disruption in cells, affecting the intracellular calcium level measurements. The 
signal-to-background ratio (S/B) for kainate, domoate and UOS-30693 was 8.0, 10.1 and 38.1 
respectively. The S/B ratio was higher with antagonist UOS-30693 because of a larger difference 
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between the maximal response and the background signal values. High levels of response (RFU) 
were observed with cells expressing GluK2 receptors, this might be the cause of the induction 
of receptors controlled by tetracycline antibiotic. Novel compounds with predicted antagonist 
activity for kainate receptors could be tested with this assay format. The LBD structure of the 
GluK2 receptor resulted in detailed structural information that can be used for the design of 
novel kainate receptor subtype-selective drugs for the treatment of epilepsy.  
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CHAPTER 6 
CONCLUSIONS AND FUTURE WORK 
 
 
6.1 NRF2 PROJECT 
The aim of this project was to utilise structure-based drug design to identify novel modulators 
of the Nrf2-Keap1 transcription pathway. The X-ray crystallographic information regarding the 
Nrf2-Keap1 interface interaction was used as the basis for a virtual screen. A commercial Nrf2 
pathway kit (DiscoverX) was then used to evaluate 122 compounds that were purchased from 
the output of this virtual screen which was useful in identifying potential modulators of the 
transcription pathway in a cell-based assay format. Two novel compounds were identified as 
potential modulators of the protein-protein interaction between Nrf2 and its repressor Keap1. 
The generation of reactive oxygen species (ROS) were monitored and results showed that only 
two compounds did not increase ROS levels, however Western blot analyses of Nrf2 were unable 
to demonstrate a translocation of the Nrf2 protein from the cytoplasm into the nucleus since no 
Nrf2 protein could be detected in the cytoplasm. As a result, it was not possible to confirm 
whether or not the two compounds of interest were having an effect on Nrf2 translocation and 
downstream genes expression. Accordingly, given the relatively weak effects of the two 
compounds and the lack of a reliable assay with which to detect downstream effects, the 
decision was made to terminate this project.  
The DiscoverX assay is a cell-based assay and requires compounds to have a good cell membrane 
permeability in order to demonstrate effects. An alternative approach would be to take a step 
backwards to use a biochemical assay to screen for molecules that disrupt the protein-protein 
interaction and thereafter build in the physicochemical properties required for cell permeability. 
In this regard, fluorescence polarization biochemical assays have been described using the 
Keap1 protein and an Nrf2-ETGE peptide as a fluorescein labelled probe (Hancock, Hélène C. 
Bertrand, et al. 2012; Jiang et al. 2014; Jnoff et al. 2014). Although the Western blot analyses 
were not successful, fluorescence microscopy could have been used in order to identify nuclear 
and cytosolic expression of Nr2 in cells (Theodore et al. 2008; Baird et al. 2013; Malloy et al. 
2013; Yu et al. 2014; Zhang et al. 2016). Alternatively, the quantification of the mRNA of Nrf2 
downstream genes can be performed using real time PCR (RT-PCR), and these methods were 
used to identify the effect of compounds in the expression of antioxidant and detoxifying 
enzymes (Buetler et al. 1995; Kanno et al. 2012b; Mathew et al. 2014; Zhuang et al. 2014). 
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However, although these alternative methodologies were considered, the low potency of the 
two compounds of interest did not justify the considerable investment in time and resource 
required to establish these techniques.  Nevertheless, despite the lack of success, the Nrf2 
transcription pathway still remains an attractive, albeit challenging, potential therapeutic target 
for the treatment of neurodegenerative diseases. 
 
6.2 AMPA PROJECT 
The aim of this project was to use a structure-based, X-ray crystallography screening approach 
to identify fragments that bind to, and allosterically modulate, the ligand-binding domain (LBD) 
of the GluA2 AMPA receptor and which might have the potential to become novel drugs with 
which to treat neurological disorders. Methods described in the literature have focused on the 
rat protein due to the increased solubility and crystallography properties in comparison to the 
human protein. A construct of the rat recombinant protein GluA2 LBD was designed according 
to previously published methods (Armstrong & Gouaux 2000; Ward et al. 2011) and was 
expressed and purified to produce a high purity protein suitable for X-ray crystallographic 
studies. The crystal structure of the rat GluA2 LBD was determined to a resolution of 1.84 Å and 
the homodimeric structure and agonist (glutamate) binding was consistent with previous data.  
In order to find novel compounds that bind to the GluA2 LBD, an XChem fragment screen was 
performed at the Diamond Light Source (Didcot, UK). The primary methodological challenge was 
to optimise the methods for crystal production such that they were suitable for large scale 
fragment screening. The optimised crystallography conditions were in a sitting drop format plate 
using 5 mg/ml protein with 5 mM zinc acetate and sodium cacodylate and a final drop ratio of 
1:1 with reservoir solution (0.09 M halogens, 0.1 M buffer system 1 pH 6.5 and 50% v/v 
precipitant mix 1, Morpheus® screen Appendix II). 
The methods involved in the fragment screen were the crystal targeting, soaking, harvesting, 
data collection and data analysis of which the crystal harvesting was the most challenging and 
time consuming due to the need for each crystal to be harvested manually. A total of 700 
fragment compounds were soaked with GluA2 LBD crystals (from 1.75 Å to 2.5 Å) in complex 
with glutamate and resulted in eight fragments located in the ligand binding domain of the 
protein. Two binding sites were identified, a site near the Gly-Thr dipeptide linker and a site in 
the dimer interface between domains S1 and S2 of the LBD. The latter had been previously 
identified as a site for positive allosteric modulators (PAMs) of AMPA receptor, PAMs binding in 
this interface have been suggested to enhance cognitive performance in animal models. The 
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binding site near the Gly-Thr linker has not been identified in the literature or any publication. 
From the eight compounds, five were located in the dimer interface and three near the Gly-Thr 
site.   
In future, functional studies (electrophysiology) will be used to characterise the functional 
effects of these compounds although it would not be surprising if no effects were observed. 
Accordingly, more detailed biophysical analyses need to be performed in order to characterise 
the affinity and other features of the ligand-protein interaction. In addition, close structural 
analogues of these compounds will need to be ordered or synthesised in the hope of identifying 
compounds with higher affinity than these presumably weak hits that have been identified in 
the XChem fragment screen.  
  
6.3 KAINATE PROJECT 
The purpose of the kainate receptor project was to provide the structural information that 
would form the basis of a structure-based drug discovery approach to identifying novel 
compounds that bound to the LBD of the rat GluK1 and GluK2 subtypes of ionotropic glutamate 
receptor, in a manner analogous to that used for the GluA2 subtype AMPA receptors. More 
specifically, the aim was to identify allosteric modulators that might be the starting point in the 
path to developing novel anti-epileptic drugs that might be more efficacious and/or better 
tolerated than existing drugs.  
The construct of the rat recombinant GluK1 and GluK2 LBD proteins was similar to those used 
previously (Naur et al. 2005). The crystals of both proteins were solved at 1.64 Å for GluK1 and 
1.95 Å for GluK2 and binding interactions with the agonist kainate were comparable to those 
published previously. In-house compounds based on literature were soaked with both protein 
crystals and one compound UOS-15592 displayed ῀20% occupancy suggesting some evidence of 
compound binding in the dimer interface of GluK2, more interestingly preliminary 
electrophysiological data suggests the same activity for GluK1 protein. This result supports the 
evidence of possible binding sites for positive allosteric modulators (PAMs) of kainate receptors, 
similar to GluA2 AMPA PAMs.  
Further work is required to establish the functional consequences of the binding of this 
compound in a cellular fluorescence or electrophysiological assay. Nevertheless, these results 
form the basis of an iterative medicinal chemistry programme based upon increasing the 
potency of compound UOS-15592.  In parallel, the LBDs of GluK1 and GluK2 could be used for 
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large-scale fragment screening using the XChem screening platform, with a particular focus on 
GluK1. Fragment hits would then be further analysed in either a biophysical assay or a functional 
assay, such as the established kainate calcium (Fluo-4 NW) or electrophysiology assays.  
Discussions are also underway with the Membrane Protein Laboratory (MPL, Diamond Light 
Source) in order to establish methodologies for the production and X-ray crystallographic 
examination of full-length human GluK1. The structural characterisation of the GluK1 and GluK2 
LBDs and potentially the full length GluK1 are important components of a structural approach 
to the development of novel allosteric modulators for the treatment of epilepsy that can reduce 
undesirable side effects and help in the treatment of refractory (intractable) epilepsy patients.  
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APPENDIX I 
Results generated by Dr. Ben Wahab 
 
1.0 Alignment Report 
 
 
Alignment and RMSD generated by MOE. 
 
The lower the RMSD value, the closer the super-position, which reflects close matching 3D 
positioning of protein residues across multiple structures. An RMSD of under 1.5 Å is said to be 
a good super-positioning. As some of the structures are apo, and some holo, the low RMSD 
represents pockets that are not highly flexible / inducible on contact with ligands.  
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2.0 Ligand interaction map (from 3VNH crystal structure) 
 
Example of the ligand interaction maps generated using MOE. Residues in green and purple are 
hydrophobic and hydrophilic respectively. Hydrogen bonding in green dash arrows, and pi-
stacking interactions in green dots lines. The grey dash surrounding the ligand represent the 
surface (edge) of Keap1 protein. Blue colour circles represent solvent contacts.  
 
3.0 Water analysis  
Within the pocket, careful analysis gave rise to a number of key waters that were present within 
at least 50% of the crystal structures OR 75 % of HOLO structures within a ≈1 Å cluster size (given 
below in reference to the 1X2R nomenclature). Waters within holo structures indicate possible 
interaction mediators. 
 
Conserved waters around the binding space: 
17, 47, 48, 713, 714, 723, 748, 772, 786, 819, 872, 874, 886, 899, 926 
Conserved waters in the bottle neck (under the pocket): 
734, 754, 822, 949 
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4.0 Pharmacophores 
ID Based 
on 
Feature 1 Feature 2 Feature 3 Feature 
4 
Exclusion 
volume 
Hits 
        
1X2R_1 1X2R SER363 ASN382 SER602 ASN382(a) 0 923 
1X2R_2 1X2R ARG483 
SER508 
SER508(a) 
ARG415 
SER602 GLN530 0 757 
1X2R_3 1X2R ARG483  
SER508 
SER508 
ARG415 
GLN 530  0 604 
1X2R_4 1X2R GLN530 SER602 GLN530(a)   0 326 
1X2R_5 1X2R SER363 ARG 380 ASN382   1 798 
3VNH_1 3VNH ARG483 
SER508 
ARG415 SER363  0 359 
3VNH_2 3VNH ARG483 
SER508 
ARG415 SER363  0 280 
3VNH_3 3VNH ARG483 
SER508 
ARG415 SER363  1 154 
3VNH_4 3VNH ARG483 
SER508 
ARG415 SER363 ARG380 1 184 
3VNH_5 3VNH ARG380 ARG415 SER363  1 28 
4IFN_1 4IFN ASN414 
ARG380  
ARG 415 
ASN414(a)  
ARG380(a) 
ARG415(a) SER602 0 1,366 
4IFN_2 4IFN ASN414 
ARG380  
ARG 415 
ASN414(a)  
ARG380(a) 
ARG415(a) SER602 1 1,364 
4IFN_3 4IFN ASN414 
ARG380  
ARG 415 
ARG415(a) SER602 TYR572 
(aro) 
0 500,000+* 
4IFN_4 4IFN ASN414 
ARG380  
ARG 415 
ASN414(a)  
ARG380(a) 
ARG415(a) TYR572 
(aro) 
0 1,314 
4IFN_5 4IFN ASN414 
ARG380  
ARG 415 
ARG415(a) SER602  0 540 
4IN4_1 4IN4 ARG483 ARG483(a) SER508 SER555 0 21,436* 
4IN4_2 4IN4 ARG483  SER508 SER555 1 500,000+* 
KEAP1 custom ARG414 SER363 SER508 
ARG483 
 0 27,138* 
KEAP2 custom SER555 ARG415 SER508 
ARG483 
  43,803* 
KEAP3 custom ARG380 
ASN387 
SER363 SER508 
 
  3 
KEAP4 custom SER363 SER602 SER555   176 
KEAP5 custom SER508 
ARG483 
GLN530 SER363  0 0 
* Considered too non-discriminatory to be of use in the docking phase 
(a) Denotes a second interaction feature with the same target as a previous feature in the 
pharmacophore 
(aro) Denotes an aromatic pi stack. The custom interactions are based on observed residues that can be 
interacting.  
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